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Abstract 
WRAP53 partly overlaps the neighboring gene TP53 in a head-to-head fashion. The 
WRAP53α isoform was identified as a natural antisense transcript to TP53, possessing 
regulatory functions involved in the induction of cellular p53 responses [1]. WRAP53 
encodes as well a protein discovered as a telomerase holoenzyme subunit important 
for proper telomere synthesis [2]. WRAP53 overexpression is frequently observed in 
cancers, presuming WRAP53 as a gene implicated in cancer cell survival [3]. The 
overall aim of this thesis has been to investigate the significance of and increase the 
knowledge about WRAP53 in breast cancer. This was accomplished performing a 
WRAP53 mutation analysis and a gene expression study analyzing cellular responses 
to WRAP53 knockdown. 
 The WRAP53 mutation analysis was performed sequencing all ten WRAP53 
coding exons and start exon 1β in 175 primary breast carcinomas. Sequence 
alterations detected in tumor were verified in corresponding blood samples and 
investigated in relation to clinical, pathological and molecular parameters. The gene 
expression study was performed inducing siRNA-mediated WRAP53 depletion in the 
MCF-7 and MDA-MB-231 breast cancer cell lines. The gene expression alterations 
caused by WRAP53 knockdown were analyzed by microarray technology and related 
to biological functions including cellular pathways and disease states. 
No distinctive somatic alterations were detected in the WRAP53 mutation 
analysis, indicating that WRAP53 mutations do not seem to be a common event in 
breast tumorgenesis. Contrarily, the genetic linked polymorphic alterations, R68G, 
F150F and A522G, were significantly associated to breast cancer-specific survival 
and exon 1β c.–245 G>C was associated with nuclear WRAP53 protein localization, a 
feature of favorable prognostic impact. Together these results suggest that WRAP53 
might be a marker of prognostic value in breast cancer. WRAP53 depletion altered the 
gene expression patterns in MCF-7 and MDA-MB-231. Despite cell line-specific 
outcomes in the pathway analyses, relating differentially expressed genes to 
biological functions, cancer and cancer-related features like cellular proliferation, 
growth and movement emerged as significant common denominators. The same was 
observed analyzing the mutual differentially expressed MCF-7 and MDA-MB-231 
genes, supporting the hypothesis that WRAP53 might be involved in tumorgenesis.  
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Sammendrag 
WRAP53 og TP53 er delvis overlappende gener, og isoformen WRAP53α er 
identifisert som et naturlig antisens transkript til TP53 med regulatoriske funksjoner 
involvert i aktivering av cellulær p53-respons [1]. Proteinet WRAP53 koder for er 
identifisert som en subenhet i enzymkomplekset telomerase, og spiller en avgjørende 
rolle i telomersyntesen [2]. Overuttrykk av WRAP53 forekommer ofte i kreft og 
studier indikerer at WRAP53 er nødvendig for kreftcellenes overlevelse [3]. Hensikten 
med denne studien har vært å undersøke betydningen av og øke kunnskapsnivået om 
WRAP53 i brystkreft. Dette ble utført ved en WRAP53 mutasjonsanalyse og en 
genekspresjonsstudie for å studere cellulære responser av å slå ut WRAP53 (såkalt 
”knockdown”). 
   I mutasjonsanalysen ble de ti kodende WRAP53 exonene og start-exon 1β 
sekvensert i 175 primære brystkarsinomer. Sekvensvariasjon detektert i tumor ble 
validert i korresponderende blodprøver, og utforsket med hensyn til kliniske, 
patologiske og molekylære parametere. Ekspresjonsstudien ble utført ved siRNA-
indusert WRAP53 knockdown i brystkreft cellelinjene MCF-7 og MDA-MB-231. 
Endringer i genuttrykk som følge av WRAP53 knockdown ble analysert ved hjelp av 
microarray teknologi og relatert til biologiske funksjoner som cellulære signalveier og 
patologiske tilstander. 
 Ingen karakteristiske somatiske endringer ble påvist i mutasjonsanalysen, noe 
som indikerer at mutasjoner i WRAP53 trolig ikke er hyppig forekommende hendelser 
i brystkreft. De genetisk koblede polymorfiene, R68G, F150F og A522G, ble funnet 
signifikant assosiert med brystkreft-spesifikk overlevelse, og exon 1β c.–245 G>C ble 
assosiert med kjernelokalisering av WRAP53 proteinet, noe som bedrer prognosene 
ved brystkreft. Disse resultatene indikerer at WRAP53 kan være en markør med 
prognostisk verdi ved brystkreft. Knockdown av WRAP53 endret genuttrykket i MCF-
7 og MDA-MB-231. Til tross for celletype-spesifikke resultater ved analysering av de 
signifikant endrede ekspresjonsnivåene i assosiasjon til biologiske funksjoner, ble 
kreft og kreft-relaterte karakteristikker som cellulær vekst, proliferasjon og bevegelse 
angitt som signifikante fellestrekk. Det samme ble observert ved analyse av gener 
med endret ekspresjonsnivå felles uttrykt i MCF-7 og MDA-MB-231, noe som støtter 
hypotesen om at WRAP53 kan være involvert i kreftutvikling. 
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1. Introduction 
1.1. Cancer 
1.1.1. Cancer etiology 
Cancer is a generic term used to describe a heterogeneous group of nearly 200 
different cancer types [4]. The development and behavior of cancers differs greatly, 
but the common cancer features are defined as unlimited cellular replication potential 
and invasion of foreign body tissues in the process towards metastatic disease [5].  
Cancer is today one of the most common human diseases worldwide, with 
persistently increasing incidence rates [6, 7]. This is observed in both economically 
developed and developing countries, and is primarily caused by population aging and 
growth. An important secondary cause is the expanding global adaption to cancer-
causing behaviors like smoking, alcohol consumption, physical inactivity and obesity 
[6]. A study by the Norwegian Cancer Society shows that as many as 30–40% of all 
cancer cases may be prevented by positive lifestyle changes [8]. In developing 
countries, late diagnosis and limited access to timely, standardized treatments are also 
contributors to the increase in cancer incidence. Preventive tools such as programs 
improving the cancer knowledge in the public, early detection and treatment will be of 
importance to reduce the growing incidence [6].  
 The latest cancer statistics from the International Agency for Research on 
Cancer (IARC), GLOBOCAN 2008
1
, reported 12,7 million new cancer cases and 7,6 
million cancer deaths worldwide in 2008. Lung cancer is the most common cancer 
overall and is also the most frequent neoplasm in men, while breast cancer occur most 
frequently in women [6, 7]. In Norway, the Cancer Registry of Norway reported 
27520 new cancer cases in 2009, ranging prostate cancer as the most frequent cancer 
in men and breast cancer as the most frequent in women [9]. 
 
1.1.2. Cancer development 
Cancer was for a long time assumed to be a disease of environmental origin. As early 
as in 1914, Theodor Boveri suggested that malignant tumors originated from cellular 
genomic abnormalities [10], but the importance of cancer genetics did not really 
                                                          
1
 GLOBOCAN 2008: Estimates of cancer incidence, mortality and prevalence worldwide in 2008, 
International Agency for research on Cancer, World Health Organization; globocan.iarc.fr 
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emerge until the 1980s. Today cancer is known as a genetic disease characterized by a 
stepwise cellular accumulation of genetic and epigenetic alterations, but the 
consideration of cancer as an environmental disease is still standing [11]. Despite the 
underlying genetic causes, only 10% of all cancer cases occur in people with a family 
history of cancer, leaving the majority to be of sporadic occurrence [12].  
Cancer development is a highly debated subject and several possible theories 
exist. A well-accepted model is the clonal evolution theory where neoplasms are 
presumed to develop from a single somatic cell. Accumulation of genomic aberrations 
over time provides selective cellular advantages promoting the cell to become a 
growing mutant clone [5, 13]. Histopathological observations of cancer progression 
supports this theory [13], even though the polyclonality observed in many tumors 
remains a contradiction to the model [14].  
 Over the last years, a supplement to the clonal evolution theory has been 
described based on the possibility of interclonal cooperation as an explanation of 
tumor polyclonality. This model do not require a single cell to obtain every genomic 
aberration necessary to reach malignancy, but indicates that partially transformed 
cells may cooperate in the process towards a malignant phenotype [14, 15]. 
Cooperation between co-dominant clones are presumed to occur in three possible 
ways (figure 1); (B) between a pre-malignant cell and a mutant daughter cell, (C) 
between two clones generated from the same pre-malignant precursor cell, or (D) 
between two pre-malignant clones generated from independent normal cells. These 
cooperative mechanisms generate a malignant phenotype faster than what is possible 
in the lineal evolution [14]. 
A competing theory in carcinogenesis is the cancer stem cell hypothesis, 
suggesting that human tumors develop from mutated normal stem or progenitor cells. 
The stem cell characteristics of self-renewal, indefinite replication potential and 
differentiation into diverse cell types are abilities highly relevant to malignancy. 
  
Figure 1: Schematic representation of  
malignant tumor development by lineal  
evolution (A) and interclonal  
cooperativity (B, C and D) [14]. 
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Studies have shown that cells with stem-cell properties are able to induce human 
tumors, and that such cells have been detected in the hematopoietic system, the 
central nervous system and the mammary gland [16].   
  Recently, the hypothesis of cancer self-seeding was introduced, presuming 
that tumor clones may leave the primary tumor by extravasation into the circulatory 
system, temporary develop at a distant site, and then return to the primary site 
generating new subpopulations [17]. Evidence shows that carcinogenesis is a complex 
process where several theories may be involved in a mutual non-exclusive way, 
indicating that human cancers may develop differently from each other [13, 14, 16, 
17]. 
 Cancer may originate from any body tissue, resulting in extreme disease 
heterogeneity. Despite this complexity, most human tumors share some common 
features necessary to reach the state of malignancy. These features are by Hanahan 
and Weinberg referred to as the “hallmarks of cancer”, and constitutes six biological 
capabilities acquired in cancer cell survival, proliferation and metastatic 
dissemination; (i) sustain proliferative signaling, (ii) evade growth suppressing 
signals, (iii) enable replicative immortality, (iv) resist apoptosis, (v) induce 
angiogenesis and (vi) activate invasion and metastasize. Two emerging hallmarks 
have during the last decade been added to the list, proving that both evasion of 
immune destruction and energy metabolism reprogramming are tumor facilitating 
actions. The cellular hallmark achievements are made possible by two enabling 
characteristics, where (i) genomic instability increases the cellular mutation rates and 
contribute to the gain of hallmark capabilities, and (ii) tumor-promoting 
inflammations recruits and utilize immune cells in the process of tumorgenesis. The 
tumor microenvironment is another element important in cancer development, 
showing that cancer progression also depends on a diversity of normal cells. From the 
early statements describing tumors as homogenous groups of cells, considerable 
complexity has evolved in the field of cancer biology [18]. 
 
1.1.3. Genetic alterations in cancer 
Tumor development is primarily caused by genetic and epigenetic alterations in 
members of two broad gene categories; the proto-oncogenes and the tumor suppressor 
genes. Proto-oncogenes normally promote cell proliferation and survival while the 
tumor suppressors restrain cellular proliferative activity, together balancing the 
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homeostasis of adult body tissue. The genetic alterations are usually of somatic 
occurrence, but germline mutations may increase cancer susceptibility by familial 
heritage [19, 20]. 
 Proto-oncogenes are altered by monoallelic gain-of-function mutations 
generating excessively active oncogenes. Protein products of oncogenes are classified 
in six categories; transcription factors, growth factors, growth factor receptors, signal 
transducers, chromatin remodelers and apoptosis regulators, all potential contributors 
to uncontrolled proliferation if overexpressed. The transition from proto-oncogenes to 
oncogenes is facilitated by gene amplifications, juxtapositions to regulatory elements 
of enhanced activity, and structural alterations caused by mutations and gene fusions. 
In human epidermal growth factor receptor 2 (HER2) positive breast cancer 
amplification of the ERBB2 proto-oncogene sustains excessive proliferative signaling 
[19, 20]. 
In contrast to the activated oncogenes, tumor suppressor genes are often 
inactivated in cancer. Biallelic alterations like point mutations, deletions, epigenetic 
promoter silencing by methylation and loss of heterozygosity result in gene loss-of-
function (figure 2). Tumor suppressor gene products inhibit improper cell cycle 
progression and maintain genomic stability by ensuring proper DNA replication, 
repair and segregation, and by inducing apoptosis in aberrant cells. Inactivation of 
such genes becomes a source to increased cellular proliferation and reduced genomic 
integrity, a phenomenon observed by the frequent inactivation of the RB1 and TP53 
tumor suppressors in cancer [11, 19].  
Tumor genomic instability is caused by inherited mutations in genes important 
to genomic integrity, or by accumulation of mutations of somatic origin during 
tumorgenesis [11]. The genetic alterations belongs to different classes of distinctive 
 
 
Figure 2: Loss of tumor suppressor 
gene function in cancer. Function 
may be lost (blue bars) in germ-line 
or somatically induced by mutations 
(vertical arrowheads), loss of 
heterozygosity or epigenetic 
promoter methylations (green 
spikes). For some tumor suppressor 
genes inactivation of one allele is 
sufficient for loss of function; the 
haploinsufficient tumor suppressors 
[11].  
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DNA sequence changes including single nucleotide substitutions, insertions, 
deletions, chromosomal rearrangements and copy number gains and losses [21]. 
Numerically, single base substitutions are the most abundant genetic variation, 
causing nonsense, missense or silent mutations. In nonsense mutations the 
substitutions introduce a premature stop codon and generate truncated, non-functional 
gene products, while the missense mutations alter the coding sequence by amino acid 
changes. Some base changes occur as synonymous, silent mutations where the amino 
acid is retained throughout the substitution [19]. 
 Another emerging field to investigate is the importance of single nucleotide 
polymorphisms (SNPs) in tumorgenesis. SNPs are single nucleotide alterations 
defined as normal sequence variations that occur in more than 1% of the population. 
SNPs are rarely disease causing, and high-frequency SNPs are not expected to have 
any major phenotypic effect since harmful lesions mainly are eliminated by the 
process of natural selection. In cancer, SNPs have potential as disease indicators and 
are used in cancer predisposition analysis, diagnosis and prognosis [19, 22]. 
Every genetic abnormality is not involved in cancer development. Mutations 
are classified as “drivers” and “passengers” based on their contribution in cancer 
development. Driver mutations confer cellular growth advantages, a known oncogenic 
feature, while the passenger mutations do not provide this advantage and therefore do 
not contribute to tumorgenesis. An important subgroup of driver mutations is the 
mutations causing cancer therapy resistance, and as a consequence increased risk of 
relapse. In cancer genetics, an important goal is to identify the cancer genes carrying 
driver mutations. Driver mutations are assumed to cluster in genes important in 
tumorgenesis, while the passengers are distributed more randomly. The identification 
of cancer genes is difficult since drivers has to be distinguished from passenger 
mutations, and because multiple low-penetrance cancer genes are believed to 
contribute in cancer development [21].    
 Epigenetic alterations are additional contributors to cancer development. 
Without changing the DNA sequence, only modifying it, epigenetic alterations 
promotes gene expression changes. Chromatin structure remodeling and DNA 
methylation are the main mechanisms to these alterations [19]. 
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1.2. Breast cancer  
1.2.1. Breast cancer etiology 
Breast cancer is the most frequent neoplasm among women worldwide, and ranks 
second after lung cancer as the most common cancer overall. GLOBOCAN 2008 
reported 1,38 million new female breast cancer cases in 2008 [7], a number 
constituting 23% of all new cancer cases and 11% of all cancer cases in the world [6, 
7]. In Norway a total of 2760 persons, distributed in 2745 women and 15 men, were 
diagnosed for breast cancer in 2009 [9].  
Similar to cancer incidence rates in general, the world breast cancer incidence 
has increased over the last decades. Western European women are burdened with the 
highest rates (89,9 per 100 000 women), while the lowest are found in Eastern African 
women (19,3 per 100 000 women). Although the incidence rates overall are higher in 
economically developed than developing regions, about half of the diagnosed cases 
and 60% of the deaths occur in developing regions [6, 7]. Breast cancer caused 
458.000 deaths in 2008 and is the leading cause of cancer death among women 
worldwide [6]. 
Breast cancer is a multifactorial disease caused by interactions of genetic and 
environmental risk factors [23]. Familial breast cancer history is the strongest 
predisposing factor despite the fact that inheritance only constitutes about 10% of all 
breast cancers. Inherited mutations in high-penetrance cancer susceptibility genes like 
BRCA1, BRCA2 and TP53 account for about 25% of the familial risk, leaving the 
remaining 75% of other genetic or environmental origin [11, 24]. Few high-
penetrance susceptibility genes have been identified, indicating that most familial 
breast cancers may be caused by alterations in multiple low-penetrance genes [25].  
 Endogenous estrogen exposure is a major contribution to breast cancer risk. 
Increased exposure by early age at menarche, nulliparity, late age at first full-term 
pregnancy and late age at menopause are associated to increased breast cancer risk. 
Breast cancer incidence is age-specific and correlates strongly with age until 
menopause, indicating that ovarian activity is a breast cancer promoting factor. 
Exogenous hormone therapy like oral contraceptives and postmenopausal hormone 
replacements are other risk increasing elements.  
International variations in breast cancer incidence suggest that environmental 
and lifestyle factors may influence the risk of breast cancer. High fat diets and alcohol 
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consumption are breast cancer risk factors as well as postmenopausal obesity, which 
also increase breast cancer risk. Mammographic density and exposure to ionizing 
radiation are also well-known risk factors to breast cancer [23].  
 
1.2.2. Breast cancer development and progression 
Breast cancer is malignant neoplasms originating from breast tissue. The adult female 
breast is an intricate organ consisting of glandular tissue surrounded by stromal 
components like adipose and connective tissue, blood and lymphatic vessels [23]. The 
mammary gland consists of 15–20 lobes, where each lobe is composed of many 
smaller lobules and is converged onto a lactiferous duct (figure 3). Secretory luminal 
epithelial cells face the hollow lumen in the branched ductal and lobular system, while 
underlying contractile myoepithelial/basal cells facilitates the glandular secretion 
[26]. The intricate normal breast anatomy contributes to the heterogeneity and 
complexity observed in breast cancer.  
 
 
 
 
 
 
 
Figure 3: Normal breast anatomy.  
The mammary gland consists of lobules converging onto 
lactiferous ducts surrounded by stromal components like 
adipose tissue. The pectoralis major muscle separates the breast 
from the ribs. Modified from 
http://medicalcenter.osu.edu/greystone/images/ei_0385.gif 
 
 
Invasive breast cancer is proposed to develop through an evolutionary 
multistep process from pre-existing benign lesions [27, 28], driven by genetic, 
epigenetic and microenvironmental changes [24]. Atypical hyperplasia is presumed to 
be an early step in breast cancer development, later evolving into ductal and lobular 
carcinomas in situ (DCIS and LCIS) (figure 4). Hyperplasia and in situ carcinomas 
acquire certain malignant properties like uncontrolled cell proliferation, but are 
considered premalignant because of their inability to invade and metastasize [28]. 
Not every premalignant lesion develops into invasive breast cancer, but 
patients diagnosed with atypical hyperplasia and in situ carcinomas are more 
susceptible to invasive breast cancer progression [28]. Invasive cells brakes through 
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the basal membrane of carcinoma in situ and invade the surrounding tissue. 
Myoepithelial/basal cells are lost in the transition from in situ carcinoma to invasive 
cancer, and it is hypothesized that this transition is facilitated by the 
myoepithelial/basal cells themselves [24]. Invasive ductal and lobular carcinomas are 
the most frequent types of breast cancer, representing about 80% and 10% of all 
diagnoses respectively [27], originating from epithelial cells in the terminal ductal 
lobular units [28]. Metastasis is the lethal aspect in breast cancer, where cells escape 
from the primary tumor site and spread to distant organs generating secondary tumors 
[24]. Even though the clonal evolution theory is well established in breast 
tumorgenesis, hypothesis like cancer self-seeding, cancer cell cooperation and 
mammary cancer stem-like cells propose different possible explanations to breast 
cancer development [14, 16, 17]. All tumors may therefore not go through every step 
of the model shown (figure 4). 
 
 
Figure 4: Hypothetical breast cancer progression model progressing through the stages from normal to 
in situ, invasive and metastatic carcinoma. The stromal compartment includes leukocytes, fibroblasts, 
myofibroblasts, and endothelial cells [24]. 
 
1.2.3. Breast cancer subtypes 
Over the last decade, an increased molecular approach to breast cancer diagnostics 
has evolved. The molecular heterogeneity observed in human cancers was primarily 
found to be explained by transcriptional variations, and this has in breast cancer led to 
a subclassification improving breast cancer taxonomy [29].  
In the year 2000, Perou et al. identified four breast cancer subtypes based on 
differences in tumor gene expression patterns [29]. In 2001 and 2003, Sorlie et al. 
evaluated this classification to include at least five different subgroups [30, 31]. Gene 
expression profiling using complementary DNA microarrays and hierarchical 
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clustering separated the tumor samples into two main branches; estrogen receptor 
(ER) positive and ER negative tumors. ER positive tumors highly express many of the 
genes expressed in normal luminal epithelial cells, and are further divided into the 
luminal A and luminal B subgroups. The ER negative tumors are separated into three 
subgroups; (i) the basal-like group highly expressing genes expressed in normal 
myoepithelial/basal cells, (ii) the ERBB2 positive group with elevated expression of 
the ERBB2 and genes in the proximity, and (iii) the normal breast-like group 
expressing genes known to be expressed in normal breast tissue like adipose tissue 
and non-epithelial tissues [31]. Luminal A is the most frequent subtype (~40%) while 
the ERBB2 positive group occur least frequently (~10%), a distribution observed to 
be conserved across ethnic groups [32]. In 2007, Herschkowitz et al. identified a new 
human subtype, claudin-low, characterized by decreased expression levels of genes 
involved in tight junctions and cell-cell adhesion [33], but this subgroup is currently 
not commonly used in breast cancer subclassification [32]. 
  The respective subgroups have also been correlated to patient survival, proven 
a significant difference in clinical outcome. The outcome, overall and relapse-free 
survival, is most beneficial in the luminal A subgroup and least beneficial in the 
ERBB2 positive and basal-like subgroups (figure 5). ERBB2 overexpression and 
inactivation of the TP53 tumor suppressor gene are poor prognostic factors frequently 
detected in the ERBB2 positive group. TP53 inactivation is as well a common event 
in the basal-like group. The luminal B subgroup also displays poor outcomes, in 
particular seen in a long follow-up [34]. A recent study by Curtis et al. analyzing gene  
 
 
 
 
 
  
Figure 5: Overall (A) and relapse-free (B) survival analysis of 49 breast cancer patients based on 
breast cancer subclassification [30]. 
 
A B 
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expression patterns in 2000 primary breast tumors expanded the subclassification 
system by identifying a total of ten subgroups [35]. The subgroups reflect the 
complexity in breast cancer biology, indicating that breast cancer might be an 
assembly of distinct diseases with different therapeutic requirements [30, 31].  
 
 
1.3. TP53 – Tumor Protein p53  
The p53 protein was discovered in 1979 as an associated protein to the Simian Virus 
40 large T antigen [36, 37]. The p53 association to this viral oncoprotein led to the 
hypothesis of p53 as a cellular oncogene product with cancer promoting abilities [38]. 
About ten years passed before the true identity of p53 as a tumor suppressor gene 
product was revealed [39]. Since then, TP53 has proven essential in human cancer 
prevention and been the target of extensive studies, resulting in fame and bynames 
like “the Guardian of the Genome” in the field of cancer genetics [40].  
Somatic TP53 mutations are reported in approximately 50% of all human 
cancers, although the mutation frequency varies between different cancer types. This 
makes TP53 the most frequent altered gene in cancer, reflecting the cancer preventive 
importance of this tumor suppressor. Inherited TP53 mutations confirm the tumor 
suppressive significance as the underlying cause of Li-Fraumeni Syndrome (LFS), a 
hereditary disorder predisposing to several types of early-onset cancers [41].  
 
1.3.1. Activation of TP53 and cellular responses 
The p53 transcription factor regulates various cellular mechanisms by binding its core 
domain to specific p53-response elements in its myriad of target genes. p53-activation 
is a cellular stress response where multiple stimuli like oncogenic activity, hypoxia, 
nucleotide depletion and DNA damage (figure 6) leads to nuclear p53 accumulation 
and transcriptional transactivation of p53 target genes [40, 42]. Active wild type (wt) 
TP53 promotes tumor suppressive actions by regulating normal cellular growth and 
survival by inducing cell cycle arrest, DNA repair, replicative senescence and/or 
apoptosis in stressed or damaged cells to prevent the rise of abnormal clones [42, 43].  
The p53 pathway involves hundreds of genes dedicated to the work of 
genomic integrity maintenance. Intrinsic and extrinsic stress stimuli are the input  
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Figure 6: A simplified scheme of the p53 pathway. MDM2 is the main p53 regulator maintaining 
constantly low p53 levels under normal conditions. Various stress stimuli activate p53 which mediates 
downstream effects by transactivation of target genes and protein-protein interactions. Severe cellular 
stress results in irreversible senescence or apoptosis, while milder stress stimuli induce transient cell 
cycle arrest and repair mechanisms [40]. 
 
signals to pathway activation, and upstream p53-mediators sense and transduce these 
signals to initiate a functional p53 response. In non-stressed cells, p53-levels are 
almost undetectable due to very short p53 half-life. This is due to p53-inactivation by 
the main p53-regulator MDM2, an E3 ubiquitin ligase mediating polyubiquitylation 
and protosomal degradation of p53. MDM2 also inhibits the biochemical activity of 
p53 by sterical blocking the p53 transactivation domains necessary in transcription 
initiation. In presence of cellular stress stimuli, the p53-mediators activate and 
stabilize p53 by post-translational modifications simultaneously as the p53-repressive 
activity of MDM2 is inhibited. Depending on the initiating stress stimuli, specific 
target genes are transcriptional transactivated. The synthesized gene products fulfill 
the cellular p53-mediated responses by inducing a reversible cell cycle arrest if the 
damage is repairable, or an irreversible senescence or apoptosis in the case of more 
severe damages [40, 42].  
 
1.3.2. TP53 mutations in breast cancer 
The TP53 mutation frequency is in breast cancer estimated to 20–40%, indicating that 
inactivation of TP53 is an important step in breast cancer development [44]. Mutated 
TP53 loses its antiproliferative properties and contributes to tumorgenesis by impaired 
cell cycle control [40]. In cancers generally, TP53 mutations are primarily missense 
mutations located in the DNA binding domain, even though tumor suppressor genes 
most commonly are inactivated by frameshift or nonsense mutations. In breast cancer, 
TP53 mutations occur most frequently in advanced stages and in breast cancer 
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subtypes of more aggressive behavior, like the ERBB2-positive and basal-like tumors 
[41]. 
 The discovery of inherited TP53 mutations as the underlying cause of LFS 
was a significant clue associating TP53 to breast cancer development. LFS patients 
are predisposed to several types of cancer, where breast cancer occurs as the most 
frequent [41, 44]. TP53 mutations are believed to be an early event in breast cancer 
development, since mutations (frequencies ranging from 0–40%) are observed already 
at DCIS stages of the disease. In addition to advanced stages and aggressive subtypes, 
younger patients and patients with inherited BRCA1 and BRCA2 mutations also show 
increased somatic TP53 mutation rates [44]. The association between TP53 
polymorphisms and breast cancer risk has also been investigated. A significant 
association has been reported in the most common TP53 SNP, an Arg/Pro 
polymorphism (rs1042522) in codon 72, exon 4, but the results remain inconclusive 
[45, 46]. 
 
1.3.3. TP53 as a prognostic and predictive marker in breast cancer 
A large number of studies have investigated the association of somatic genetic 
alterations in TP53 to the therapeutic prediction and prognosis in breast cancer [44].  
A predictive factor is a marker associated with the prediction of treatment-specific 
responses, while a prognostic factor is a marker associated with clinical outcome, 
such as overall and disease-free survival, at the time of diagnosis if the disease is left 
untreated [23]. 
 In 1999, Pharoah et al. published a meta-analysis concerning the prognostic 
value of TP53 in breast cancer. 16 studies with over 3500 patients were included, and 
despite contradictory results, most studies correlated TP53 mutations to a significantly 
poorer prognosis compared to wt TP53 breast cancer cases. TP53 was in several of 
these studies also identified as an independent prognostic marker [47]. Comparable 
results were published by Olivier et al. in 2006, where 18 out of 20 studies identified 
mutated TP53 as a marker of poor prognosis in breast cancer [48]. Any inconsistency 
in these studies may have been caused by a possible publication bias where non-
significant findings were left unpublished, or by methodological differences [47]. 
TP53 mutations have primarily been detected by immunohistochemistry (IHC) 
and DNA sequencing. Mutated TP53 often results in an inactive, but stable protein 
accumulating in the nucleus of the tumor cells. By the use of antibodies, these 
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mutations are detectable by IHC. Mutations resulting in unstable or truncated p53 
proteins are on the other hand not detectable, and nuclear wt p53 accumulation in 
response to cellular stress may be a source to false positive results using this method. 
DNA sequencing identifies TP53 mutations with a greater specificity and sensitivity 
than IHC. Still, an underestimate probably exist because most studies only sequenced 
the conserved DNA binding domain (exon 5-8), while nearly 10% of the mutations 
are found outside this area. DNA sequencing shows a stronger association between 
TP53 mutations and breast cancer prognosis than what is attainable with IHC [44, 47]. 
This could be of clinical value by using TP53 status in the process towards more 
individualized treatment of breast cancer patients [48].  
The predictive value of TP53 in breast cancer is less clear than the prognostic 
implication. The TP53 antiproliferative abilities of cell cycle control, DNA repair and 
apoptosis have led to several studies investigating the possibility of TP53 mutations as 
therapy response predictors by the use of DNA-damaging agents like chemotherapy 
and radiation [44]. The results from these studies are conflicting, but indicate that 
TP53 mutations are associated to poor treatment responses [44, 49], and imply that a 
functional p53 pathway is required to induce drug-mediated cell cycle arrest or 
apoptosis [48]. Publications by Takahashi et al. (2008) and Miller et al. (2005) present 
TP53 mutation status alone as a weak predictor, and that the expression profile of a 
gene set reflecting the TP53 mutation status signature is a more accurate predictive 
tool to estimate breast cancer outcome. The Takahashi and Miller publications present 
two different gene sets (genes significant differentially expressed in mutant and wt 
TP53 breast cancer cases) of 33 and 32 genes, respectively. Unexpectedly, the gene 
sets do not overlap, but both show a stronger association to specific therapy response 
predictions and clinical outcome than TP53 status alone [49, 50].  
 
1.4. WRAP53 – WD repeat containing, antisense to TP53  
1.4.1. Gene nomenclature and discovery 
WRAP53 is the abbreviated form of WD repeat containing, antisense to TP53, which 
is the official gene name approved by the HUGO Gene Nomenclature Committee. 
The nomenclature is derived from the antisense and protein coding characteristics of 
the gene [1], and the gene products structural homology to members in the WD40 
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protein family [2]. The WRAP53 characteristics were discovered by three different 
research groups, and the findings were published almost concurrently in the beginning 
of 2009. 
WRAP53 as an antisense gene to TP53 and a p53-regulatory transcript was 
discovered by Mahmoudi and colleagues at Cancer Centrum Karolinska (CCK),  
Karolinska Institutet [1]. Venteicher and colleagues at Stanford University identified 
the WRAP53 protein as a telomerase subunit, and proved at the same time its 
involvement in telomerase trafficking to the Cajal bodies
2
 (CBs) and telomere 
synthesis [2]. Tycowski and colleagues at Yale University followed by identifying the 
WRAP53 protein as a protein promoting transport of a specific subgroup of small 
nuclear RNAs (snRNAs) to the CBs [51]. Since the gene discoveries, several different 
gene names have been in use (TCAB1 / WDR79 / FLJ10385 / DKCB3), but the gene 
will in this thesis be referred to as WRAP53.  
 
1.4.2. WRAP53 – a cis-antisense transcript to TP53 
WRAP53 is located on the short arm of chromosome 17 (17p13.1), on the opposite 
DNA strand and upstream of TP53. Mahmoudi and colleagues at CCK cloned the 
WRAP53 gene, and identified three different non-coding start exons and at least 17 
alternatively spliced transcript variants (figure 7). The start exons were named 1α, 
1β and 1γ, each contributing to different gene isoforms, which from here will be 
referred to as WRAP53α, WRAP53β and WRAP53γ [1].  
The chromosomal location of WRAP53 results in a direct overlap between 
exon 1α in the WRAP53α isoform and the first exon in TP53 [1, 52]. The genes 
overlap in a head-to-head fashion (5' to 5') by up to 227 base pairs (bp), depending on 
the WRAP53 and TP53 transcription start sites that might vary between different 
transcripts (figure 8). The overlap between the WRAP53γ isoform and TP53 will only 
give overlap between precursor mRNAs, not the mature transcripts. The WRAP53β 
transcription start site (i.e. exon 1β) is located downstream of WRAP53 exon 1α and 
lack p53 complementarity. The TP53 overlapping parts of WRAP53α will on the other 
hand give transcripts with perfect complementarity, somewhat makes WRAP53 a 
natural antisense transcript (NAT) of TP53 [1].  
                                                          
2
 CBs are membraneless organelles found in the nucleus of plant and animal cells involved in several 
functions like RNA modifications, assembly and maturation of ribonucleoproteins (RNPs) and 
telomere synthesis [61]. 
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Figure 7: WRAP53 splice variants.  
Yellow bars equal WRAP53 translated regions while red bars equal untranslated regions. Start (ATG) 
and stop (TAA) codons for full length WRAP53 protein is written in bold, while alternative start 
codons are indicated as well. Dash lined bars equal introns included in the mature transcript [53]. 
 
 
 
Figure 8: Organization of the WRAP53 gene and the overlapping regions of WRAP53 and TP53. 
Yellow bars equal WRAP53 translated regions while red bars equal untranslated regions. The start 
(ATG) and stop (TAA) codon indicate the WRAP53 coding region. The WRAP53α major transcription 
start site is indicated in the figure, but additional upstream sites exist. WRAP53β and WRAP53γ are 
initiated from separate transcription sites [1]. 
 
 
NATs are a group of regulatory single stranded RNAs generated through 
antisense transcription, a mechanism promoting transcription from the opposite strand 
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of a protein-coding sense strand. Bidirectional transcription like this makes NATs 
display transcript complementarity to their corresponding sense mRNA transcripts, 
affecting mRNA stability, transport and/or translation by transcriptional and post-
transcriptional mechanisms [54, 55]. NATs were first described as gene regulatory 
elements in bacteria, but antisense transcription is now also known as a widespread 
phenomenon in eukaryote genomes, influencing eukaryote gene expression [56]. 
Differences in functional properties categorizes NATs into two main groups; 
(i) trans-encoded antisense RNAs transcribed from separate, non-overlapping loci 
sharing complementary sequences, and (ii) cis-encoded antisense RNAs transcribed 
from overlapping loci on opposite DNA-strands [55]. Hybridization of sense and 
antisense transcripts generates sense-antisense pairs (SAPs), but SAPs formed by 
trans-encoded NATs will because of the non-overlapping loci just show partial 
complementarity due to interruption by multiple mismatching base pairs. This give 
trans-encoded NATs the ability to base pair with and regulate the expression of 
several different sense transcripts, somewhat is the case in microRNA regulation. On 
the other hand, cis-encoded NATs base pairs perfectly with their sense transcripts, 
resulting in unique relationships to their sense counterparts [56]. WRAP53 belongs to 
the group of cis-encoded NATs, regulating the expression of its overlapping gene 
TP53 [1]. 
The presence of NATs has been known since their discovery in 1981, but their 
functional significance has remained obscure. Antisense regulation is largely 
presumed to depend on complementary base pairing, but a model presented by 
Munroe and Zhu in 2006 propose five different (Class I-V) antisense regulation 
mechanisms. Class I, II and III are transcriptional regulation models where the sense 
gene expression may be influenced by (i) the competition or sharing of transcriptional 
factors by overlapping genes, resulting in negative correlation or co-expression 
respectively (Class I), (ii) by bidirectional transcriptional interference due to DNA 
molecule constraints like RNA polymerase collisions (Class II), or (iii) by SAPs 
recruitment of transcriptional promoting or inhibiting factors generating epigenetic 
alterations like DNA-methylations or chromatin remodeling (Class III). The two post-
transcriptional regulatory mechanisms are like Class III carried out by the formation 
of SAPs. In Class IV, RNA duplex formation may mask sense-specific binding sites 
required for expression, preventing the binding of expression promoting factors. In 
Class V, SAPs recruits factors that may influence downstream gene expression. The 
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production of short interfering RNAs (siRNA) from the double stranded SAPs is one 
example, resulting in degradation of corresponding mRNA transcripts and translation 
inhibition [55].  
Even though SAPs are believed to be of great impact in antisense regulation, 
detection of endogenous RNA duplexes in human cells has shown itself difficult. This 
is also the case for WRAP53/p53 duplexes, somewhat indicates that RNA duplexes 
might be transient and/or labile cellular regulatory mechanisms [1]. 
 
1.4.3. Antisense WRAP53-mediated regulation of p53 
Antisense WRAP53 transcription gives rise to RNA transcripts which post-
transcriptionally regulates the cellular levels of p53. The regulatory effect is restricted 
to the WRAP53α isoform, and is achieved by hybridization of the antisense exon 1α in 
WRAP53α mRNA to the sense exon 1 localized in the 5' untranslated region of p53 
mRNA (figure 8). Antisense transcripts are potential regulators of their corresponding 
sense transcripts stability, transport and/or translation, and the antisense WRAP53-
mediated regulation mechanism has shown to be of importance in the cell protective 
p53-responses generated upon exposure to stressful stimuli [1, 52]. 
  Gene expression studies of normal human tissues and cancer cell lines further 
revealed a positively correlated WRAP53α and TP53 expression, although the 
expression of TP53 occur at 100-fold higher levels than WRAP53α. Further cell line 
studies showed that WRAP53α knockdown by siRNA transfection decreased cellular 
p53 RNA levels by 83% and suppressed induction of the p53 protein by DNA 
damage, while WRAP53α overexpression increased p53 RNA levels 3-fold. 
Overexpressed WRAP53α also increased the cellular level of p53-induced apoptosis. 
In the same study, blockage of the WRAP53α/p53 RNA hybridization reduced p53 
RNA levels similar to WRAP53α knockdown, indicating that the WRAP53-mediated 
p53 regulation is sustained through this RNA-RNA interaction. The WRAP53-
regulation of p53 occurs in a non-reciprocal manner, meaning that altered expression 
levels of TP53 do not influence WRAP53 expression [1]. 
The results from these studies strongly indicate that WRAP53 plays a critical 
role in the regulation of p53. It may seem that antisense WRAP53α transcripts are 
essential in maintaining basal levels of p53, but also in the induction of p53-responses 
by stabilizing the p53 mRNA and preventing its degradation upon DNA damage. 
WRAP53α is also able to regulate levels of mutated p53, rising the interesting 
A B 
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question concerning WRAP53 as a new molecular target in treatment of TP53 mutated 
human cancers [1, 52]. 
 
1.4.4. Discovery of the WRAP53 protein (TCAB1)  
In contrast to most regulatory RNAs, WRAP53 encodes a protein. The WRAP53 
protein consists of 548 amino acids and carries six WD40 repeat domains [57] which 
make it homologous to proteins in the WD40 protein family. WRAP53 was recently 
identified as a subunit in the telomerase complex, where it is essential in telomerase 
trafficking to CBs and in telomere synthesis [2, 58]. An alternative protein name used 
is Telomerase Cajal Body protein 1 (TCAB1), which is descriptive of the telomerase- 
associated protein function [57]. 
 Telomerase is a RNP complex catalyzing elongation of the chromosome ends 
by the addition of telomeric repeats (TTAGGG) [19]. Telomerase activity is almost 
absent in most somatic tissues, but is detected in germline cells and in early 
embryonic development to obtain telomere lengths sufficient for life [19, 59]. 
Telomeres protects the genome from losing genetic information during DNA 
replicative chromosome shortening, which is an important key factor in maintaining 
cellular genomic stability. Absence of telomerase activity leads to progressive 
telomere shortening. Critically short telomeres are recognized as double strand DNA 
breaks, and may lead to telomere fusions and cellular replicative senescence or 
apoptosis [59, 60]. Telomere shortening is a tumor suppressive action, reflected in the 
fact that about 90% of human tumors reactivate cellular telomerase activity [18]. 
 The telomerase holoenzyme complex consists of at least three main 
components; (i) the enzymatic subunit telomerase reverse transcriptase (TERT), (ii) 
the telomerase RNA component (TERC) which is the RNA template, and (iii) 
dyskerin, a RNA-binding protein involved in assembly and stability of telomerase and 
other cellular RNPs [58]. The telomerase complex also includes several associated 
proteins necessary to proper in vivo function [60]. The TERC subunit is a non-coding 
snRNA, i.e. small nuclear RNA molecules found in eukaryotic organisms guiding the 
modification of other RNA molecules [61]. Small nucleolar RNAs (snoRNAs) is a 
large subgroup of the snRNAs involved in ribosomal RNA modifications in the 
nucleoli
3
 and splicosomal RNA modifications in the CBs [2, 51]. The snoRNAs are 
                                                          
3
 The nucleoli are membraneless subnuclear organelles involved in ribosomal RNA synthesis, 
processing and assembly [19]. 
22 
 
further divided into two groups based on the presence of one out of two different 
conserved structural motifs; (i) the C/D box snoRNAs which guide methylation, and 
(ii) the H/ACA box snoRNAs which guide pseudouridylation [51]. Dyskerin is able to 
recognize the H/ACA box motif, and is essential in assembly and stability of 
snoRNPs, telomerase included. The mechanism behind the selective transportation of 
snoRNPs to the nucleoli or CBs was for a long time poorly understood, but a possible 
explanation was given in a publication by Venteicher et al. in 2009, where the 
WRAP53 protein was identified as a subunit of the telomerase holoenzyme complex 
[2]. 
 WRAP53 was discovered by the identification of possible new dyskerin-
interacting proteins. In addition, the study showed that WRAP53 was able to interact 
with TERT and TERC, and that telomerase activity depended on the presence of 
WRAP53. These observations indicated that WRAP53 was a part of the enzymatic 
active human telomerase complex. Further studies showed that WRAP53 accumulated 
in the CBs, and that it specifically interacted with a subgroup of snoRNAs that are 
called small Cajal body specific RNAs (scaRNAs) [2]. The scaRNPs are similar to the 
snoRNPs, but more complex because they contains two structural motifs; a 
combination of one C/D box and one H/ACA box, two C/D box motifs or two 
H/ACA box motifs. scaRNAs that contains one or two H/ACA box motifs also 
contain another structural motif called the CAB box. The CAB box is a conserved 
tetranucleotide (UGAG) present in the H/ACA motif, essential for CB localization of 
scaRNAs [51]. Specific binding of WRAP53 to this CAB box is what regulates the 
specific localization to and retention of scaRNAs, including TERC, in the CBs [2, 
51]. 
 
1.4.5. The WRAP53 protein and telomerase activity 
Identification of WRAP53 revealed a protein structural homologous to proteins in the 
WD40 repeat protein family [2]. The WD40 repeat proteins are a large protein family 
abundantly expressed in eukaryotes. The name is derived from the structure of the 
repeated domain which contains a conserved tryptophan (W) and aspartic acid (D) 
dipeptide and expands about 40 amino acids in length. WD40 repeat proteins are 
involved in a diverse range of cellular functions such as transcriptional regulation, cell 
cycle control, apoptosis and signal transduction, but the most common function is 
their implication in protein complex assembly [62]. 
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  The discovery of WRAP53 as a telomerase subunit also revealed that the 
protein is of importance in telomerase trafficking and telomere synthesis. Telomerase 
activity depends on WRAP53-mediated trafficking of TERC to the CBs, and further 
trafficking to the telomeres during the cell cycle S-phase for telomere elongation. This 
specific trafficking is mediated by the interaction between WRAP53 and the TERC 
CAB box domain. WRAP53 depletion prevents TERC from localizing to the CBs [2], 
but active complexes containing TERT, TERC and dyskerin can still be created. The 
effect of WRAP53 depletion is observed as reduced amounts of TERC localized in 
the CB and by the telomeres. This indicates that reduced WRAP53 levels repress 
telomerase functionality, and that WRAP53-mediated CB localization is essential to 
telomere maintenance [2, 58].  Discoveries by Mahmoudi and colleagues show that 
the WRAP53 protein mainly is generated from the WRAP53β isoforms [3], and that 
the protein is essential in CB formation. WRAP53 knockdown makes existing CBs 
collapse, and prevents new formation. CBs are not vital cellular organelles, but their 
absence probably reduce the efficiency of CB-mediated processes [63]. 
 CAB box mutations are other elements influencing CB-specific trafficking of 
scaRNAs, including TERC. CAB box mutated scaRNAs are not able to bind to 
WRAP53, and mislocalize to the nucleoli [51]. In the same way as WRAP53 
depletion, CAB box mutations inhibit telomere synthesis and leads to progressive 
telomere shortening [2, 51]. The fact that telomerase activity distinguishes cancer 
cells from normal somatic cells, has for a long time kept telomerase as a promising 
therapeutic target in cancer therapy. Unfortunately, the development of drugs 
targeting the enzymatic core of telomerase has been difficult. The discovery of 
WRAP53 may now open to new therapeutic strategies, as dysfunctional WRAP53 
results in telomere shortening [58]. 
 
1.4.6. WRAP53 in cancer  
Several studies imply that WRAP53 may be involved in tumor promoting actions 
because of its impact on p53-regulation and telomerase activity, both cellular 
functions altered in tumorgenesis. 
Discoveries by Mahmoudi and colleagues indicate that WRAP53 might have 
oncogenic properties and be involved in cellular transformation. This statement is 
based on the observation of elevated WRAP53 expression levels in cancer cells 
compared to immortalized and normal cells. Overexpressed WRAP53 promoted 
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anchorage-independent colony growth, which is a cancer cell characteristic. WRAP53 
knockdown in cancer cells by siRNA treatment induced massive apoptosis through 
the mitochondrial-mediated pathway, but the same did not occur in non-transformed 
cells. This imply that cancer cells are more sensitive to depleted WRAP53 levels, and 
that cancer cells depend on WRAP53 expression to survive, somewhat strengthens the 
WRAP53 oncogene hypothesis [3]. The same study also generated results indicating 
that WRAP53 may be of prognostic value in primary head and neck cancer. WRAP53 
overexpression in cell lines obtained from primary head and neck tumors correlated to 
poor patient outcome, while lower expression levels correlated to a more beneficial 
outcome. This was further confirmed by the observation that increased WRAP53 
expression levels associated to decreased sensitivity to radiation therapy, a common 
therapeutic strategy used in head and neck cancer [3]. 
Dysfunctional WRAP53 protein disrupts telomerase trafficking and is one of 
several underlying causes of Dyskeratosis congenita (DC). DC is an inherited 
syndrome where telomere shortening and reduced stem and progenitor cell function 
results in defective tissue maintenance, bone marrow failure and cancer 
predisposition. Zhoung et al. identified four different missense WRAP53 mutations 
located in various exons in two out of nine unrelated DC patients. Absence of these 
genetic alterations in control subjects declined the findings as common 
polymorphisms. Compared to wt WRAP53 patients, reduced WRAP53 expression and 
impaired CB-specific accumulation were observed in the mutated patients, indicating 
mutation-mediated protein deficiency and possible novel cancer susceptibility factors 
in DC patients [64]. 
 Specific genetic alterations in WRAP53 are also related to increased cancer risks. 
Studies show that two linkage disequilibrium
4
 (LD) SNPs, an Arg/Gly polymorphism 
in codon 68 (rs2287499), exon 2, and a Phe/Phe polymorphism in codon 150 
(rs2287498), exon 3, is significantly associated with an increased risk of ER negative 
breast cancers [65]. The rs2287498 polymorphism is as well associated with an 
increased risk of invasive ovarian cancer [66].  
 
                                                          
4
 LD is a non-random association of alleles at separated but linked loci. LD loci lie so close that they 
are not segregated by recombinations and because of this inherited together as a package [19].  
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1.5. Aims of the study 
The WRAP53 gene was identified as an antisense transcript to TP53 and its regulatory 
effect has proven essential in the initiation of p53 pathway responses. WRAP53 
depletion is discovered as a pro-apoptotic factor in cancerous cells, and its gene 
product as a subunit in the telomerase holoenzyme complex. Despite limited 
knowledge about WRAP53 functionality, the gene is proposed to be involved in 
carcinogenesis. The p53 pathway and telomerase activity are cellular mechanisms 
frequently altered in cancer cells by inactivation and upregulation respectively, and 
WRAP53 expression seems to be necessary both to p53 and telomerase function [1-3]. 
Impairment in such cellular key mechanisms by genetic alterations in WRAP53 might 
be a contributor to cancer development. The overall aim in this thesis is to study the 
importance of and increase the knowledge about WRAP53 in breast cancer. 
 
The intermediate aims in this study are; 
i) To perform a WRAP53 mutation analysis on DNA from primary breast carcinomas 
searching for somatic genetic alterations that might be associated with development 
and progression of breast cancer. Such findings may contribute to the understanding 
of a new predictive and/or prognostic marker in breast cancer. Prior to the mutation 
analysis a new DNA sequencing method was introduced as a sub-aim of this study.  
 
ii) To perform gene expression studies in WRAP53 depleted breast cancer cell lines.  
This functional study may increase the knowledge about genes regulated by WRAP53, 
directly or indirectly. Such knowledge may contribute to better understanding of the 
cellular signaling pathways and networks WRAP53 is involved in, and potentially to 
the identification of novel therapeutic targets in breast cancer therapy.  
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2. Materials 
2.1. Ethical considerations 
Medical research projects using human biological samples and personal clinical data 
are imposed to follow valid ethical guidelines. In the current study, this is covered by 
approval of the Regional Committees for Medical Research Ethics and by written 
informed consent obtained from the patients prior to the study. All samples and 
clinical data were de-identified, and national and institutional guidelines considering 
biobanking are followed.  
 
2.2. Patient Materials  
The patient materials used in this study is a series of 212 primary breast cancer cases 
sequentially collected at Ullevål University Hospital from 1990–1994 (from here 
referred to as ULL-samples). The mean age of the patients was 64,4 years (ranging 
from 28,2–91,5 years), and all patients were treated in accordance with Norwegian 
national guidelines at the time of diagnosis [34]. The Ullevål cohort also contains 
blood samples from 119 of the patients collected from 1994–1996. Time range from 
diagnosis to blood collection varied from 0–6 years [65]. Clinical patient information 
was last updated in 2006, resulting in an observation time from 12–16 years [34]. 
Tissue from the primary breast tumors were snap frozen and stored at  
–80°C. DNA was isolated from both tumor tissue and peripheral leukocytes using a 
standardized method of phenol-chloroform extraction and ethanol precipitation 
(Model 340A Nucleic Acid Extractor, Applied Biosystems) [34]. 
In this study, genomic DNA from 175 ULL tumor samples was included in the 
WRAP53 mutation analysis to search for genetic alterations that might be associated 
to breast cancer. DNA from blood samples available were used to distinguish between 
the findings of germline and somatic origin. Sample excluding criterions were 
inadequate sample volumes and low DNA concentrations (< 5 ng/µL DNA quantified 
by the NanoDrop
®
 ND-1000 Spectrophotometer, Saveen Werner).  
 
 
 
27 
 
2.3. Cell lines 
Breast cancer cell lines are extensively used to investigate breast cancer biology, 
pathology and therapy responses [67]. Among all commercial cell lines available, 
MCF-7 and MDA-MB-231 are the most commonly used in breast cancer research 
[68]. These were also the cell lines used in the WRAP53 knockdown and gene 
expression study, chosen because they represent two main types of breast cancer. 
MCF-7 is a human breast adenocarcinoma cell line derived by the Michigan 
Cancer Foundation (from where the name is derived) in 1973 [68]. The cell line is 
established from a pleural effusion obtained from a 69 years old female Caucasian. 
MCF-7 has preserved several differentiated mammary epithelium characteristics, and 
is because of this useful in breast cancer studies [69]. The MCF-7 cell line is ER 
positive, progesterone receptor (PR) positive, HER2 negative, wt TP53 and subtyped 
as luminal [67]. The MCF-7 cell line was obtained from Interlab Cell Line Collection, 
Genova, Italy. 
MDA-MB-231 is a human breast adenocarcinoma cell line derived by the  
M. D. Andersons Hospital and Tumor Institute, Texas, in 1973 [70]. The cell line is 
established from a pleural effusion obtained from a 51 years old female Caucasian 
[70, 71]. MDA-MB-231 is ER negative, PR negative and HER2 negative (also known 
as triple negative breast cancer). It harbors a TP53 mutation (Arg>Lys in codon 280, 
exon 8 [72]) and is subtyped as basal-like [67]. The MDA-MB-231 cell line was 
obtained from American Type Culture Collection, Manassas, Virginia, USA. 
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3. Methods 
3.1. Patient sample preparation 
The WRAP53 mutation analysis was performed on genomic DNA isolated from the 
sample series collected at Ullevål University Hospital from 1990–1996 (chapter 2.2).  
 
3.1.1. DNA isolation 
DNA was previously isolated from the ULL tumor (ULL-T) and blood (ULL-B) 
samples by a phenol-chloroform extraction method followed by an ethanol 
precipitation using the Model 340A Nucleic Acid Extractor (Applied Biosystems) 
[34]. Phenol-chloroform extraction is a liquid-liquid extraction method based on 
sample component separation between an aqueous and an organic phase, and the 
method is commonly used to purify nucleic acids from complex biological samples 
[73]. 
 To isolate the DNA, samples were mixed with a preheated solution of Lysis 
Buffer and Proteinase K to heat-inactivate endogenous nucleases. The Lysis Buffer 
contained a chaotropic agent (urea) and an anionic surfactant (n-lauroyl sarcosine), 
lysing the cells and denaturizing nucleases and proteins. The proteins were further 
degraded by Proteinase K, and a chelating buffer agent, cyclohexaminediamine 
tetraacetic acid, restrained DNase activity by binding the enzymatic cofactors of 
divalent cations. 
 The separation phase was induced by the addition of phenol-chloroform reagent 
(50/50 v/v) to the lysate. Nucleic acids were restrained in the upper aqueous phase, 
while peptides were extracted to the lower organic phase and disposed to waste. 
Depending on the protein concentration in the sample, the phenol-chloroform step 
could be repeated to increase the nucleic acid purity. 
 Addition of 95% ethanol to the sample gave precipitation of the DNA. By pre-
adding sodium acetate, sodium bound to the DNA phosphate groups and eased the 
DNA precipitation. Precipitated DNA was transferred to a sample tube and dissolved 
in Trizma
®
 base/Ethylenediaminetetra-acetic acid (EDTA)-buffer. The chelating 
abilities of EDTA inhibited DNase activity by binding divalent cations [74]. The 
isolated DNA was stored at 4°C.  
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3.1.2. DNA quantification  
The DNA concentrations of the patient samples analyzed in this study was quantified 
using a NanoDrop
®
 ND-1000 Spectrophotometer (protocol in Appendix A). 
NanoDrop
®
 ND-1000 is a cuvette free spectrophotometer preforming absorbance 
measurements in the 220–750 nm spectrum using a sample volume of 1,0 µl. Two 
fiber optic cables in contact with the sample and a xenon lamp light source 
accomplish the sample measurement, and the transmitted light intensity is detected. 
The NanoDrop
®
 ND-1000 Spectrophotometer accurately measures the concentration 
of double stranded DNA (dsDNA) up to 3700 ng/µl without dilution [75].   
 Nucleic acids absorb electromagnetic radiation at the wavelength of 260 nm, and 
therefore the absorbance measurements do not distinguish between the different types 
of nucleic acids (RNA, single stranded DNA or dsDNA), or other compounds that 
absorb the same wavelength. DNA purity is determined using a ratio of sample 
absorbance measured at 260 and 280 nm (260/280 ratio). A ratio ~1,8 indicates pure 
DNA solution, while ratios < 1,8 indicate presence of contaminants like proteins, 
phenols or other compounds that absorb 280 nm [75]. High DNA purity is not a 
requirement in the polymerase chain reaction (PCR), but the presence of contaminants 
may inhibit the DNA polymerase and influence the PCR efficiency [19]. 
 The measured DNA concentrations were used in calculations to make PCR 
sample dilutions containing 5 ng/µl DNA. The samples were diluted in DNase/RNase 
free water (GIBCO, Ref 10977-35). 
 
 
3.2. Introducing the BigDye
®
 Direct Cycle Sequencing Kit Method  
Prior to the WRAP53 mutation analysis (described beneath) a new DNA sequencing 
method was introduced at the Department of Genetics, and the testing and 
adjustments of the method was a subtask of the work presented in this thesis. The 
existing method used the BigDye
®
 Terminator v1.1 Cycle Sequencing Kit (Applied 
Biosystems), but an improved version, the BigDye
®
 Direct Cycle Sequencing Kit 
(Applied Biosystems) was recently launched in the market. The BigDye
®
 Direct 
Cycle Sequencing Kit promotes a faster workflow with fewer steps and read lengths 
starting as close as one base from the primer. Both kits use universal M13 sequencing 
primers, requiring M13-modified PCR primers in the PCR amplification step. 
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 The workflow of both methods involves DNA template preparation, PCR, 
agarose gel electrophoresis (optional), PCR product purification, cycle sequencing, 
sequencing product purification and capillary electrophoresis. The main differences 
are the steps of PCR and sequencing product purification. The BigDye
®
 Terminator 
v1.1 Cycle Sequencing Kit requires separate steps of vacuum based filtration to purify 
the PCR products, and a Sephadex
™
 gel filtration method to purify the dye terminator 
sequencing products prior to electrophoresis [76]. In the BigDye
®
 Direct Cycle 
Sequencing Kit, the PCR product purification step is combined with the cycle 
sequencing reaction. The BigDye
®
 Direct Sequencing Master Mix contains reagents 
to perform both cycle sequencing and PCR product purification. Unincorporated PCR 
primers are degraded, while the M13 sequencing primers are protected from this 
treatment, resulting in optimal cycle sequencing conditions. The purification of the 
dye terminator sequencing products are accomplished by adding a bead-based 
purification solution directly to the samples using the BigDye
®
 XTerminator
™ 
Purification Kit (Applied Biosystems) [77].  
  The DNA sequencing methods procedures and sequence quality was 
compared sequencing TP53, a gene frequently analyzed at the Department of 
Genetics, giving a proper basis of comparison. Reduced work load, improved 
sequence quality and acceptable cost levels were the foundation for introducing the 
BigDye
®
 Direct Cycle Sequencing Kit as the new standard sequencing method at the 
Department.  
 
 
3.3. WRAP53 mutation analysis  
The WRAP53 mutation analysis was performed using the Sanger sequencing method. 
All ten coding exons and start exon 1β was sequenced in the search for genetic 
alterations. The reason for not sequencing the other two WRAP53 start exons, 1α and 
1γ, is because β-transcripts occur more abundantly in cells than α- and γ-transcripts, 
and that WRAP53 proteins primarily are synthesized from the β-isoforms [78]. 
Genetic alterations in the β-transcripts might because of this be of greater importance, 
especially when it comes to protein function, than the two other transcript isoforms. 
The DNA sequencing was performed using the Applied Biosystems 3730 DNA 
Analyzer in accordance to the supplier’s instrument protocol [79]. All the exons were 
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sequenced in both directions based on independent PCR amplifications generated 
prior to the forward and reverse cycle sequencing reactions, in order to obtain high-
quality sequencing data.  
  The BigDye
®
 Direct Cycle Sequencing Kit procedure (protocol in Appendix 
B) consists of six main steps. The first step is a PCR amplification followed by an 
agarose gel electrophoresis as a PCR quality control. The Sanger sequencing reaction 
generates the sequencing products which are further purified prior to capillary 
electrophoresis. The last step is SecScape software (v2.7, Applied Biosystems) data 
analysis and interpretation.  
 
3.3.1. Polymerase chain reaction  
PCR is an in vitro DNA cloning method that selectively amplifies target DNA 
sequences by the use of specific primers. In a cyclic process of DNA denaturation, 
primer annealing and extension, the selected DNA sequence amplifies exponentially. 
PCR is an extremely robust, but also very sensitive method [19], which highlights the 
importance of including negative controls without target sequences to monitor the 
possible occurrence of interfering contaminants.  
 Altogether, thirteen WRAP53 primer pairs (Eurogentec) were used to amplify 
the ten WRAP53 coding exons and start exon 1β using PCR. The WRAP53-specific 
localization of the primers were controlled before they were designed as described in 
the supplemental material of the article “Disruption of telomerase trafficking by 
TCAB1 mutation causes dyskeratosis congenita” (Zhoung et al. 2011) [64] (table 1). 
The primers were modified with a universal M13 sequence at the 5' end; 
M13 forward primer sequence: 5' -TGTAAAACGACGGCCAGT-3' 
M13 reverse primer sequence: 5' -CAGGAAACAGCTATGACC-3' 
 The WRAP53 primers specificity was tested prior to the mutation analysis by 
PCR amplification and agarose gel electrophoretic separation of the WRAP53 exons 
of current interest. The test was performed on MDA-MB-231 isolated genomic DNA 
using the BigDye
® 
Direct Cycle Sequencing Kit (Applied Biosystems).  
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3.3.2. Agarose gel electrophoresis 
The PCR specificity and PCR product quality was qualitatively controlled by agarose 
gel (1,5% agarose, recipe in Appendix F) electrophoresis. Electrophoresis is a method 
separating charged molecules in an electric field, forcing the negatively charged DNA 
molecules to migrate towards the positive electrode. Because of the negatively 
charged phosphate groups, DNA molecules have the same netto charge per unit 
length, making DNA fragment size the factor of separation. In a polymerized agarose 
gel, small molecules migrates faster and longer than the larger ones, and the use of a 
DNA-ladder (φX 174-Hae III digest, TaKaRa) makes it possible to estimate the 
fragment sizes [19].  
The results from the electrophoresis were visualized by GelRed
™
 nucleic acid 
staining (GelRed
™
 Nucleic Acid Gel Stain, Biotium) and ultraviolet (UV) gel 
irradiation. GelRed
™ 
is a fluorescent dye binding nucleic acids through intercalations 
and electrostatic interactions. UV irradiation excites the dye molecules which 
subsequently emit the excess energy as visible fluorescent light [80]. The results were 
developed using the GeneGenius Bio Imaging System (Syngene) and GeneSnap 
Software (v7.01.07, Syngene).  
 
3.3.3. Sanger sequencing method 
DNA sequencing is a term including all methods used to determine the order of the 
nitrogen bases in the DNA molecule. Sanger sequencing (also known as the dideoxy 
sequencing or chain termination method) is a frequently used method, and is in many 
Exon Forward primer (5') 
Tm 
(°C) 
Reverse primer (3') 
Tm 
(°C) 
PCR fragment 
lenght (bp) 
2A 
(exon 1β) 
GGGAACGGGAAACCTTCTAA 62,6 GACAGCAGTCCGGAGCTAAC 64,8 371 
2B CTAATCTCCGCTGTGCTTCC 63,7 TCTTCTGCAGGAAGGCTTGT 62,6 350 
2C GGGACCCAGTTTCTCTCTCC 64,8 CTGGAGAAGTGGGTCTCAGG 64,8 311 
3 GTGGAGTCTGGGGAGATGAA 63,7 GGGCATCCCTCTCCTAGAAA 63,7 304 
4 CAGCCCTAGCCCTACACTTG 64,8 TGCTGCCACAAGAAATTCAC 61,6 414 
5 TCTGAGCTCACCCTTGAACA 62,6 CTGACCAGCCCCTCTGATAA 63,7 357 
6 ACACCCAGCCTCATTTTTGT 61,6 GGAAGGAAAGGGCTGAAAAC 62,6 392 
7 TCATATCTGGGACGCATTCA 61,6 GTACAGAGGACGGCGTGAAC 64,8 411 
8A GCTTGTGACAGACAGCATGG 63,7 TCTCAGGGTGTGACCCCTAC 64,8 363 
8B TCTGTATGCCTGGGATGATG 62,6 ATTGGTGGTCACCTCTCGAC 63,7 383 
9 CTGAAGGAGTGCCTGGAGAC 64,8 ACCCTACAGCTGGGCTCTG 64,9 259 
10 CCTCTGCCAGCAAATCTCTC 63,7 TCTCTGTGGGCTCAGGAAAC 63,7 351 
11 AGAGGGAGCAAGTGTCCTCA 63,7 GCCTGGTTTCAGGACCAATA 62,6 436 
Table 1: WRAP53 primers used in the PCR amplification step of the mutation analysis 
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research communities considered as the golden standard sequencing method. Even 
though next generation sequencing has occurred as a revolutionizing tool in cancer 
genome characterization, Sanger sequencing is still commonly used in small-scale 
experiments. The method is as well used to confirm sequence alterations and 
complete fragments difficultly sequenced by massively parallel sequencing 
approaches. Sanger sequencing is based on enzymatic DNA synthesis and random 
inhibition of the growing chains, creating premature terminated transcript of various 
lengths. Transcript elongation in DNA synthesis depends on free hydroxyl groups at 
the deoxynucleotide triphosphate (dNTP) 3' carbon and formation of phosphodiester 
bonds. The premature termination in Sanger sequencing is induced by the presence of 
base-specific dideoxynucleotide triphosphates (ddNTPs), analogues to the dNTPs 
where the 3' carbon hydroxyl groups are replaced by hydrogen atoms. The hydrogen 
atoms inhibit the formation of phosphodiester bonds and terminates the DNA 
synthesis [19].  
 In Sanger sequencing, the ddNTPs terminates the DNA fragment sequenced in 
every single base position occupied by corresponding dNTPs. Fluorescent labeling of 
the ddNTPs by dye molecules with different emission spectra makes it possible to 
determine the base terminating each fragment (figure 9A), and in combination with 
the fragment lengths determine the order and position of the bases in the DNA 
molecule [19]. 
 
3.3.4. Sequencing product purification: BigDye
®
 XTerminator
™
 Purification Kit 
Purification of sequencing reaction products is a necessary step to ensure high quality 
capillary electrophoresis sequencing results. The purification step removes excess 
components like unincorporated fluorescent tagged ddNTPs and salts that might 
interfere with the results. The BigDye
®
 XTerminator
™
 Purification Kit (Applied 
Biosystems) is a bead-based purification method that captures and immobilizes the 
unwanted components by vortexing the reaction plate. Centrifugation of the vortexed 
plate sediments the insoluble fraction of beads and captured components, creating a 
supernatant of purified dye-labeled sequencing products that directly can be injected 
in the capillary electrophoresis instrument for analysis [81].  
 The BigDye
®
 XTerminator
™
 Purification Kit consists of two different 
solutions; (i) the bead-containing XTerminator
™
 Solution that captures the excess 
ddNTPs and salts, and (ii) the SAM
™
 Solution that enhances the performance of the 
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XTerminator
™
 Solution and stabilizes the purified sample. A premix of these 
solutions is added to the samples after the cycle sequencing reaction, and  proper 
vortexing is important to ensure appropriate mixing and purification [81]. 
 
3.3.5. Capillary electrophoresis: Applied Biosystems 3730 DNA Analyzer  
The Applied Biosystems 3730 DNA Analyzer is a capillary-based automated DNA 
sequencer [82]. In capillary electrophoresis, charged molecules are separated inside a 
narrow capillary tube by the influence of an electric field. To separate DNA fragments 
of constant size-to-charge ratio, the capillary is filled with a polymer separating the 
fragments according to size. The samples are electrokinetic injected into the capillary 
end and migrates with size-dependent velocity towards the positive electrode in the 
opposite end of the capillary. Near the positive electrode every capillary displays a 
detection window. The 3730 DNA Analyzer uses a laser-induced fluorescence 
detection method. The signal from the DNA fragments passing the detection window 
is captured as a result of laser irradiation generating a ddNTP base-specific 
fluorescent light. By combining the migration time and the emission spectrum of the 
fluorescent light, the order of the nitrogen bases in the sequenced DNA fragment are 
determined (figure 9A) [82, 83].  
The Applied Biosystems 3730 DNA Analyzer is a 48 capillary instrument 
using POP-7
™
 Performance Optimized Polymer (Applied Biosystems) developed to 
give longer read lengths and shorter run times. Processing of the raw data file displays 
the analyzed sample data as an electropherogram (figure 9B) [82].  
 
 
Figure 9: Fluorescent labeled cycle sequencing dye terminator products with squared terminating 
ddNTPs (A) and sample electropherograms displaying the DNA nitrogen base order by base color-
specific peaks (B) (Applied Biosystems, 2009).  
 
 
3.3.6. SeqScape v2.7 sequencing data analysis 
SeqScape v2.7 is an Applied Biosystems software tool used to analyze and identify 
sample genetic alterations to a consensus sequence. Mutation analysis, SNP discovery 
A B 
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and validation are SeqScape applications [84] used in this study. The sequencing data 
were analyzed in accordance with the National Center for Biotechnology Information 
(NCBI) WRAP53 Reference Sequence NG_028245.1 [85], and comprised start exon 
1β, the entire coding WRAP53 region (exon 2–11) and the intronic sequences of 30 bp 
prior to and following each exon in the case of splice mutations. 
To generate interpretable sample electropherograms, the SeqScape software 
processes the raw data files obtained from the Applied Biosystems 3730 DNA 
Analyzer. Some important and necessary processing steps are (i) the multicomponent 
analysis that filters the four fluorescent dye signals in distinct spectral components to 
avoid spectral overlap interference, (ii) basecalling that adjusts the fluorescent signals 
and assigns one base to each peak, and (iii) the mobility shift correction that rectifies 
changes in the electrophoretic mobility of sequencing products imposed by the 
association with differently labeled ddNTPs [82]. The forward and reverse sample 
sequences are assembled and compared to the consensus sequence [85], and 
deviations from the consensus sequence detected by the software is reported [84].  
 
3.3.7. Statistical and bioinformatics data analyses 
The statistical analyses were performed using IBM SPSS version 19. The results from 
the WRAP53 mutation analysis were investigated according to potential associations 
within the detected genetic alterations, and association of genetic alterations in 
WRAP53 with breast cancer-specific survival and other known clinical patient 
parameters. The Chi-square and Fisher`s exact tests were used when appropriate to 
determine the strength of relation between two categorical variables, like the WRAP53 
genetic alterations and the presence of lymph node metastasis. The Chi-square test is 
not recommended used if 20% or more of the cells have expected observation counts 
less than five. The Fisher`s exact test is then the alternative statistical approach [86]. 
The association between detected WRAP53 genetic alterations and breast cancer 
survival was tested using the Kaplan-Meier survival plot and the Logrank test 
comparing the survival distributions under different conditions. Overall, p-values ≤ 
0,05 were considered statistically significant. Frequency plots were generated using 
Microsoft Excel 2010. 
 The level of genetic linkage in the dataset was investigated using the 
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Haploview software
5
 (v4.2, Broad Institute). Haploview is a bioinformatics tool 
designed to perform LD and haplotype block analyses and to estimate haplotype 
frequencies [87]. Haplotypes are loci on the same chromosomal segment that tends to 
be inherited together as blocks [19]. The level of genetic linkage between loci is 
measured by statistically calculating the genetic distance between the loci, a measure 
based on the expected recombination fraction. Genetically linked loci lie close 
together and do not segregate independently by recombinations, reducing the genetic 
distance and creates haplotype blocks inherited together for generations [19, 73]. The 
likelihood of LD were calculated based on a combination of D' and LOD score values. 
D'=1 is known as complete LD, while D'<1 indicates LD disruption. The LOD score 
compares the likelihood of obtaining the test data if the loci are linked, versus not 
linked. A positive LOD score favors linkage, while linkage is not likely present by 
negative scores [19, 88].  
 Haploview also checks conformance with the Hardy-Weinberg (HW) 
equilibrium due to possible genotype selections. The HW equilibrium states that the 
genetic variation in a population remains constant throughout generations in the 
absence of disturbing factors, and predicts that genotypes and allele frequencies 
remains constant because they are in equilibrium [89].  
The detected WRAP53 sequence alterations were investigated using the 
SNP500Cancer [90] and the NCBI dbSNP [91] databases. The databases contain 
overview of gene-specific SNPs and other minor genetic variations like small 
insertions and deletions, and are frequently used databases in SNP studies.  
 
 
3.4. Gene expression study 
Downregulation of WRAP53 has been suggested to influences the p53 pathway, the 
telomere synthesis and the level of apoptosis [1-3]. WRAP53 may also, directly or 
indirectly, possess other regulatory functions and involvements in cellular pathways, 
roles completely unknown today. The field of WRAP53 research aims for a greater 
understanding of the gene`s function, and in particular knowledge related to cancer 
diseases. An analysis comparing gene expression patterns in WRAP53 normal 
expressing and siRNA-treated WRAP53 depleted cell lines, in the current study 
                                                          
5
 Available from http://www.broadinstitute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/downloads 
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focused on breast cancer, is a relevant approach to reach the goal.  
  The gene expression study was performed in collaboration with Farnebo and 
colleagues at the Department of Oncology-Pathology, CCK, Karolinska Institutet, 
Stockholm. The cell culturing, siRNA transfection and RNA isolation was 
accomplished at CCK, while the gene expression analyses, data processing and 
interpretation of results were performed as a part of the work included in this study. 
 
3.4.1. Cell culturing 
The MCF-7 and MDA-MB-231 cell lines were obtained from the Department of 
Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, and sent to 
CCK in a container of dry ice. 
The MCF-7 and MDA MB 231 cells were maintained in Dulbecco`s Modified 
Eagle Medium (HyClone, Thermo Scientific) supported with 10% fetal bovine serum 
(HyClone, Thermo Scientific) and 2,5 µg/ml placmocine (InvivoGen) at 37°C and 5% 
CO2 humidified incubators. The cells were cultured for two weeks before siRNA 
transfection to ensure that the processes of thawing and new culture establishment not 
influenced the gene expression patterns of the cells. Cell passaging was performed 
twice a week to both cell lines [92].  
 
3.4.2. siRNA transfection  
The highly reduced WRAP53 gene expression levels in MCF-7 and MDA-MB-231 
was induced using a WRAP53 siRNA (Qiagen) targeting exon 2 (siWRAP53#2, 5'- 
AACGGGAGCCTTTCTGAAGAA-3') resulting in WRAP53 knockdown independent 
of the different gene isoforms. siRNAs are short double stranded RNAs of 20–25 base 
pairs in length frequently used in in vitro gene silencing [19]. The transient siRNA 
transfection was accomplished using the HIPerFECT Transfection Reagent (Qiagen) 
[92], a mix of cationic and neutral lipids that promotes siRNA uptake and intracellular 
siRNA release [93].  
The experimental setup included non-treated control (NTC) cells, siRNA 
control (siC) transfected cells, and siWRAP53#2 transfected cells for each cell line at 
two different time points (table 2). The siC used was a negative control siRNA (20 
nmol, Qiagen) consisting of lipids and scrambled siRNA oligos to ensure that the 
transfection procedure itself does not influence the gene expression patterns in the 
cells. Prior to the transfection, 30000 cells/ml (2 ml/well) was seeded in 6 well plates. 
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By 24 hours after the seeding, the cells were siRNA transfected using 10 nM siC or 
10 nM siWRAP53#2 combined with 6,0 µl HIPerFECT per cell culture [92]. RNA 
was harvested from single cultures (NTC cells) and biological triplicates (siC and 
siWRAP53#2 transfected cells, different cultures) 40 and 72 hours after transfection 
in both cell lines.  
 
Table 2: The experimental setup in the gene expression study. RNA was harvested from single cultures 
(NTC cells) and biological triplicates (siC and siWRAP53#2 transfected cells) 40 and 72 hours after 
transfection. 
Cell line Treatment Replicate 
MCF-7 
NTC 1 
siC 
1 
2 
3 
siWRAP53#2 
1 
2 
3 
MDA-MB-231 
NTC 1 
siC 
1 
2 
3 
siWRAP53#2 
1 
2 
3 
 
Lipid-mediated transfection is a method where liposomes, lipid-formed 
vesicles, transfer and release the siRNA to the intracellular environment. Cationic 
lipids, amphiphilic molecules with a cationic hydrophilic headgroup and a 
hydrophobic tail, are most commonly used. In aqueous environments, cationic lipids 
form vesicles with the hydrophilic headgroups on the exterior and the hydrophobic 
tails in the interior. Complexion of liposomes and siRNAs creates lipoplexes able to 
interact with the cell membranes and promote endosomal uptake. Small lipoplexes 
establish an electrostatic interaction between the positively charged lipoplex and the 
negatively charged cell membrane, while the larger lipoplexes are endocytosed via 
clathrin coated pits. To avoid endosomal-lysosomal fusion and siRNA destruction, the 
cationic lipids are often combined with neutral helper-lipids, like cholesterol, which 
destabilizes the endosomal membrane and mediates siRNA escape. Intracellular 
siRNAs are processed by the RNA interference pathway and promotes gene 
knockdown by mRNA degradation and transcription repression [19, 94].  
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3.4.3. RNA isolation and microarray sample preparation 
Total RNA was extracted from the MCF-7 and MDA-MB-231 cell lines using the 
TRIzol
®
 reagent (Invitrogen), a monophasic solution of phenol and guanidine 
isothiocyanate. The TRIzol
®
 RNA isolation method is a guanidine isothiocyanate-
phenol-chloroform liquid-liquid extraction separating RNA from complex biological 
samples, and generates an aqueous phase containing pure, high-quality RNA [95].  
 During sample and TRIzol
®
 homogenization, the cells are lysed. Despite 
cellular disruption and cell component solubilizing, TRIzol
®
 maintains the RNA 
integrity due to high RNase activity inhibition. Adding chloroform to the lysate 
induces component phase separation. RNA is restrained in the aqueous phase, while 
the DNA and proteins are extracted into the organic phase. Isopropanol precipitates 
RNA from the aqueous phase, and the precipitate is then washed to remove impurities 
[95, 96]. The precipitated RNA is further purified using the RNeasy MinElute 
CleanUp Kit (Qiagen) prior to RNA concentration and purity measurements. Pure 
RNA samples displays a 260/280 ratio of ~2,0 and a 260/230 ratio in the range of 1,8–
2,2. Lower ratios may indicate the presence of co-purified impurities [75]. 
 The TRIzol
®
 reagent contains possible hazardous compounds. Phenol is toxic 
and corrosive, while guanidine isothiocyanate is an irritant. Proper handling in a 
closed fume and with appropriate personal safety equipment is recommended [96].  
 The WRAP53 knockdown efficiency in each cell line was verified at protein 
level by Western blot analyses and at mRNA level by real-time quantitative PCR 
(qPCR) (KAPA SYBR
®
 FAST, KAPA Biosystems) [92]. In Western blot analysis, 
proteins are based on size and charge separated by gel electrophoresis, blotted onto a 
membrane and detected using labeled specific antibodies (WRAP53 C2 antibody, 
diluted 1:3000, Innovagen). Housekeeping proteins (here β-actin) and protein-specific 
antibodies (Monoclonal Anti-β-actin antibody produced in mouse, diluted 1:5000, 
Sigma Aldrich
®
) are commonly used as loading controls to ensure proper Western 
blot interpretations.  
qPCR is a PCR-derived method combined with a reverse transcription reaction 
to both quantify and amplify the target sequence and detect gene expression changes. 
Continuous quantification is achieved by the use of a fluorescent reporter molecule 
where the signal intensity is proportional to the amount of amplified product. The 
KAPA SYBR
® 
FAST method uses the non-specific fluorescent dye SYBR Green I. 
Free SYBR Green I in solution emits a restricted fluorescent signal, but bound to 
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dsDNA the signal intensity increases drastically. By monitoring the intensity of the 
fluorescent signals, the gene expression levels are quantified [19]. 
The RNA samples returned from CCK were stored at –80°C. Sample aliquots 
were used to prepare dilutions of 50 ng/µl RNA to use in the microarray experiment. 
DNase/RNase free water was used as dilution agent. The dilution concentrations and 
purity were measured using the NanDrop
®
 ND-1000 Spectrophotometer the same way 
as described in Appendix A, but with the RNA application (RNA-40). The dilutions 
were stored at –80 °C.  
 
3.4.4. Microarray-based gene expression profiling  
The gene expression analyses was performed using the One-Color Microarray-Based 
Gene Expression Analysis and SurePrint G3 Hmn GE 8x60K Microarrays (Agilent 
Technologies, protocol in Appendix C). RNA from the siC and siWRAP53#2 
transfected cell cultures were analyzed in biological triplicates, while RNA from the 
NTC cell cultures were analyzed in technical duplicates only.  
 Gene expression can be quantified measuring the mRNA transcript or protein 
levels by various techniques. DNA microarrays are tools allowing fluorescent labeled 
complementary RNA (cRNA) transcripts to hybridize to gene-specific complementary 
DNA (cDNA) or synthetic oligonucleotide probes, determining the relative expression 
levels of their corresponding genes. The intensity of the fluorescent signal is 
proportional to the relative abundance of specific cRNAs in the hybridized sample, 
which further reflects the occurrence of the corresponding mRNAs in the original 
sample. Large-scale and genome-wide transcript profiling was introduced in the late 
1990s [19], and today several suppliers offer gene expression analysis tools where the 
expression levels of hundreds and thousands of genes are quantified simultaneously. 
The DNA microarrays make it possible to generate gene expression snapshots at 
different sampling times and conditions, answering the question of which genes are 
differently expressed between the analyzed samples.  
The 8x60K microarrays used in the current study are designed by Agilent 
Technologies and printed using the Agilent SurePrint technology. Each array contains 
eight SurePrint sub-arrays consisting of 60 000 in situ synthesized oligonucleotide 
probes, each gene represented by several probes. The SurePrint technology generates 
60 nucleotides long probes immobilized to fixed positions on surface-coated glass 
wafers. In situ probe synthesis prints the oligonucleotides directly onto the glass 
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microarray surface, and the coating strongly binds the probes to the array. The 
SurePrint technology prints thousands of probes at once, one nucleotide at a time, 
using the phosphoramidite chemistry [97]. Phosphoramidites are nucleotide analogs 
where the nucleotide reactive hydroxyl, phosphate and amine groups are chemically 
blocked by protective groups like dimethoxytrityl (DMT), methyl (Me) and isopropyl 
(iPr) to prevent undesired side reactions (figure 10), generating only the desired 
synthesized products. To link phosphoramidites monomers to oligonucleotide probes, 
the blocking groups are selectively removed. In the deprotection step, the DMT group 
is removed from the 5' hydroxyl group and the reactivity necessary to add the next 
nucleotide is reinduced. The iPr group protecting the 3' end of the adding nucleotide 
then departs and creates an intermediate that couples to the growing oligonucleotide. 
The last cycle step is oxidation to stabilize the phosphate linkage [97, 98], and the 
cycle is in total repeated 60 times to complete the oligonucleotides. The probes are 
then permanently bound to the microarray surface, and the surface is treated to reduce 
the amount of background signals [97].  
 
Figure 10: SurePrint technology in situ oligonucleotide probe synthesis by phosphoramidite chemistry. 
Removal of the DMT and iPr groups reinduces the reactivity necessary to couple phosphoramidite 
monomers into oligonucleotide probes. An oxidation step stabilizes the phosphate linkage connecting 
the monomers [97]. 
 
Microarray-based analyses are multi-step procedures where user-induced, 
sample and procedure variations might affect the microarray data. To eliminate such 
non-biological variation, positive controls are included in the analyses. The first step 
in the One-Color Microarray-Based Gene Expression Analysis (Agilent 
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Technologies) is to add One-Color Spike Mix (Agilent Technologies), a positive 
control consisting of ten different in vitro synthesized polyadenylated transcripts 
generated from the Adenovirus E1A gene, to the samples. The positive control 
transcripts hybridize to complementary probes on the array and reduces the non-
biological variation in microarray data processing [99].    
  The fluorescent labeled cRNA hybridizing to the microarray is created in a 
two-step process of cDNA and cRNA 
synthesis. An oligo(dT)-T7 promoter primer 
is incorporated by hybridizing to the mRNA 
poly-A tails. The mRNA is then converted 
to cDNA in a reverse transcription reaction. 
After second strand cDNA synthesis, a T7 
RNA polymerase creates labeled cRNA by  
incorporating Cyanine 3 (Cy3)-labeled 
cytosines (figure 11) [100]. The T7 RNA 
polymerase is isolated from the T7 
bacteriophage and is commonly in used in in 
vitro RNA synthesis. The T7 RNA 
polymerase is extreme promoter-specific 
and catalyzes RNA synthesis by binding to 
the T7 RNA polymerase-specific binding 
site in the synthetic T7 promoter primer 
[73]. 
Figure 11: Schematic presentation of the cRNA    
synthesis in the One-Color Microarray-Based         
Gene Expression Analysis (Agilent Technologies) [100].   
 
The amplified, labeled cRNA has to be purified prior to hybridization. The 
purification step was performed using the RNeasy
® 
Mini Kit (Qiagen), a spin column 
method where the RNA-binding silica membrane has a binding capacity of 100 µg 
RNA. High-salt buffers and ethanol was added to optimize the binding conditions, 
and contaminants and excess fluids were washed away. The pure membrane-bound 
cRNA was then eluted in DNase/RNase free water [101]. The cRNA concentration 
and purity was measured using the microarray RNA application in the NanoDrop
® 
ND-1000 Spectrophotometer. To proceed to the microarray hybridization step, a 
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cRNA yield of > 1,65 µg and specific activity of > 9,0 pmol Cy3 per µg cRNA are 
required [100]. The cRNA quantifications were also used to calculate the required 
sample volumes in the same step (Appendix C, step 4). 
The purified cRNA was treated in a pre-hybridization reaction to ensure high-
quality microarray data. The cRNA was mixed with a 10x Blocking Agent (Agilent 
Technologies) that minimizes non-specific array binding, and a 25x Fragmentation 
Buffer (Agilent Technologies) that fragments the cRNA to optimal sized targets to 
microarray hybridization [102]. After adding the 2x Hi-RPM Hybridization Buffer 
(Agilent Technologies), the samples were applied to the microarrays and hybridized 
for 17 hours. The cRNA fragments hybridize to their complementary probes and are 
in this way permanently attached to the array surface. All unbound compounds are 
removed in the wash step, creating microarrays of specific hybridized cRNA 
fragments ready to be scanned [100]. 
  When scanning (Microarray Scanner with SureScan High Resolution 
Technology, Agilent Technologies) the microarrays, a laser beam irradiates the 
hybridized cRNA fragments and excites the Cy3 dye. The intensity of the emitted 
fluorescent light is detected and correlated to the expression levels of the cRNA 
corresponding genes. Cy3 conjugates are exited maximally at 550 nm while the 
emission peak maximum is detected at 570 nm [19]. The detected intensity values are 
then transformed to digital images of the microarrays.  
After the microarrays are scanned, the Feature Extraction software (v10.7.3.1, 
Agilent Technologies) reads and processes the raw microarray images. The software 
finds and places the microarray grids, discards outlier pixels, determine probe 
intensities and ratios, flags outlier probes and performs statistical calculations 
generating quality control sample reports [103].  
 
3.4.5. Gene expression data analysis 
DNA microarray experiments generate enormous data amounts that have to be pre-
processed prior to further analysis. The GeneSpring GX software (v12.0, Agilent 
Technologies) was used to normalize and filter the data. The normalized signal values 
were log2 transformed, baseline corrected and 75th percentile shift normalized, as 
recommended by the vendor. Normalization minimizes the impact of non-biological 
variation like unequal cRNA quantities, differences in inter-chip hybridization and 
differences between manufactured chips to expose the actual biological differences. In 
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75th percentile normalization, the 75th percentile signal intensity is calculated for 
each array and subtracted from all the expression values on the array. Baseline 
transformation does not affect the statistical analyses, but improves the data 
visualization in sample plot and map presentations in GeneSpring [104].  
  Sample quality control is a GeneSpring application where poor quality 
samples and probes can be eliminated. A principal component analysis (PCA) 
compares sample gene expression profiles, and shows variations and unknown trends 
in the dataset. The principal components are vectors capturing the data variance, and 
the samples are grouped according to gene expression similarities. Samples 
representing equal experimental conditions should be similar to each other and group 
closely in the PCA plot. Divergence from this alignment might be due to poor sample 
quality or actual biological variation. The PCA plot allows evaluation of deviating 
samples, the extent of variance accepted and if ambiguous samples should be 
eliminated prior to analysis [104, 105]. Probe filtering is as well a part of the data 
quality control and eliminates probes with unreliable expression measurements. This 
process excludes probes representing genes not expressed at significant levels in any 
of the samples, generating a list of quality probes for further statistical analysis [105]. 
Following normalization and quality control, the microarray data was analyzed 
using a combination of the Significance Analysis of Microarrays (SAM) and the 
Ingenuity Pathways Analysis (IPA) (Ingenuity
®
 Systems). SAM
6
 is an R-package, 
Excel add-in application which by gene-specific t-tests determines if gene expression 
alterations are statistically significant [106]. The microarray data was analyzed using 
the SAM two class unpaired test, grouping gene expression data from the NTC, siC 
and siWRAP53#2 transfected cells within each cell line at the different time points, 
investigating the genes with different expression patterns between the groups. The 
false discovery rate (FDR) estimates define the expected fraction of false positives 
among the significant results [107], i.e. the risk of falsely rejecting the null hypothesis 
(type I error) [86]. FDR estimates up to approximately 5% are generally accepted. 
Overall, differences in the gene expression pattern of the NTC cells and siC 
transfected cells within each cell line should be negligible. Comparison of the gene 
expression patterns in the siC and siWRAP53#2 transfected cells should on the other 
hand view the WRAP53 knockdown effect. 
                                                          
6
 Available from http://www-stat.stanford.edu/~tibs/SAM/ 
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The statistical significant differentially expressed genes obtained by SAM 
were further analyzed using the IPA software. IPA is a web-based
7
 bioinformatics 
tool that allows complex data analyses and increased data understanding by the view 
of current molecular interactions, biological functions and diseases. The cellular 
importance of gene expression changes might as well be analyzed, as IPA predicts the 
downstream biological effects of such changes, an application used to analyze the 
microarray data in the current study. The IPA core analysis relates the experimental 
dataset molecules to the information in the Ingenuity Knowledge Base and identifies 
the signaling and metabolic pathways, networks of interconnected molecules, and 
biological functions and disease states most significant to the dataset of interest [108]. 
The results are provided with p-values, FDR values and ratios. The p-values are 
calculated by the Fisher`s exact test and estimate if the association between a group of 
molecules in the dataset and a given biological function in the Ingenuity Knowledge 
Base occur randomly by chance. Smaller p-values indicate more significant 
associations, and p-values ≤ 0,05 were considered statistically significant. The FDR 
values are calculated by the Benjamini-Hochberg (B-H) method adjusting p-values by 
multiple testing [109, 110], and the FDR cut off was set to 5%. The ratios are the 
number of molecules from the dataset of interest represented in different pathways 
relative to the total number of molecules in the pathway [111]. 
IPA requires input gene lists that merely consist of unique, characterized 
genes. To identify the genes represented by the probes detected as statistically 
significant by SAM, the Stanford Microarray Database SOURCE
8
 was used. 
SOURCE unifies probe data from different microarray platforms (Affymetrix, 
Agilent, Heebo/meebo, Illumina) and relates imported probe identification lists to the 
specific probe corresponding genes [112]. 
 
 
  
                                                          
7
 Available from www.ingenuity.com 
8
 Available from http://smd.stanford.edu/cgi-bin/source/sourceBatchSearch 
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4. Results 
4.1. WRAP53 mutation analysis 
To investigate the importance of somatic WRAP53 mutations in breast cancer, the 
tumor samples in the ULL cohort were screened for WRAP53 mutations by 
sequencing the entire WRAP53 coding region (exon 2–11), start exon 1β and the exon 
flanking intronic regions (30 bps). WRAP53 sequence alterations were detected in 
accordance with the NCBI WRAP53 Reference Sequence NG_028245.1 [85] using 
the SeqScape software (v2.7, Applied Biosystems). A complete overview of the 
findings diverging from the WRAP53 Reference Sequence is presented in Appendix 
D, table 10. 
The WRAP53 primers specificity was tested prior to the mutation analysis by 
PCR amplification of MDA-MB-231 genomic DNA and separation of the PCR 
products by agarose gel electrophoresis. The primer pairs generated specific PCR 
amplification products of expected size (table 1) and in sufficient quantities, and were 
further used in the mutation analysis.  
To ensure high-quality sequencing results, the WRAP53 fragments were 
sequenced in both forward and reverse direction based on independent PCR 
amplifications prior to the direction-specific cycle sequencing reactions. A complete 
WRAP53 mutation screening of the ULL tumor samples therefore required nearly 
4600 sequencing reactions and subsequent electropherograms to be interpreted. 
Approximately 70% of the sequenced fragments were covered by complete forward 
and reverse high-quality sequences, while the remaining part was covered by forward, 
reverse or a combination of the latter sequence directions, still generating result of 
adequate quality. The detected WRAP53 sequence alterations in the ULL tumor 
samples were confirmed by the occurrence in both forward and reverse sequencing 
direction from the two independent PCR products. By analyzing a selection of tumor 
corresponding blood samples, known germ-line variation were validated, whereas 
new germ-line variants were distinguished from somatic mutations (WRAP53 
fragments analyzed in blood are in Appendix D, table 10 marked *
 
).  
 
4.4.1. Sequence alterations in the WRAP53 gene  
Compared to the NCBI WRAP53 Reference Sequence NG_028245.1 [85], one or 
more WRAP53 sequence alterations were detected in 86 out of the 175 (49%) 
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analyzed ULL tumor samples. The majority of the alterations were single base 
substitutions (in total 154 detected substitutions) of which many (109/154, 70%) were 
non-synonymous and therefore predicted to induce amino acid exchanges. The 
remaining (45/154, 30%) were synonymous, silent alterations where the amino acid 
order and protein structure remains unchanged (table 3) [19]. Indel mutations
9
 were 
detected in only two of the cases (ULL-T-142 and ULL-T-253). 
Five different base substitutions were detected in the coding region of 
WRAP53; (i) R68G, (ii) F150F, (iii) A436A, (iv) A522G and (v) A522A (table 3), of 
which the R68G and A552G are non-synonymous alterations resulting in amino acid 
substitutions from arginine and alanine to glycine, respectively. The same alteration 
found in tumor DNA was also detected when analyzing the corresponding blood 
samples, revealing that the base substitutions were germline and not somatic 
alterations.  
 Single nucleotide substitutions were also detected in the non-coding start exon 
1β and the flanking intronic sequences (table 3). Of the sequence alterations in the 
non-coding WRAP53 regions, the G>C base change in exon 1β occurred most 
frequently (4/154, 2,5%). The occurrence of the variant in exon 1β was verified in 
blood sample from the same patients, suggesting a common polymorphism. The 
question whether also the rare intronic variants were germline or somatic alterations 
were investigating using the SNP500Cancer [90] and NCBI dbSNP [91] databases, 
due to lack of patient blood samples. The databases classified all current registered 
WRAP53 alterations as SNPs, i.e. normal population variations. Two possible novel 
intronic SNPs (intron 2 and 3) were identified, not previously registered in the current 
databases. 
Intronic alterations might affect mRNA splicing if occurring in conserved 
splice site consensus sequences [19]. At the Department of Genetics, the criterion to 
define somatic sequence alterations as potential splice mutations requires an alteration 
localized within the two first bps prior to or following the coding regions. According 
to this criterion, none of the WRAP53 intronic alterations found in the ULL tumor 
samples were classified as mRNA splice-affecting alterations.  
Somatic mutations in the WRAP53 gene do not seem to be a common event in 
breast tumorgenesis, although there is a little uncertainty concerning the indels, which 
                                                          
9
 Indel mutation is a generic term used to describe DNA insertions and deletions [19]. 
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will be addressed beneath. Thus, the focus will further be on the SNPs in the WRAP53 
coding region, R68G, F150F and A522G, and the non-coding c.–245G>C (figure 12), 
all detected in at least two breast tumors in the ULL series of patients. The occurrence 
and disease related effect of the four SNPs was investigated by exploring the 
association to clinical, pathological and molecular parameters.   
  
Table 3: Detected WRAP53 single base substitutions in the ULL tumor samples. Alterations verified in 
blood samples are marked *. Chr = chromosome, ¤ = possible novel WRAP53 SNPs not registered in 
the SNP500Cancer and NCBI dbSNP databases, - = data not available.  
Localization Chr position 
Base 
change 
Coding 
description 
Codon 
change 
Amino 
acid 
Protein 
change 
rs number 
Exon 1β* 17, 7591722 G>C c.–245G>C - - - rs17883670 
Exon 2* 17, 7592168 C>G c.202C>G CGG>GGG Arg>Gly p.R68G rs2287499 
Exon 3* 17, 7592560 C>T c.450C>T TTC>TTT Phe>Phe p.F150F rs2287498 
Exon 10 17, 7606350 T>C c.1308T>C GCT>GCC Ala>Ala p.A436A rs34016213 
Exon 11* 17, 7606722 C>G c.1565C>G GCG>GGG Ala>Gly p.A522G rs7640 
Exon 11* 17, 7606723 G>A c.1566G>A GCG>GCA Ala>Ala p.A522A rs148329158 
Intron 2 17, 7592527 C>G c.432–15C>G - - - ¤ 
Intron 3 17, 7592657 G>A c.530+17G>A - - - ¤ 
Intron 5 17, 7604174 C>T c.731+27C>T - - - rs138634236 
Intron 6 17, 7604965 C>T c.823–10C>T - - - rs117192546 
Intron 8 17, 7606031 G>A c.1165–30G>A - - - rs149142873 
 
 
 
Figure 12: Frequency plot presenting the genotype distributions of the non-coding WRAP53  
c.–245G>C and the coding WRAP53 c.202C>G (R68G), c.450C>T (F150F) and c.1565C>G (A522G) 
SNPs detected in the ULL tumor samples.  
 
4.4.2. WRAP53 indel sequence variations 
In two of the ULL tumor samples, ULL-T-142 and ULL-T-253, WRAP53 indel 
sequence alterations were detected. The indels were not registered in the 
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SNP500Cancer or NCBI dbSNP databases, indicating identification of possible novel 
sequence alterations. The alterations were localized close together in exon 11, 
suggesting a potential functional region of WRAP53 that may be a target of somatic 
mutations. Sequencing the blood sample (ULL-B-253) revealed the same indel 
alteration as the one uncovered in the tumor sample (ULL-T-253) (figure 13), 
excluding the idea of this WRAP53 indel alteration as a cancer-related somatic 
mutation. The alteration is instead a WRAP53 germline variant present in all body 
cells of this patient. Blood samples from the ULL-T-142 patient do not exist, and it is 
not possible to determine whether the indel alteration is of somatic or germline origin.  
 The detected indel alterations were complex changes occurring in a region 
with a common SNP variant (A522G), which complicated the identification and 
annotation of the indels. Also, it was not possible to determine if the A522G SNP was 
present in these samples in addition to the indel alterations, and consequently the SNP 
in the two samples are not available and excluded from further statistical analyses. 
 Annotation of the ULL-T-142 sample predicts two possible frameshift 
alterations according to the presence or absence of the A522G SNP; (i) 
c.1566_1567insG and (ii) c.1564_1567delCGinsGGG, respectively. In the ULL-T-
253 sample, the alteration was predicted a frameshift caused by c.1565_1568delGC.  
According to the NCBI WRAP53 Reference Sequence NG_028245.1 [85], all these 
annotated indels introduce premature stop codons generating truncated gene products. 
Since the ULL-T-253 indel was identified as a germline alteration, there is a 
possibility that the ULL-T-142 indel might be a germline variant as well, but lack of 
patient blood samples makes this undeterminable. There were no obvious similarities 
in clinicopathological and molecular characteristics between the two patients. 
 
 
A 
Figure 13: SeqScape electropherogram 
presenting the ULL-T-253 WRAP53 indel 
alteration in exon 11. Deletions and 
insertions result in double peaks in both 
forward (normal) and reverse (italic) 
sequencing direction. The red dots are 
SeqScape flags due to interpretation 
uncertainties.  
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4.4.3. WRAP53 SNPs in linkage disequilibrium 
In 2007, Garcia-Closas et al. introduced the association between the WRAP53 R68G 
SNP and the risk of developing ER negative breast cancer. The R68G SNP was 
observed to be in LD with the F150F SNP [65], an association of interest to validate 
in the ULL tumor samples.  
The pair-wise association between the R68G, F150F, A522G and 1β c.–
245G>C SNPs were investigated using the Chi-square and Fisher`s exact tests.  
Due to few observations in the groups of R68G and F150F minor homozygous 
genotypes (G/G and T/T, respectively), these observations were merged with the 
heterozygous genotypes within each SNP prior to the statistical analyses. In the pair-
wise SNPs association analyses, all three A522G nucleotide variants were included, 
but were then merged like the R68G and F150F nucleotide variants for the subsequent 
analyses. The null hypothesis indicated no association between the occurrences of the 
different WRAP53 SNPs, while the alternative hypothesis indicated a significant 
association. Statistical significant associations were observed between the R68G and 
F150F, R68G and A522G (figure 14), and F150F and A522G SNPs, all with p-values 
< 0,001. This implies a non-random occurrence of WRAP53 R68G, F150F and 
A522G in the breast cancer patients, where the homozygous minor genotypes and the 
heterozygous genotypes respectively are inherited together. 
 
 
Figure 14: The Chi-square test result indicates a statistical significant association between the 
WRAP53 R68G and A522G SNPs (p < 0,001).  
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Genetic linked loci defines haplotypes, i.e. alleles on the same chromosomal  
 segment inherited together as blocks [19]. The Haploview software (v4.2, Broad 
Institute) was used to further investigate whether the associated WRAP53 SNPs were 
genetic linked. The degree of genetic linkage within the dataset is visualized in a LD 
plot (figure 15 A) and specified by LOD scores (table 4). The Haploview result 
strongly indicated that the WRAP53 R68G, F150F and A522G SNPs occur in LD as a 
haplotype block, supporting the findings in the Chi-square and Fisher`s exact test 
analyses of the same SNPs. Haploview further confirmed that the HW equilibrium 
was fulfilled, meaning there is no selection of specific WRAP53 genotypes in the 
breast cancer patients. The WRAP53 haplotype block generated by Haploview shows 
the marker SNPs, the haplotypes and their frequencies, and reveals that CCC is the 
most frequent genotype among the ULL breast cancer patients (figure 15 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Color scheme based on D' and LOD score values. Bright red D' = 1 and LOD > 2, light blue 
D' = 1 and LOD < 2. Number in the squares are D' values (values of 1,0 are not shown). The physical 
position of each SNP is shown above the plot (A). The WRAP53 haplotype block with marker numbers, 
the haplotypes and the haplotype frequencies (B).  
 
 
   
WRAP53 SNPs (rs numbers) LOD score 
rs2287498 (F150F) and rs7640 (A522G) 12,6 
rs2287499 (R68G) and rs7640 (A522G) 17,0 
rs2287499 (R68G) and rs2287498 (F150F) 23,9 
rs17883670 (c.–245G>C) and rs2287499 (R68G) 0,27 
rs17883670 (c.–245G>C) and rs2287498 (F150F) 0,18 
rs17883670 (c.–245G>C) and rs7640 (A522G) 0,56 
B 
A 
Table 4: LOD scores from the Haploview (v4.2, Broad Institute) haplotype analysis 
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4.4.4. Association of WRAP53 SNPs to clinicopathological and molecular data 
The WRAP53 SNPs R68G, F150F, A522G and 1β c.–245G>C were individually 
explored in order to reveal their associations to clinical, pathological and molecular 
patient parameters. The statistical analyses was performed using the Chi-square and 
Fisher`s exact tests. The SNPs occurrence were tested against the following current 
clinicopathological parameters in breast cancer; (i) age of disease onset (cases divided 
in two groups, < > 55 years, due to pre and post menopause since endogenous 
hormonal levels are a breast cancer risk factor), (ii) lymph node status (positive or 
negative according to the presence of lymph node metastasis), (iii) tumor size (T1– 
T4
10
) [113], (iv) histological grade (G1–G411) [113], (v) TP53-status (wt or mutated), 
(vi) ER status (positive or negative) and (vii) breast cancer subtypes (luminal A, 
luminal B, ERBB2 positive, basal-like and normal breast-like). In addition, the 
molecular parameter of cellular WRAP53 protein localization (nuclear, cytoplasmic 
or combined) was included to investigate the functional SNPs effect in accordance 
with unpublished findings associating cellular WRAP53 localization with breast 
cancer prognosis (Langerod et al., unpublished data). Complete clinical information 
was not available to all samples. The null hypothesis indicated no association between 
the current WRAP53 SNPs and the clinical, pathological and/or molecular parameters, 
while the alternative hypothesis indicated a significant association.  
 No statistical significant results were obtained investigating the association of 
the WRAP53 SNPs (R68G, F150F, A522G and 1β c.–245G>C) with the patient 
parameters listed above, except two findings concerning cellular WRAP53 protein 
localization. The heterozygous WRAP53 c.–245G>C genotype (G/C) was found 
associated with nuclear WRAP53 localization (p=0,052) (figure 16). This finding is 
intriguing since nuclear WRAP53 localization is presumed associated with favorable 
prognosis in breast cancer patients compared to cytoplasmic localization (Langerod et 
al., unpublished data). The R68G SNP was associated to cellular WRAP53 
localization (p=0,036) combining the nuclear and cytoplasmic protein distributions. 
Positive nuclear and negative cytoplasmic WRAP53 localization improves breast 
cancer prognosis in contrast to the counterpart of negative nuclear and positive 
                                                          
10
 T1=primary tumor < 2,0 cm in diameter, T2=primary tumor > 2,0 < 5,0 cm in diameter, T3=primary  
   tumor > 5,0 cm in diameter and T4=primary tumor independent of size, but the tumor infiltrates skin  
   or breast tissue [113]. 
11
 G1=well differentiated (low grade), G2=moderately differentiated (intermediate grade), G3=poorly  
   differentiated (high grade) and G4=undifferentiated (high grade) [113]. 
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cytoplasmic localization. The combinations in between by positive or negative 
nuclear and cytoplasmic protein localizations displays similar, intermediate 
prognostic impact (Langerod et al., unpublished data).The R68G major homozygous 
(C/C) genotype is fairly even distributed between the four annotated groups of 
WRAP53 localization. The heterozygous (C/G) and minor homozygous (G/G) 
genotypes are on the other hand primarily distributed between negative or positive 
nuclear and cytoplasmic WRAP53 localization (p=0,036) (figure 17).  
 
 
Figure 16: The Fisher`s exact test indicates a statistical significant association between the WRAP53 
c.-245G>C SNP and nuclear WRAP53 localization (p=0,052). Due to background staining, nuclear 
stain > 5% was considered positive results. IHC=immunohistochemistry. 
 
 
 
Figure 17: The Chi-square test indicates a statistical significant association between the 
WRAP53 R68G SNP and subcellular WRAP53 protein localization (p=0,036). Due to 
background staining, nuclear and cytoplasmic stain > 5% was considered positive results. 
IHC=immunohistochemistry. 
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4.4.5. WRAP53 SNPs and survival analyses 
The prognostic value of the four SNPs, WRAP53 R68G, F150F, A522G and c.–
245G>C were investigated using the Kaplan-Meier survival plot and the Logrank test. 
The null hypothesis indicated no association between the current WRAP53 SNPs and 
breast cancer-specific survival, while the alternative hypothesis indicated a significant 
association. 
 The F150F SNP was the only WRAP53 sequence alteration associated with 
breast cancer-specific survival (p=0,048) (figure 18), where the heterozygous (C/T) 
genotype seems to reduce the mean survival time with approximately 30 months 
(table 5). The same trend was observed for both the R68G (p=0,114) and A522G 
(p=0,133) SNPs, without showing statistical significance levels, but still indicating 
that the heterozygous and minor homozygous genotypes might be associated with 
reduced survival. 
 
Figure 18: The Kaplan-Meier survival plot and Logrank test indicated a statistical significant 
association between the WRAP53 F150F (c.450C>T) SNP and breast cancer-specific survival 
(p=0,048).  
 
 TP53 mutation status and ER status are significant and well established 
prognostic markers in breast cancer. The WRAP53 SNPs significantly (F150F) or 
trend (R68G and A522G) associated with survival were further analyzed to 
investigate whether the SNP genotypes influenced breast cancer-specific survival 
differentially according to TP53 mutation and ER status.  
Both TP53 mutation and ER status stratification revealed significant A522G 
genotype-dependent differences in survival. The heterozygous (C/G) and minor 
homozygous (G/G) genotype carriers were significantly associated with poorer 
p=0,048 
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prognosis compared to the major homozygous (C/C) genotype carriers in wt TP53 
tumors (p=0,055), whereas the survival in TP53 mutated tumors were not influenced 
(p=0,926) (figure 19 A and B). Interestingly, a similar result was seen by stratifying 
for ER status where reduced survival was associated with ER positive tumors in 
patients carrying the WRAP53 heterozygous (C/G) and minor homozygous (G/G) 
genotypes (p=0,017), while survival in the ER negative tumors were not influenced 
(p=0,476) (figure 19 C and D). The R68G SNP survival analysis showed similar 
results by significantly reduced survival of heterozygous (C/G) and minor 
homozygous (G/G) genotypes compared to the major homozygous (C/C) genotype in 
wt TP53 and ER positive tumors (p=0,030 and 0,004, respectively), while no 
significant difference in survival was observed in the TP53 mutated and ER negative 
tumors (p=0,625 and 0,702, respectively). 
  The results from the F150F SNP survival analysis diverged compared to the 
A522G and R68G results. There was no statistical significant survival difference in wt 
TP53 and TP53 mutated tumors according to genotype (p=0,072 and 0,922, 
respectively). Despite the absent statistical significance, a possible trend was present 
in the wt TP53 tumor patients indicating that heterozygous (C/T) and minor 
homozygous (T/T) genotype carriers seemed to be associated with poorer survival 
compared to the major homozygous (C/C) genotype carriers. By ER status 
stratification, the result was in accordance with the A522G and R68G outcomes. ER 
positive patients carrying the heterozygous (C/T) and minor homozygous (T/T) 
genotypes were significantly associated with poorer survival compared to the major 
homozygous (C/C) genotype carriers (p=0,040), while no significant survival 
difference was observed in the ER negative tumor patients (p=0,216) (table 5).   
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Figure 19: The Kaplan-Meier survival plots and Logrank tests indicated a statistical significant 
association between the A522G SNP and breast cancer-specific survival in wt TP53 (A) and ER 
positive (C) tumors (p=0,055 and 0,017, respectively). No significant difference in survival was 
observed in TP53 mutated (B) and ER negative (D) tumors (p=0,926 and 0,476, respectively).  
 
 
 
Table 5: The effect of WRAP53 SNPs on unstratified mean survival times and mean survival times 
stratified according to TP53 mutation and ER status in the ULL tumor samples  
WRAP53 
SNPs 
Genotype 
Mean survival 
time prior to 
stratification 
(months) 
Mean survival time after stratification (months) 
ER status TP53 mutation status 
ER positive ER negative TP53 wt 
TP53 
mutated 
R68G 
C/C 131,9 144,7 113,9 148,6 73,5 
C/G+G/G 112,9 101,5 121,7 122,4 80,3 
F150F 
C/C 132,6 140,0 120,1 147,3 77,2 
C/T+T/T 101,7 102,9 72,5 117,1 70,0 
A522G 
C/C 134,5 148,1 117,0 150,8 68,7 
C/G+G/G 118,5 112,5 115,2 130,2 83,3 
 
 
p=0,017 
C 
p=0,476 
D 
p=0,926 p=0,055 
B A 
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4.2. Gene expression study 
To increase the knowledge about cellular WRAP53 regulatory functions, gene 
expression analyses was performed in WRAP53 normal expressing and WRAP53 
depleted breast cancer cell lines. The MCF-7 and MDA-MD-231 cell lines were 
cultured and transiently transfected with an siRNA targeting WRAP53 exon 2. RNA 
was harvested from NTC cells, siC and siWRAP53#2 transfected cells in each cell 
line 40 and 72 hours after transfection. Gene expression differences according to the 
WRAP53 knockdown within the respective cell lines were investigated using the 
SurePrint G3 Hmn GE 8x60K Microarray (Agilent Technologies). 
 
4.2.1. WRAP53 knockdown efficiency and RNA isolation 
The MCF-7 and MDA-MB-231 WRAP53 knockdown efficiency was measured 
quantifying the cellular WRAP53 protein and mRNA levels by Western blot and 
qPCR analyses, respectively. Normally, WRAP53 is more abundantly expressed in the 
MDA-MB-231 than the MCF-7 cell line, visualized by stronger siC protein bands that 
reflects normal WRAP53 protein levels (figure 20). The WRAP53 knockdown 
efficiency was most advantageous in the MCF-7 cell line, measured to 75% 72 hours 
after transfection. At the same time point in the MDA-MB-231 cell line, the 
knockdown efficiency was measured to 70% (figure 21). β-actin was stably expressed 
in both cell lines independently of siRNA transfections and time points (figure 20), 
indicating that the reduced WRAP53 protein levels were caused by the targeted 
WRAP53 knockdown.  
The purity of the TRIzol
® 
isolated RNA samples was measured by 260/280 
ratios within the range of 1,75–1,95 and 260/230 ratios within the range of 1,62–2,41.  
 
 
 
 
Figure 20: Western blot analysis quantifyed the WRAP53 protein levels in the siC and 
siWRAP53#2 transfected MCF-7 and MDA-MB-231 cell lines 40 and 72 hours after transfection. 
β-actin was used as loading control. WRAP53 knockdown efficiency was determined using the 
Bradford assay (Bio-Rad Laboratories) and detected using the SuperSignal West Femto Maximum 
Sensitivity Substrate (Thermo Scientific). Farnebo and colleagues, CCK (January 2012). 
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Figure 21: MCF-7 and MDA-MB-231 WRAP53 knockdown efficiency measured 40 (green) and 72 
(blue) hours after siRNA transfection using the KAPA SYBR
®
 FAST qPCR (KAPA Biosystems). 
Farnebo and colleagues, CCK (January 2012). 
  
 
4.2.2. Quantification and purity assessments of purified cRNA  
High-quality cRNA samples are crucial to the success of an Agilent Gene Expression 
experiment. All samples had a cRNA yield within the range of 4,91–8,77 µg and a 
specific activity within the range of 9,38–14,44 pmol Cy3 per µg cRNA, all in 
accordance with the Agilent Gene Expression experiment procedure requirements 
(chapter 3.4.4) [100].  
 
4.2.3. GeneSpring GX 12.0; preprocessing microarray data  
The Feature Extraction software (Agilent Technologies) processed raw microarray 
images files were further processed using the GeneSpring GX 12.0 software. The 
microarray data was normalized using the 75th percentile shift method, and probe 
filtration generated a list of 35636 quality probes further included in the downstream 
gene expression data analyses.  
The GeneSpring sample quality control revealed one sample (MDA-MB-231 
siWRAP53#2 transfected cells, 40 hours, triplicate 1) (table 2) diverging from the 
sample majority localization in the PCA plot. The remaining corresponding replicates 
(MDA-MB-231 siWRAP53#2 transfected cells, 40 hours, triplicate 2 and 3) clustered 
together, indicating that biological variation probably was not the cause of 
divergence. To avoid unreliable measurements affecting the gene expression data, 
MDA-MB-231 siWRAP53#2 triplicate 1 was eliminated from the dataset. 
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Removing the divergent sample, the GeneSpring PCA plot clustered the MCF-
7 and MDA-MB-231 cell lines separately in two distinct groups (figure 22). Variation 
was still present in the cell line-specific samples, but mainly distributed on the minor 
variance y- and z-axes components. Samples of similar experimental conditions are 
expected clustering together, but there was no clear trends of treatment-specific 
clustering within the cells lines.  
 
 
Figure 22: PCA plot visualizing microarray 
sample variations. Red squares equal MCF-
7, while blue triangles equal MDA-MB-231. 
Cell line specificity dominates the clustering. 
The x-axis (component 1) captures 37,7%, 
the y-axis (component 2) 15,9% and the z-
axis (component 3) 6,9% of the dataset 
variations. 
 
 
 
 
 
 
4.2.4. Significance Analysis of Microarrays 
To investigate the influence of WRAP53 depletion according to MCF-7 and MDA-
MB-231 gene expression alterations, the GeneSpring GX 12.0 preprocessed 
expression data was analyzed using SAM. SAM identifies and lists significant 
differentially expressed genes between groups of samples. 
The SAM two class unpaired test analyzed differences in gene expression 
patterns between the (i) NTC cells and siC transfected cells, and (ii) the siC and 
siWRAP53#2 transfected cells within each cell line at both time points. There were no 
significant gene expression differences between the NTC cells and siC transfected 
cells at any time point, indicating that the siRNA transfection procedure itself did not 
influence with the gene expression patterns. Prospective gene expression differences 
in the siWRAP53#2 transfected cells are thus WRAP53 knockdown-specific cellular 
responses. 
 Comparing gene expression patterns in the siC and siWRAP53#2 transfected 
cells within each cell line according to time points revealed considerable differences. 
In the MCF-7 cell line, the siWRAP53#2 transfected cells displayed 32 probes 
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(FDR=5,3%) representing genes of significant different expression levels compared to 
the siC transfected cells after 40 hours, all upregulated. 72 hours after transfection, the 
number of probes representing significant differentially expressed genes was 
expanded to 420 (FDR=0,5%), distributed in 406 upregulations and 14 
downregulations (figure 23). The cellular WRAP53 knockdown response in MDA-
MB-231 seemed to occur more slowly than in MCF-7, showing no significant 
differences in gene expression patterns after 40 hours. By 72 hours, the WRAP53 
depletion effect in MDA-MB-231 was more prominent by significant altered 
expression levels of 453 (FDR=10,5%) gene-representing probes. WRAP53 was 
among the significantly downregulated genes in the siWRAP53#2 transfected cells in 
both cell lines, and the only downregulated gene in MDA-MB-231, indicating 
efficient WRAP53 knockdown. 
 
 
Figure 23: SAM plot visualizing the gene expression patterns in the MCF-7 siC and siWRAP53#2 
transfected cells 72 hours after siRNA transfection. The red dots represent significant upregulated 
genes in the siWRAP53#2 transfected cells compared to the siC transfected cells. The green dots 
represent significantly downregulated genes in the siWRAP53#2 transfected cells compared to the siC 
transfected cells. The black dots represents genes expressed at equal levels in both groups. SAM 
estimated 420 probes representing genes with significantly altered expression levels (FDR=0,5%). 
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4.2.5. Pathway analyses 
To investigate the impact of MCF-7 and MDA-MB-231 WRAP53 depletion in 
accordance to biological functions, pathway analysis using IPA was performed. The 
SAM output lists of significant differentially expressed genes within each cell line 
were used in the pathway analyses. Prior to the analyses, the gene lists were processed 
using the Stanford Microarray Database SOURCE to identify probes of missing gene 
annotations to create lists exclusively containing distinctive, characterized genes. The 
pathway analyses p-value was calculated using the right-tailed Fisher`s exact test, and 
the B-H adjusted p-value for multiple testing was applied for gene lists with more 
than 100 genes. Due to overall restricted alterations in gene expression 
downregulations and limited cellular WRAP53 knockdown response 40 hours after 
transfection, only significant upregulated genes at 72 hours were analyzed (gene lists 
in Appendix E). The top five most significant pathway analyses results of biological 
functions including diseases and disorders, molecular and cellular functions, 
canonical pathways and transcription factors are summarized in table 6 and 7.  
The functional analyses identify the biological functions in the Ingenuity 
Knowledge Base that are most significant to the molecules in the dataset. The 
canonical pathway analysis identifies the pathways most significant to the dataset, and 
the association significance is measured in two ways: (i) a ratio of the number of 
molecules that map to the canonical pathway is displayed, and (ii) a calculated p-
value determining the probability that the association between the genes in the dataset 
and the canonical pathway is explained by chance. The transcription factor analysis in 
IPA predicts the transcription factors expected to be involved in regulation of the 
genes in the gene set. The Fisher`s exact test and B-H p-value threshold was set to 
0,05, accepting a FDR of 5%, to identify biological functions significantly associated 
to the gene expression alterations in the gene dataset [114].  
 
 
Table 6: Summary of pathway analysis (IPA) of MCF-7 significant upregulated genes (299 genes) 72 
hours after transfection. B-H = Benjamini-Hochberg.  
 Diseases and disorders B-H p-value #Molecules 
 Cancer 5,39×10
-9
 – 6,38×10-2 131 
 Gastrointestinal Disease 3,09×10
-8
 – 6,38×10-2 75 
 Dermatological Diseases and Conditions 1,59×10
-5
 – 5,63×10-2 56 
 Developmental Disorder 1,59×10
-5
 – 4,73×10-2 34 
 Genetic Disorder 1,59×10
-5
 – 5,15×10-2 88 
 Molecular and cellular functions B-H p-value #Molecules 
 Cell Death 4,41×10
-7
 – 6,38×10-2 108 
 Cellular Movement 8,25×10
-6
 – 6,38×10-2 75 
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 Cellular Growth and Proliferation 2,53×10
-5
 – 6,25×10-2 104 
 Free Radical Scavenging 4,24×10
-5
 – 6,04×10-2 25 
 Cell Morphology 2,10×10
-4
 – 5,53×10-2 65 
 Canonical pathways B-H p-value Ratio 
 VDR/RXR Activation 7,92×10
-2
 7/79 (0,089) 
 Aryl Hydrocarbon Receptor Signaling 7,92×10
-2
 9/145 (0,062) 
 p53 Signaling 9,71×10
-2
 7/95 (0,074) 
 Semaphorin Signaling in Neurons 9,71×10
-2
 5/52 (0,096) 
 Extrinsic Prothrombin Activation Pathway 9,71×10
-2
 3/16 (0,188) 
 Transcription factors p-value  #Target molecules 
 ATF2 6,85×10
-9
 12 
 FOSL2 1,26×10
-8
 9 
 ATF3 3,61×10
-8
 10 
 TP53  7,42×10
-8
 45 
 TP63 7,66×10
-8
 16 
 
 
 
Table 7: Summary of pathway analysis (IPA) of MDA-MB-231 significant upregulated genes (249 
genes) 72 hours after transfection. B-H = Benjamini-Hochberg. 
 Diseases and disorders B-H p-value #Molecules 
 Dermatological Diseases and Conditions 5,33×10
-5
 – 7,48×10-2 34 
 Genetic Disorder 5,33×10
-5
 – 7,48×10-2 56 
 Cancer 5,33×10
-5
 – 7,48×10-2 84 
 Gastrointestinal Disease 5,33×10
-5
 – 7,48×10-2 59 
 Inflammatory Response 1,19×10
-3
 – 7,48×10-2 45 
 Molecular and cellular functions B-H p-value #Molecules 
 Cellular Movement 1,01×10
-5
 – 7,48×10-2 60 
 Cellular Growth and Proliferation 1,54×10
-4 – 7,48×10-2 74 
 Antigen Presentation 2,04×10
-3
 – 7,48×10-2 23 
 Cell-To-Cell Signaling and Interaction 6,32×10
-3
 – 7,48×10-2 40 
 Cellular Development 8,67×10
-3
 – 7,48×10-2 65 
 Canonical pathways B-H p-value Ratio 
 Differential Regulation of Cytokine Production 
in Intestinal Epithelial Cells by IL-17A and IL-
17F 
2,07×10
-3
 5/23 (0,217) 
 Role of IL-17A in Psoriasis 2,07×10
-3
 4/13 (0,038) 
 Airway Pathology in Chronic Obstructive 
Pulmonary Disease 
8,71×10
-3
 3/8 (0,375) 
 Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 
2,39×10
-2
 8/142 (0,056) 
 Role of IL-17A in Arthritis 3,08×10
-2
 5/60 (0,083) 
 Transcription factors p-value  #Target molecules 
 FOXL2 2,12×10
-10
 11 
 RELA 7,35×10
-7
 17 
 ESR1 2,79×10
-6
 16 
 NFkB (complex) 3,59×10
-6
 22 
 TFAP2A 3,28×10
-5
 8 
 
4.2.6. Significant mutually expressed MCF-7 and MDA-MB-231 genes 
In order to understand the biological effects of WRAP53 knockdown, the mutually 
expressed MCF-7 and MDA-MB-231 genes were investigated. The MCF-7 and 
MDA-MB-231 response to WRAP53 depletion primarily occurred as gene expression 
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upregulations. The lists of distinctive, characterized MCF-7 and MDA-MB-231 
upregulated genes (299 and 249 genes, respectively) 72 hours after transfection were 
used to identify mutually upregulated genes using a Venn diagram tool [115]. Venn 
diagrams visualizes the relations between different data sets [116], and 29 mutually 
upregulated genes were identified in the two cell lines (figure 24 and table 8). The 
mutually expressed genes were further included in the pathway analysis, and the 
results are summarized in table 9.  
 
 
Figure 24: Venn diagram [115] visualizing the relation of mutually expressed upregulated genes (29 
genes) in the MCF-7 and MDA-MB-231 cell lines 72 hours after transfection. 
 
 
Table 9: Summary of pathway analysis (IPA) of MCF-7 and MDA-MB-231 mutually significant 
upregulated genes (29 genes) 72 hours after transfection 
     Diseases and disorders                                                               p-value                        #Molecules 
 Cancer  1,77×10
-7
 – 4,94×10-2 15 
 Gastrointestinal disease  1,77×10
-7
 – 4,94×10-2 14 
 Neurological disease 1,59×10
-4
 – 4,50×10-2 7 
 Reproductive system disease 3,62×10
-4
 – 3,35×10-2 12 
 Dermatological diseases and conditions 5,14×10
-4
 – 4,50×10-2 8 
     Molecular and cellular functions                                              p-value                        #Molecules 
 Cellular growth and proliferation 4,20×10
-5
 – 4,82×10-2 14 
 Cellular function and maintenance 4,31×10
-5
 – 4,66×10-2 14 
 Cell death 1,30×10
-4 – 4,66×10-2 14 
 Cellular movement 1,40×10
-4
 – 4,33×10-2 12 
 Cellular development 7,45×10
-4
 – 4,44×10-2 11 
     Canonical pathways                                                                   p-value                              Ratio 
 VDR/RXR Activation 7,66×10
-3
 2/79 (0,025) 
 Role of Macrophages, Fibroblasts and Endothelial 
Cells in Rheumatoid Arthritis 
1,18×10
-2
 3/324 (0,009) 
 Airway Pathology in Chronic Obstructive Pulmonary 
Disease 
1,35×10
-2
 1/8 (0,125) 
 Hepatic Fibrosis / Hepatic Stellate Cell Activation 2,21×10
-2
 2/142 (0,014) 
 Dendritic Cell Maturation 2,29×10
-2
 2/177 (0,011) 
Transcription factors                                                                   p-value               #Target molecules 
 ATF3 1,32×10
-4
 3 
 ESR1 2,18×10
-4
 5 
 ATF2 3,30×10
-4
 3 
 NR1D1 4,00×10
-4
 2 
 NR3C1 8,96×10
-4
 6 
Genes 
CACNG6 EVPLL MEF2C THBD 
CCDC80 FSIP2 MMP1 TM4SF1 
CLDN1 GABARAPL1 NUPR1 TNFRSF11B 
CMAHP ITGB8 OSBPL5 TNFSF9 
COL20A1 KLK6 SERPINB5 UCHL1 
CYB5RL LHPP SLC13A3  
CYP1B1 LTB SLC16A14  
EDA2R MAP2 SOX4  
Table 8: Mutually significant MCF-7 and MDA-MB-231 
upregulated genes 72 hours after transfection 
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5. Discussion 
5.1. WRAP53 mutation analysis  
5.1.1. Experimental considerations 
The ULL samples were sequenced for WRAP53 mutations using the newly introduced 
BigDye
®
 Direct Cycle Sequencing Kit and the BigDye
®
 XTerminator
™ 
Purification 
Kit (Applied Biosystems). The new Sanger sequencing method was successfully 
introduced in the lab, resulting in improved sequence quality and reduced work load. 
Sanger sequencing has since its development in the mid-1970s been the dominating 
sequencing method, and although the low throughput is a limitation compared to what 
next generation sequencing can provide [19], the method still has advantages in 
smaller targeted studies, such as the one presented. The Sanger sequencing read 
length is today ~750 bps, longer than in several next generation sequencing methods 
[19, 117]. Sanger sequencing often displays poor quality sequences the first 15–40 
bases and further when exceeding ~700 bases, but no sequenced WRAP53 fragments 
exceeded such lengths (table 1), and all fragments displayed high quality sequences 
read as close as one base from the primers.  
To ensure high-quality sequencing results, all the current WRAP53 fragments 
were sequenced in both forward and reverse direction. Generally, there is no 
guarantee that the sequencing approach used detects every single genetic alteration 
present, due to low percentage of mutant cells in the sample or the character of the 
mutation. In some cases, alterations have been observed detectable in one of the 
sequencing directions only. Optimally, every sequenced fragment should be 
interpreted in both sequencing directions, but in this pilot study performing WRAP53 
mutation screening, high-quality unidirectional sequences was considered satisfying 
when one direction failed. Bidirectional scoring will be of greater importance in for 
instance diagnostic sequencing approaches. Sequence electropherograms should 
generally be interpreted by at least two independent persons to ensure objective and 
correct sequencing data annotations. This is so far not done in this study, but the data 
was otherwise analyzed in accordance with the guidelines at the Department of 
Genetics. 
The 175 ULL tumor samples included in the WRAP53 mutation analysis are a 
representative selection of Norwegian breast cancer patients from the early 1990s, 
potentially with a negligible bias towards larger tumor sizes. Mutations are defined as 
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permanent genetic alterations occurring in < 1% of the population [19], but increased 
mutations frequencies are often observed in cancer patients. The number of ULL 
tumor samples may be considered slightly small in the mutation analysis coherence, 
but should be sufficient to detect possible medium and high frequency cancer-related 
WRAP53 mutations. The size of the cohort indicates that the findings anyway should 
be validated in larger studies. An advantage of the ULL cohort is that it contains 
patient information collected over several years, making it possible to relate findings 
to important clinical, pathological and molecular parameters.   
 
5.1.2. Sequence alterations in the WRAP53 gene 
No obvious somatic sequence alterations were detected in the WRAP53 mutation 
analysis, indicating that mutations in the WRAP53 gene do not seem to be a common 
event in breast tumorgenesis. The detected alterations were primarily single 
nucleotide substitutions classified as normal variations, but two likely germline indels 
were detected as well.  
Next generation sequencing has become a revolutionizing tool in tumor 
characterization, and a study just published has for the first time sequenced the whole 
exome in 100 primary breast cancer cases to make a survey of mutated cancer genes. 
Somatic driver mutations were detected in frequently mutated genes like BRCA1, 
TP53, RB1, PTEN, GATA3 and PIK3CA known to be involved in breast cancer 
development, confirming existing knowledge. WRAP53 was not reported as one of the 
somatically altered genes [118], supporting the outcome in our study. The sensitivity 
of next generation sequencing is not too well known, so there is still a possibility that 
WRAP53 actually might be a low-frequency mutated gene. Such mutations are 
however rarely conclusive factors in pathological processes, an assertion that might 
question the importance of WRAP53 in breast cancer.  
 The R68G and A522G SNPs were the only detected non-synonymous base 
substitutions, causing amino acid changes from arginine and alanine to glycine, 
respectively. Arginine is a polar, positively charged amino acid, while alanine and 
glycine are non-polar and neutral. Amino acid substitutions might affect protein 
structure and function, but the actual functional effect is often hard to predict. As a 
result of the A522G SNP, the chemical properties of non-polarity and neutrality are 
maintained throughout the substitution, while as a result of the R68G SNP, the 
substitution alters the chemical properties from polar and positively charged to non-
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polar and neutral. Replacing amino acids of similar chemical properties (conservative 
substitutions) have less effect on protein structure and function than replacing amino 
acids of different chemical properties (non-conservative substitutions) [19]. Because 
of this, the R68G SNP could be expected to affect the WRAP53 protein to a greater 
extent than the A522G SNP. 
Sequence alterations occur frequently in the human genome, but are not 
necessarily drivers of malignance. Malignant alterations affect protein structure and 
function, and mainly occurs in functional sequences like coding regions, promoters, 
other regulatory sequences and splice sites [19]. The WRAP53 protein belongs to the 
WD40 protein family and contains six highly conserved WD40 repeats important to 
proper function. All the detected WRAP53 sequence alterations are localized outside 
these current repeats [57]. The non-synonymous R68G and A522G alterations are in 
addition classified as natural sequence variants [90, 91], indicating that the detected 
WRAP53 alterations do not severely affect protein function. Still, the SNPs might be 
involved in features of less obvious character like cancer susceptibility or therapy 
response modulations [119].  
  In 2011, Zhong et al. detected four WRAP53 base substitutions (Phe164Leu, 
His376Tyr, Arg398Trp and Gly435Arg) in a group of Dyskeratosis congenita 
patients, and referred to the alterations as possible disease-causing factors. The DC 
diagnosis brings along increased cancer susceptibility, a possible link to WRAP53 
involvement in cancer development. The WRAP53 germline mutations detected in the 
DC patients are located close to or in the highly conserved WD40 repeats, predicted 
to alter the WRAP53 protein function. The alterations detected in the DC patients do 
not overlap with the WRAP53 alterations detected in the ULL tumor samples, 
supporting the hypothesis that indicates benign WRAP53 alterations. Although 
intriguing findings related to WRAP53 was presented in the DC study, few included 
study participants is a weakness to consideration [64].  
The WRAP53 indel alterations detected in the ULL-T-142 and ULL-T-253 
samples are most likely germline alterations, even though this was only confirmed in 
one of the patients (ULL-B-235). It cannot be excluded that the other patient (ULL-T-
142) still may have a somatic mutation. Prior to the blood sample analysis, the 
detected indels created a hypothesis suggesting a potential functional WRAP53 region 
within exon 11 targeted by somatic mutations. This hypothesis was however rejected 
when the ULL-T-253 indel was identified as a germline alteration. Cellular effects 
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induced by frameshift alterations may be hard to predict, but common consequences 
on the protein level are induced premature stop codons creating truncated protein 
unable of proper function or any function at all [19]. Premature stop codons were 
proven in both indel variants, relatively unexpected according to the probable 
germline status. Polymorphic indels tend to localize towards the end of the protein 
and therefore avoid the nonsense altering effects [120]. Although premature stop 
codon was detected in the indels, the localization towards the end of the WRAP53 
coding region might preserve protein functionality, but this remains speculative. 
Another conceivable explanation to the indel alterations is that PCR and 
sequencing reaction artifacts due to DNA polymerase slippage in repetitive sequences 
(figure 13, seven following guanine bases) might cause frameshifts [19]. In our study, 
the WRAP53 indel alterations were still detected by re-analyzing both tumor samples 
and the blood sample, indicating that artifacts probably not are the sequence altering 
cause. The low incidence of indel alterations requires results validation in larger 
studies. 
The absence of somatic WRAP53 mutations in the ULL tumor samples 
changed the focus from mutations towards the detected SNPs. SNP analyses are 
primarily not performed in tumor samples due to cancer-induced genomic aberrations, 
but in blood samples. This study was originally not a SNP analysis, so the tumor 
detected SNPs, although verified in blood, was used to investigate the WRAP53 SNPs 
influence in breast cancer.  
 
5.1.3. WRAP53 SNPs in linkage disequilibrium 
The results from the statistical analyses investigating the relation between the 
WRAP53 c.–245G>C, R68G, F150F and A522G SNPs indicated a significant 
association between R68G, F150F and A522G. These results were further confirmed 
in the Haploview (v4.2, Broad Institute) analysis, defining R68G, F150F and A522G 
as genetic linked in a haplotype block where CCC was the most frequent genotype 
(figure 15).  
The results verified the findings presented by Garcia-Closas et al. (2007) 
indicating that the WRAP53 R68G and F150F SNPs occur in LD [65]. In addition, the 
A522G SNP occurred as a new marker in the same haplotype block, an observation 
not previously reported. High LOD scores suggested that the three SNPs are closely 
linked, where the greatest level of linkage was observed between the R68G and 
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F150F SNPs (D'=1, LOD score=23,9). The R68G and A522G occur with a D'=0,96, a 
value suggesting strong, but not complete linkage (D'<1). Linkage to the c.–245G>C 
SNP was on the other hand rejected due to low LOD scores (figure 15 and table 4). 
Estimates of D' values highly depends on sample sizes, so only D' values close to one 
are considered as reliable LD measures, indicating minimal recombination. 
Intermediate values are more difficult to interpret and should not be used to measure 
LD levels [88]. Loci inherited together as haplotypes are interesting features because 
the non-random heritage might reflect biological functional effects depending on 
specific loci and/or genotype combinations under normal or pathological conditions.    
 No deviation from the HW equilibrium was detected investigating WRAP53 
c.–245G>C, R68G, F150F and A522G SNPs genotype frequencies in the breast 
cancer patients. Cancer is a disease characterized by accumulation of genomic 
aberrations, and genotype specific selection promoting additional oncogenic behavior 
is a possible scenario in accordance with the theory of natural selection. 
 
5.1.4. Association of WRAP53 SNPs to clinicopathological and molecular data 
The statistical analyses investigating the association of the WRAP53 SNPs  
(c.–245G>C, R68G, F150F and A522G) to clinical, pathological and molecular 
parameters revealed no significant results except two findings related to subcellular 
WRAP53 protein localization. SNPs represent normal sequence variations and are 
generally not expected to strongly associate to clinicopathological parameters. The 
associations to WRAP53 localization were found intriguing by the indicative that the 
subcellular distribution of WRAP53 influences breast cancer prognosis (Langerod et 
al., unpublished data).   
  The exon 1β c.–245G>C heterozygous (G/C) genotype was significantly 
associated with nuclear WRAP53 localization, a feature of favorable breast cancer 
prognosis, but did not predict improved breast cancer outcome compared with the 
homozygous (G/G) genotype in the survival analysis (p=0,47). The low heterozygous 
(G/C) genotype frequency (figure 16) introduced a weakness in the statistical analyses 
that might affect the results. Although nuclear WRAP53 localization displays 
prognostic value in breast cancer, the prognostic feature may not be directly related to 
c.–245G>C genotype. Still, the association is intriguing and should be further 
validated in larger studies.  
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The R68G heterozygous (C/G) and minor homozygous (G/G) genotypes 
significantly associated with combinatory negative or positive nuclear and 
cytoplasmic protein localization (figure 17), the two sub-cellular protein distribution 
alternatives of least distinctive prognostic impact. The association with WRAP53 
distribution might indicate that the c.–245G>C and R68G SNPs are involved in 
cellular WRAP53 localization. There are no publications discussing possible 
underlying causes of breast tumor differences in cellular WRAP53 localization, or 
probable reasons why nuclear WRAP53 localization is a positive prognostic factor 
(Langerod et al., unpublished data). The following perspectives will because of this 
remain speculative. 
 The c.–245G>C and R68G SNPs might be associated to protein localization, 
although the low number of observations slightly reduces the confidence of the 
current statement. The association between c.–245G>C and nuclear WRAP53 
localization could be expected reflected in the breast cancer survival analyses, but it 
was not (p=0,47). Exon 1β is non-coding and should not be important to protein 
structure and function, but its potential regulatory activity could be affected by 
sequence alterations further involved in protein localization. Since the R68G SNP 
associated with the WRAP53 distributions of least utility according to prognosis, the 
result that indicated a statistical not significant relation between R68G and survival, 
although an observed trend (p=0,114), was not unexpected. There is a possibility that 
the R68G SNP could be located near or within a cellular localization signal, but no 
such WRAP53 regions are currently known.  
 The increased breast cancer-specific survival by nuclear WRAP53 localization 
is an interesting observation. One hypothesis discuss that WRAP53 might be involved 
in DNA repair mechanisms, detaining the accumulation of somatic mutations 
(Langerod et al., unpublished data). This is classical tumor suppressor gene functions, 
and a conflicting hypothesis due to previous publications discussing WRAP53 
functions in cancer. Tumor suppressor genes are in cancer frequently inactivated by 
mutational events [11], a feature not directly supported by the detected alterations in 
the WRAP53 mutation analysis, but loss of heterozygosity and epigenetic methylation 
are as well mechanisms that might affect WRAP53 function. 
Another possible hypothesis concerning sub-cellular WRAP53 protein 
localization involves the WRAP53 overexpression observed in cancer cells. WRAP53 
overexpression increases the p53 antisense transcript levels, subsequently increasing 
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cellular p53 activity [1]. p53 is a key molecule in DNA repair and apoptosis [40], 
important anti-tumorigenic mechanisms. WRAP53 is as well reported to regulate 
cellular levels of mutated p53 [1], an intriguing observation since TP53 mutated 
tumors with nuclear WRAP53 localization in particular display improved prognosis 
(Langerod et al., unpublished data).  
 
5.1.5. WRAP53 SNPs and survival analyses 
One of the four SNPs analyzed, WRAP53 F150F, was found significantly associated 
with breast cancer-specific survival. It is uncommon that one SNP displays such 
significant influence on survival, and in particular when the alteration is silent. 
Despite less significant results, a clear trend was observed in the R68G (p=0,114) and 
A522G (p=0,133) SNPs, indicating that the respective heterozygous and minor 
homozygous genotypes overall associated with a poorer breast cancer prognosis. 
 The genetically linked WRAP53 SNPs (R68G, F150F and A522G) and the 
defined haplotype block make it difficult to determine the actual cause of the reduced 
survival in F150F heterozygous (C/T) and minor homozygous (T/T) genotype carriers 
compared to the major homozygous (C/C) genotype carriers. The difference in 
survival might be a direct cause of the F150F SNP, or it could be an indirect effect 
caused by the WRAP53 haplotype. The publication by Garcia-Closas et al. (2007) 
indicates that the LD R68G and F150F SNPs also are genetically linked to TP53 
SNPs [65]. TP53 is a well-known prognostic marker of breast cancer and some SNPs, 
e.g. Arg72Pro, have been suggested to associate with survival [121]. There is a 
possibility that the haplotype involves other SNPs of greater influence to breast cancer 
survival, mediating the difference in survival observed by the WRAP53 F150F SNP. 
An extended SNP analysis including WRAP53 and neighboring genes will be 
necessary to outline this possibility. 
The survival analyses stratified for TP53 mutation and ER status revealed 
interesting results regarding WRAP53 SNPs (R68G, F150F and A522G) genotypes. 
The heterozygous and minor homozygous genotypes were significant (R68G and 
A552G) or borderline significant (F150F) associated with reduced survival in wt 
TP53 tumors, and overall associated with significant reduced survival in ER positive 
tumors compared to the major homozygous genotypes. No genotype-dependent 
survival differences were observed in the TP53 mutated and ER negative tumors.  
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 TP53 mutation status and ER status are strongly associated with different 
breast cancer subtypes. TP53 mutations and ER negativity occur commonly together 
and is related to poor prognosis compared to patients with wt TP53 and ER positivity 
[30]. The overall poor prognosis might be an explanation why no WRAP53 SNPs 
genotype-dependent differences in survival was detected in the TP53 mutated and ER 
negative tumors. The alternative hypothesis is that the SNPs genotype-related survival 
only affects the wt TP53 and/or ER positive tumors.  
ER positivity is a tumor characteristic that is associated with favorable breast 
cancer prognosis. This is among other things due to available targeted hormonal 
therapies like tamoxifen and aromatase inhibitors. The WRAP53 SNPs were able to 
split the patients into a good and poor prognosis group, and may have the potential to 
predict who benefits from hormonal treatment. Further investigation is needed to 
validate the findings and understand the possible mechanisms. An analogue to the 
observation in the ER positive tumors is the metabolic capacity of Cytochrome P450 
2D6 (CYP2D6) and the response to tamoxifen treatment. Tamoxifen is an estrogen 
receptor antagonist prodrug metabolized by CYP2D6, a gene of highly phenotypic 
variabilities that affects the enzymatic capacity. Poor metabolizers have very little or 
no CYP2D6 activity and responds poorly to tamoxifen treatment while responders 
display normal metabolic capacity and responds well [122], roughly dividing ER 
positive tumors in two groups. 
 The underlying causes of the different prognostic effects seen in wt TP53 
versus mutated TP53, and in ER positive versus ER negative tumors are hard to 
predict. Since the WRAP53 SNPs (R68G, F150F and A522G) induces similar effects 
on survival and the SNPs are inherited together and possibly selected for, WRAP53 
seem to be a gene of importance in breast tumorgenesis. The significant differences in 
survival observed in wt TP53 and in ER positive tumors might be used therapeutically 
to avoid over-treatment of the WRAP53 SNPs major homozygous genotype carriers, 
and perhaps intensify the treatment of heterozygous and minor homozygous genotype 
carriers.  
The WRAP53 sequence alterations detected in the current study are interesting 
in relation to breast tumorgenesis, and the findings should be validated in larger 
studies. The potential of WRAP53 SNPs used as biomarkers in wt TP53 and ER 
positive breast cancer patients is intriguing, and whether this may be related to 
hormonal treatment responses should be investigated. Further research is as well 
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needed to in general investigate the importance of WRAP53 in breast cancer, due to 
the limited knowledge about WRAP53 functionality. The results from this study 
indicate that WRAP53 might be a marker of prognostic value in breast cancer, and the 
importance of the WRAP53 SNPs genotypes in relation to protein localization and 
breast cancer-specific survival should be further studied. 
 
 
5.2. Gene expression study 
5.2.1. Experimental considerations 
Breast cancer cell lines are model systems extensively used to investigate and better 
understand breast cancer. In this study, MCF-7 and MDA-MB-231 were used to 
explore the cellular responses to WRAP53 knockdown. MCF-7 and MDA-MB-231 
are the most commonly used cell lines in breast cancer research, and were chosen 
because of their extensive use and their differences according to e.g. TP53 mutation 
and ER status, features characteristic of the two main sub-types of breast cancer, the 
luminal and basal-like. Differences in TP53 mutations status was especially 
emphasized in the experimental study design due to the reported WRAP53-mediated 
p53 regulatory mechanism [1]. Other cell lines could have been included in the study 
as well, but due to the probable hypothesis creating study content, uncertainties 
according to expected findings and the economical aspect, the size of the study was 
moderated.  
The MCF-7 and MDA-MB-231 WRAP53 knockdown was performed using an 
siRNA targeting WRAP53 exon 2 (Qiagen) inducing an isoform-independent 
knockdown. Another WRAP53 siRNA targeting exon 6 is offered by the same vendor, 
but the WRAP53 exon 2 targeting siRNA has proven to be most efficient according to 
experiences made by Farnebo and colleagues at CCK (90% WRAP53 mRNA 
knockdown) [123]. WRAP53α and WRAP53γ generates certain splice variants lacking 
exon 2, the siWRAP53#2-specific binding site (figure 7), which is a possible cause of 
the incomplete WRAP53 knockdown in our system. In this study, only one siRNA 
was used in the WRAP53 knockdown to restrain the number of variables affecting the 
cellular responses to WRAP53 depletion. A mix containing several siRNAs targeting 
the same genes is commonly used in transfection experiments.  
73 
 
RNA was harvested from the MCF-7 and MDA-MB-231 cells 40 and 72 hours 
after siRNA transfection. WRAP53 depletion is previously reported to induce 
apoptosis in cancerous cells 48–62 hours after transfection [3]. This was not observed 
when the MCF-7 and MDA-MB-231 cells were siC or siWRAP53#2 transfected and 
subsequently stained for Annexin V at 36, 48, 60 and 72 hours after transfection. The 
observations from the optimization of the siRNA transfections uncovered that the 
WRAP53 depleted MCF-7 and MDA-MB-231 cells did not enter apoptosis 72 hours 
after transfection, which made it possible to obtain a more complete WRAP53 
knockdown.  
RNA was harvested from the MCF-7 and MDA-MB-231 siC and 
siWRAP53#2 transfected cells cultured in triplicates, and from the NTC cells grown 
as single samples (table 2). Microarray-based analyses are multi-step procedures 
influenced by numerous sources of variation, but analyzing samples in replicates 
increases the results reliability. To compensate the lack of NTC cell replicates, the 
samples were analyzed twice using microarrays as technical duplicates. By using 
biological replicates, experimental variation was measured and made it possible to 
remove outliers from the dataset. The replicates contributed to determine if gene 
expression differences between measurements were caused by actual biological 
variations or randomly, and increased robustness of the conclusions. High cost of 
microarrays often restrains the number of included replicates, but the costs should 
always be considered versus data quality. Technical replicates are used in larger 
sample series to control that the experimental conditions are reproducible and do not 
affect the gene expression experiments and results over time [124].   
 Microarray data quality control was performed using the GeneSpring GX 12.0 
software (Agilent Technologies) PCA plot to capture dataset variance. Samples from 
the same experimental condition are expected to group closely to each other [104], 
and deviant sample grouping might be explained  by poor sample quality or actual 
biological variation. By eliminating one sample outlier (MDA-MB-231 siWRAP53#2 
transfected cells, 40 hours, triplicate 1), the cell line-specific samples grouped 
together in the PCA plot (figure 22). There was on the other hand no specific trends in 
the alignment of each respective group according to siRNA treatment (NTC cells, siC 
and siWRAP53#2 transfected cells). This may be due to the small number of samples 
analyzed or experimental variation, but the most probable cause is that the actual 
siWRAP53#2-induced gene expression changes are minor to and dominated by the 
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cell line-specific gene expression patterns. To minimize the impact of experimental 
variabilities, the samples were placed on the microarrays randomly. 
5.2.2. Considerations regarding bioinformatics and statistical analyses  
Microarray gene expression analyses generate huge amounts of data and introduce 
challenging assignments according to data processing and interpretation.  
 In accordance with the recommendations from Agilent Technologies, the 
microarray data was normalized using the 75th percentile shift method. Percentile 
normalization presumes that a certain level of expression values is equal for all arrays. 
Both the 50th and 75th percentile is frequently used, as well as other methods like 
quantile and housekeeping genes normalization [104, 125]. However, in gene 
expression analyses, the 75th percentile normalization is often preferred because it is 
a more robust method for measuring small intensity values, and because the percentile 
should be well within the range of detectable data [126]. 
 The statistical significant WRAP53 knockdown-induced gene expression 
changes were identified using SAM. SAM is a commonly used analytical tool in 
microarray experiments, handling huge datasets in a non-parametric approach that not 
requires normal distributed data [127]. Compared to conventional t-tests for the same 
approach, SAM is proven superior for microarray data analyses [106]. Several 
statistical correction methods have been developed to restrain the fraction of false 
positive results by analyzing huge amounts of data. Bonferroni is a frequently used 
method, but the analysis is very conservative. FDR is a more sensitive method, an 
important consideration choosing SAM in this study, even though the risk of false 
positive results increases coincidentally compared to the Bonferroni method [106].  
 IPA was used in the pathway analysis to associate significant gene expression 
alterations to biological functions. A weakness of the analysis is that the outcomes are 
merely based on the dataset gene identifications, excluding the genes significance 
levels according to expression alterations. A more weighted analysis including such 
information could to a greater extent list the most significant biological results in the 
datasets. Another challenge using IPA is the wideness of the biological functional 
outcomes, an aspect that might complicate the work of understanding connections and 
draw conclusions. An advantage using IPA is that that the Ingenuity Knowledge Base 
contains manually curated data from scientific articles [108]. 
 
5.2.3. WRAP53 knockdown efficiency and RNA isolation 
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The MCF-7 and MDA-MB-231 WRAP53 knockdown efficiency was evaluated by 
qPCR and Western blot analyses, and by qPCR quantified to 75% and 70% (figure 
21), respectively. Despite incomplete knockdown, the results were considered 
satisfactory. The loading control (here β-actin) was used to ensure proper Western 
blot interpretations. The controls are used to assure that gel lanes are equally loaded 
with sample, an important aspect when protein expression levels are compared 
between different samples. Loading controls usually display constant cell type-
specific expressions, so the expression levels should not vary between sample lanes 
[128], indicating actual siRNA-induced WRAP53 depletion in this study (figure 20). 
The WRAP53 knockdown was more prominent in the MCF-7 than the MDA-
MB-231 cell line reflected by lower protein band intensities (figure 20). This might be 
a result of the initial abundant MDA-MB-231 WRAP53 expression levels or a delayed 
knockdown compared to the MCF-7 cell line. Another feature is that MCF-7 cells do 
not express the WRAP53γ isoform [1], but this is probably not the explanation to the 
differences in WRAP53 knockdown efficiency, since WRAP53γ overall is the least 
abundant expressed isoform [78]. 
 The purity of the MCF-7 and MDA-MB-231 RNA samples were measured 
using the NanoDrop
®
 ND-1000 Spectrophotometer. The calculated 260/280 ratios 
from these measurements were slightly lower (ranging from 1,75–1,95) than the 
recommendations for pure RNA. Reduced ratios indicate presence of co-purified 
contaminants like proteins or phenols absorbing at or near 280 nm [75]. The TRIzol
®
 
reagent used for RNA isolation is a phenolic solution containing guanidine 
isothiocyanate strongly absorbing at 230 and 270 nm [129], and residues might affect 
RNA purity. The measured 260/230 RNA ratios were primarily within the 
recommended range of pure RNA.  
 Despite the low 260/280 RNA ratios, there were no signs that reduced RNA 
purity affected the quality of the microarray analyses. The yield of cRNA and the 
specific activity according to cRNA Cy3 incorporation (Appendix C, step 4) fulfilled 
the quality requirements in the microarray procedure. Sample quality was after 
microarray scanning further evaluated by the Feature Extraction software (Agilent 
Technologies), approving all samples. 
 
5.2.4. Significance Analysis of Microarrays 
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Cell line specific gene expression changes as a response to siRNA WRAP53 
knockdown was investigated using SAM. WRAP53 depletion primarily resulted in 
upregulation of gene expression, most clearly detected 72 hours after transfection. No 
significant changes were detected comparing gene expression patterns in the NTC 
cells and the siC transfected cell within each cell line, indicating that the siRNA 
transfection procedure itself did not influence with the cellular gene expression levels.  
Gene expression alterations in the siWRAP53#2 transfected cells were thus caused by 
WRAP53-targeted gene silencing. In addition, WRAP53 was observed significantly 
downregulated in both cell lines 72 hours after transfection, designating efficient 
knockdown.   
 The results generated from SAM reflected the qPCR and Western blot 
findings, indicating that the WRAP53 knockdown response occurred more slowly in 
the MDA-MB-231 than the MCF-7 cell line. The MCF-7 gene expression alterations 
occurred more prominently throughout the whole experiment, with overall greater 
fold change and lower FDR values than observed in the MDA-MD-231 cell line 
(Appendix E, table 11 and 12). The aim was to generate SAM gene lists of 
manageable sizes (300–600 genes) for the downstream data analyses, and with low 
FDR values (ideally FDR < 5%) to obtain as reliable gene datasets as possible 
restraining the incidence of falsely positive results. In the MDA-MB-231 cell line, 
data reliability according to significant differentially expressed genes was reduced, 
giving an increased FDR value. In this case, satisfactory FDR values resulted in fewer 
listed genes, a disadvantage in the following pathway analyses according to the aim of 
widely studying the cellular responses by WRAP53 knockdown. To obtain a list of 
MCF-7 comparable numbers of genes a FDR value of 10,5% was accepted, an action 
giving decreased but still sufficient data reliability, but an important aspect to 
consider in further data analyses and interpretations. 
 
5.2.5. Pathway analyses 
To investigate the biological functions associated with MCF-7 and MDA-MB-231 
upregulated genes 72 hours after WRAP53 siRNA transfection, pathway analyses 
using IPA were performed. The IPA calculated p-values helped identify significant 
cellular functions, pathways and molecules in the WRAP53 siRNA-induced gene 
expression alterations, and acted as starting points for further investigation to 
understand the biological implications of the significant results. In the process 
77 
 
towards biological comprehension, the necessity of exploring supportive evidence and 
potential interesting biological results, even without statistical significance, should not 
be underestimated [109].  
 Overall, the most interesting findings in the pathway analyses were the results 
significantly associating cancer and cancer-related characteristics with the MCF-7 and 
MDA-MB-231 upregulated gene datasets. In both cell lines, cancer was listed as the 
most significant disease (table 6 and 7), and the same was observed analyzing the 
MCF-7 and MDA-MB-231 mutually upregulated genes (table 9). Both cell lines, with 
an extensive number of mapped molecules, displayed significant associations to the 
biological functions of cellular movement, growth and proliferation, well 
acknowledged cancer hallmarks [18]. This may indicate that WRAP53 knockdown 
actually induces cellular responses favoring tumorigenic activities. The pathway 
analyses results are merely based on the gene expression differences induced by 
WRAP53 depletion, and cancer associations were no obvious outcomes. In accordance 
with the aims of this study, the cancer-related results will be the main focus of the 
discussion. 
In the MCF-7 cell line, WRAP53 knockdown did not result in any statistical 
significant canonical pathways (p > 0,05) (table 6). However, the p53 signaling still 
occurred as an interesting result (p=0,097). WRAP53 is reported to regulate 
endogenous p53 mRNA and protein levels, and downregulated WRAP53 expression 
to suppress p53 induction upon DNA-damage [1]. Increased p53 activity was thus not 
an expected response to WRAP53 knockdown, but the p53 transcription factor 
regulates the expression of a myriad of target genes which might cause increased p53 
signaling. The MCF-7 upregulated genes in the p53 signaling pathway primarily 
encoded cell cycle inhibitors and p53-induced pro-apoptotic proteins, features of 
possible relation to the occurrence of cell death as the top significant biological 
function. WRAP53 depletion by siRNA treatment is reported to induce apoptosis in 
cancerous cells 48–62 hours after transfection [3], but this was not observed in either 
the MCF-7 or MDA-MB-231 cell line. The upregulated p53 signaling might still be a 
post-transfectional cellular stress response, a hypothesis supported by the upregulation 
of cell death-related genes counteracting with the outcomes of cancer promoting 
characteristics.  
 Another pathway of notice from the analysis of MCF-7, although not 
statistical significant, was the Vitamin D Receptor (VDR)/Retinoic Acid X Receptor 
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(RXR) activation, a significant pathway when analyzing the mutually upregulated 
MCF-7 and MDA-MB-231 genes (table 9). The VDR is a nuclear receptor that 
transcriptionally regulates its target genes by binding the vitamin D ligand. Activated 
VDR dimerizes with the RXR, which modulates the transcriptional activity [130]. The 
VDR receptor are under normal conditions involved in multiple cellular pathways, but 
different polymorphic variants are reported involved in several types of cancers as 
well [131], a possible relation to the cancer-related outcomes. Despite interesting 
biological results, the MCF-7 borderline significant p-values and relatively low ratios 
require careful interpretation.     
Of the top five listed significant transcription factors, TP53 and TP63 were 
found to regulate a considerable fraction of the MCF-7 upregulated genes (table 6). 
p53 dysregulation is a well-known oncogenic feature, but TP53 also regulates 
numerous target genes under normal cellular conditions. TP63 belongs to the “p53 
family” of genes and displays a TP53 sequence homology in the DNA-binding 
domain of > 60%. The sequence homology results in mutually shared target genes, 
and may explain the observations in the MCF-7 dataset even though TP63 primarily is 
involved different cellular processes than TP53, such as skin and limb formation 
[132]. MCF-7 WRAP53 depletion seems to upregulate numerous TP53 and TP63 
regulated genes, an outcome presumed to be associated with a possible cellular stress 
response. The ATF3 and FOSL2 were also interesting transcription factors, 
considering the cancer-related results from the pathway analysis. ATF3 is activated by 
various signals, including many encountered by tumor cells, but is also involved in 
cellular stress responses [133], while FOSL2 belongs to a gene family important in 
cell proliferation, differentiation, and transformation regulation [134]. 
Although cancer was listed as the most significant disease, and cellular 
movement, growth and proliferation as top biological functions, the most striking 
result from the MDA-MB-231 pathway analysis was that most categories displayed 
immune systemic characteristics (table 7). Biological functional results including 
inflammatory response, antigen presentation, cell-to-cell signaling and interactions, 
and cellular development are all immune-related mechanisms. Three of the listed 
canonical pathways were also immune response-associated and identified interleukin-
17A (IL-17A) as a molecule of particular interest. IL-17A belongs to the interleukin 
17 (IL-17) family of proinflammatory cytokines, and induces the production of other 
cytokines and chemokines creating inflammatory environments. The IL-17 family is 
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associated with a diversity of human diseases [135], but the role of IL-17 in 
malignancies is unclear. Conflicting data exists concerning a potential involvement in 
cancer, indicating both IL-17-induced angiogenesis and T-cell-mediated tumor 
rejection [136]. In addition, one study has reported an association between IL-17A 
gene polymorphisms and breast cancer risk and prognosis [137]. Tumor-promoting 
inflammations have the last decade become a field of great attention in research on 
tumor development, where innate immune cells are presumed to create an 
inflammatory tumor environment promoting multiple cancer hallmarks capabilities 
[18].  
The IPA results emphasizing the immune system were further reflected in the 
transcription factors that regulated the expression levels of the MDA-MB-231 
upregulated genes (table 7). NFκB is a complex of gene regulatory proteins, including 
RELA, activated in many stressful, inflammatory and innate immune responses. In the 
MDA-MB-231 gene set, NFκB and RELA were the transcription factors regulating the 
expression of the major fraction of upregulated genes. Active NFκB increases the 
transcription level of hundreds of target genes involved in inflammatory and innate 
immune responses, but excessive NFκB signaling is also observed various human 
cancers [5].  
Another interesting transcription factor was the estrogen receptor 1 (ESR1), 
mediating the actions of estrogen. Normally, ESR1 is involved in sexual development 
and reproductive function, but is also detected in pathological states like endometrial 
and breast cancer [138]. ERS1 is as well a key molecule in breast cancer by 
characterization of the main subtypes [30], and as a predictive marker of targeted 
hormonal therapy. ESR1 is one of the first evidences of personalized medicine based 
on molecular knowledge [23]. It is therefore intriguing to find a possible association 
to WRAP53.  
 The upregulation of immune responses in the MDA-MB-231cell line most 
likely was a response to WRAP53 depletion, although there are to our knowledge no 
publications that indicate such an association. Gene expression silencing through 
RNA interference using siRNAs has become a powerful tool to study gene functions. 
This strategy relies on a high degree of specificity to obtain efficient gene silencing, 
but different non-specific effects, including activation of the immune system, have 
been reported. The pathways for siRNA recognition and immune system activation 
are not completely understood, but Toll-like receptors (TLRs) seem to be central 
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participants. TLRs activate the innate immune system by recognizing pathogen-
associated molecular patterns like viral dsRNAs, the same molecular structure found 
in siRNAs. TLR ligand activation by siRNAs triggers downstream activation of the 
interferon regulatory factor, NFκB and MAPK pathways, leading to increased 
expression levels of interferon (INF) and proinflammatory cytokines mediating an 
unwanted immune response [139, 140]. The immunogenic activity of siRNAs mainly 
seem to be associated to specific structural motifs, delivery methods using cationic 
lipids and increasing siRNA concentrations, although contradictory observations exist 
[140]. To avoid siRNA-induced non-specific immune responses it is recommended to 
be conscious of the siRNA design, use low siRNA concentrations (10–20 nM) and 
several siRNAs targeting a specific gene [141]. 
 In the MDA-MB-231 cell line, there are reasons to assume that the immune 
response outcomes from the pathway analyses were actual effects of the WRAP53 
knockdown. The responses were not present in the MDA-MB-231 siC transfected 
cells, indicating satisfactory transfection conditions. No typical INF stimulated genes 
(including JAK1, TYK2, STAT1, STAT2 and IRF9) [139] were upregulated by the 
siWRAP53#2 transfection. However, it is not possible to totally exclude the 
alternative explanation of a non-specific immune response. The results should 
therefore be validated, e.g. by using other siRNAs to target WRAP53 in the MDA-
MB-231 cell line [141]. 
Since the MCF-7 and MDA-MB-231 pathway analyses displayed similar 
results including cancer and cancer-related characteristics, the aim was to find 
indications of one or several biological functions associated with WRAP53 
knockdown prominent enough to be detected in both cell lines. According to the 
general cancer features like cellular growth, proliferation and movement, there is a 
possibility that WRAP53 could be involved in cancer-related biological functions 
present in different cells types and tissues. A Venn-diagram tool [115] identified 29 
shared MCF-7 and MDA-MB-231 upregulated genes (figure 24, table 8), and the 
subsequent pathway analysis results listed cancer as the most significant disease (table 
9). Cellular growth, proliferation and movement were repeatedly displayed as 
significant biological functions, supporting the assumption that WRAP53 might be 
involved in cancer promoting activities. The MCF-7 and MDA-MB-231 genetic 
overlap was not extensive (29 out of 299 and 249 genes, respectively), but cancer still 
emerged as a significant outcome. The list of mutually upregulated genes (table 8) 
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was investigated pursuant to classical cancer-associated features like proliferation, 
cell cycle control, DNA repair, apoptosis and telomerase function using the NCBI 
Gene database
12
, but no distinctive functions emerged. Cancer is a heterogeneous 
group of genetic diseases involved in dysregulation of complex cellular pathways and 
mechanisms. Lack of consistent functions of the mutually expressed MCF-7 and 
MDA-MB-231 genes made it difficult to further specify the cancer-related findings. 
The pathway analysis of the mutually upregulated genes displayed results 
comparable with the cell line-specific analyses, but there were some deviant 
outcomes. VDR/RXR activation was listed as the most significant canonical pathway, 
and NR1D1 and NR3C1 were listed as significant transcription factors in addition to 
the previous reported ATF3, ESR1 and ATF2 (table 9). IPA assess the biological 
functions most significant to the dataset of interest [108], but the number of genes 
analyzed might affect the levels of statistical significance. In the MCF-7 pathway 
analysis, VDR/RXR activation was not displayed as a statistical significant result 
although the ratio (table 6) was higher compared to the corresponding significant 
outcome of VDR/RXR activation by analysis of the 29 MCF-7 and MDA-MB-231 
mutually upregulated genes (table 9). Small number of genes may influence the 
outcome of statistical analyses, and therefore, the importance of VDR/RXR activation 
by WRAP53 knockdown should be interpreted cautiously. The NR1D1 and NR3C1 
transcription factors showed statistical significance in the separate MCF-7 and MDA-
MB-231 analyses as well, although not as the top five most significant results. This 
strengthens the data reliability despite the low gene number in the MCF-7 and MDA-
MB-231 mutual analysis. NR1D1 and NR3C1 are receptors involved in cellular 
proliferation, differentiation and inflammatory responses [142, 143], relevant 
mechanisms in cancer.   
The MCF-7 and MDA-MB-231 WRAP53 knockdown resulted in cell type-
specific biological responses, but cancer and cancer-related characteristics like 
cellular growth, proliferation and movement emerged as common denominators. The 
MCF-7 and MDA-MB-231 are quite different cell lines, a possible explanation to the 
differences in cellular responses from silencing the same gene. The WRAP53 
knockdown responses might as well reflect the breast cancer subtypes from which the 
cell lines were retrieved, and give knowledge of their different biology. Although 
                                                          
12
 Available from http://www.ncbi.nlm.nih.gov/gene/ 
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TP53 mutation status was an important consideration in the study design, it is difficult 
to directly relate the cell line differences of TP53 mutation and ER status to the 
pathway analyses outcomes. In the MCF-7 analysis, p53 signaling and the TP53 and 
TP63 transcription factors emerged as interesting results. The same results were not 
observed in the MDA-MB-231 cell line, a difference that might be related to TP53 
mutation status. The MCF-7 cell line is wt TP53, and there is a possibility that the 
TP53 mutated MDA-MB-231 is unable to activate p53 signaling. In addition, the 
statistical significance of the ESR1 transcription factor was observed in the MDA-
MB-231 cell line, although the cell line is derived from an ER negative tumor. This 
indicates that WRAP53 knockdown might induce different responses in distinct cell 
types and tissues, making it difficult to study the specific biological aspects of 
interest. The possible non-specific immune systemic effects in the MDA-MB-231 cell 
line might as well be a contributory factor to the differences observed.  
WRAP53 depletion has been reported associated with apoptosis in cancerous 
cells and progressive telomere shortening [3, 64], but cancer-related outcomes were 
not the expected and evident results by WRAP53 knockdown. The findings support 
the hypothesis of WRAP53 involvement in cancer development, but IPA relates the 
gene datasets to relatively wide biological functions and makes it hard to answer 
specific questions. No specific pathway promoting an explanation of WRAP53 
influence in breast cancer was identified, but the results do not exclude WRAP53 as a 
gene involved in tumorgenesis. The results should be validated in patient cohorts or 
by functional studies including other WRAP53 siRNAs and breast cancer cells lines to 
ensure efficient, specific knockdown. Further research will be needed to understand 
the possible influence of WRAP53 in breast cancer, and the potential of WRAP53 as a 
therapeutic target. Increased knowledge concerning normal WRAP53 function should 
also be pursued prior to a future potential in targeted cancer therapy. 
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6. Conclusion 
The significance of WRAP53 in breast cancer was investigated performing a WRAP53 
mutation analysis in primary breast carcinomas and a gene expression study in 
WRAP53 depleted breast cancer cell lines as an approach to increase the knowledge 
about WRAP53 cellular signaling pathways and networks. 
 Somatic WRAP53 mutations do not seem to be important events in breast 
tumorgenesis, but detected WRAP53 SNPs, directly or indirectly, displayed significant 
impact on breast cancer-specific survival. The haplotype SNPs, R68G, F150F and 
A522G, all displayed genotype-dependent survival, and the effect was most 
prominent when stratifying for the TP53 mutation and ER status. The survival of wt 
TP53 and ER positive tumors were influenced by WRAP53 SNPs genotypes, while 
the outcomes in TP53 mutated and ER negative tumors were unaffected. The exon 1β 
c.–245G>C SNP was found associated with nuclear WRAP53 localization, a feature 
of favorable prognostic impact in breast cancer (Langerod et al, unpublished data). 
The SNP results indicate that WRAP53 might be a marker of prognostic value in 
breast cancer. The SNP haplotype however complicates the interpretation of WRAP53 
significance in breast tumorgenesis, since the R68G SNP occurs in a haplotype that 
includes at least one SNP known to affect breast cancer prognosis [65, 121].  
WRAP53 depletion in the MCF-7 and MDA-MB-231 cell lines induced gene 
expression alterations and cell type-specific responses, but cancer and cancer-related 
characteristics emerged as common denominators. These results suggest that WRAP53 
might be involved in tumorgenesis, although no classical cancer genes were identified 
among the genes that showed expression alterations. No obvious cancer-related 
pathways or networks were identified to clarify the actual roles of WRAP53 in cancer. 
Further research will thus be needed in the search for new therapeutic targets related 
to WRAP53 function, and increased knowledge about normal WRAP53 functionality 
should also be pursued prior to therapeutic targeting.   
 The current study aimed to elucidate the function of WRAP53 using two 
different approaches. Although is difficult to directly connect the results from the 
mutation analysis and gene expression study, they both suggest that WRAP53 might 
be involved in tumorgenesis. The results should be validated in independent studies, 
and further research will be needed to understand the importance of WRAP53 in 
breast cancer.  
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7. Future aspects 
Further investigation of the WRAP53 gene is of current interest according to its 
potential involvement in tumorgenesis. The association with p53 regulation and 
telomerase activity are also features of interest in this context. The exact biological 
functions of WRAP53 are today probably not fully known, but will be important to 
reveal in the process towards a greater understanding of WRAP53 significance in 
cancer development, and especially in breast cancer that was the focus of this study. 
Suggestions to further WRAP53 studies are subsequently listed; 
 
• DNA sequence the WRAP53 start exon 1α. Exon 1α is the p53 regulatory region of  
  WRAP53, and sequence alterations might influence the sense/antisense regulation  
  and affect p53 activity. 
• Validate the findings from the WRAP53 mutations analysis in larger studies,  
  especially to investigate the frequency and possible importance of indel alterations.  
• Correlate the WRAP53 SNPs (R68G, F150F and A522G) and haplotypes with  
  WRAP53 gene expression levels, and further relate these results to breast cancer-  
  specific survival.    
• Investigate whether the WRAP53 SNPs are involved in sub-cellular WRAP53  
  protein localization due to the prognostic impact observed in breast cancer.  
• Try to modulate the effect induced by WRAP53 SNPs on protein function.  
  Restricted knowledge about WRAP53 structure may thus be an analysis limitation.   
• Further investigate the data obtained from the gene expression study using other  
  bioinformatics tools, including gene ontology approaches in order to study WRAP53  
  functionality. 
• Repeat the gene expression study using other WRAP53 siRNAs to validate the  
  findings, but also investigate if immune response activation in the MDA-MB-231 is  
  a non-specific response or actually caused by WRAP53 depletion.  
• Irradiate cultured cell lines and compare WRAP53 gene expression patterns before  
  and after radiation. Radiation is a stress stimulus causing DNA damage responses,  
  and may be an approach to investigate if WRAP53 is involved in DNA repair  
  mechanisms. 
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APPENDIX A: Protocol – NanoDrop® ND-1000 Spectrophotometer  
To perform NanoDrop
®
 ND-1000 Spectrophotometer absorbance measurements, the 
instrument has to be connected to a computer. Turn on the computer and open the 
instrument software (ND-1000 Software v7.3.1, Thermo Scientific). Clean the optical 
surfaces using lens-cleaning tissues (Special lens-leaning tissue, Assistent
®
, No 1019) 
and initialize the instrument by pipetting 1,0 µl DNase/RNase free water (GIBCO, 
Ref 10977-035) onto the lower measurement pedestal, lower the sampling arm and 
press OK using the operating software. Make sure to use the instrument DNA-
application (DNA-50) by DNA measurements. Initiate a blank measurement using the 
DNA dilution agent, and by pressing BLANK. Spectral sample measurements are 
performed the same way by pipetting 1,0 μl sample, and pressing MEASURE. Keep 
the samples on ice while measuring and wipe the optical surfaces using lens-cleaning 
tissue between each measurement to prevent sample carryover. Reblank the 
instrument for every tenth sample measured. Clean the optical surfaces and print the 
result report when finished (Thermo Fisher Scientific Inc, 2008). 
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APPENDIX B: Protocol – BigDye® Direct Cycle Sequencing Kit  
Primary reference: BigDye
®
 Direct Cycle Sequencing Kit Protocol (Life 
Technologies). 
Commercial kits were used in the WRAP53 mutation analysis; 
 • BigDye® Direct Cycle Sequencing Kit (Applied Biosystems, Part. No. 4458688). 
 • BigDye® XTerminator™ Purification Kit (Applied Biosystems, Part. No. 4376484). 
 
The BigDye
®
 Direct Cycle Sequencing Kit and 3730 DNA Analyzer operation 
procedures involve contact with possible hazardous compounds. The XTerminator
™ 
Solution and 10x 3730 Buffer with EDTA are irritant to eyes, respiratory system and 
skin, and the EDTA buffer might as well cause eye damage. The SAM
™
 Solution and 
POP-7
™
 Performance Optimized Polymer are irritants to eyes and skin. Chemicals 
should be handled with care and by wearing appropriate personal safety equipment. 
Use gloves all times to protect the samples. 
 
STEP 1: PCR amplification 
1.1) For each forward or reverse reaction, add the components as displayed in table 1  
       to an appropriate reaction plate (MicroAmp
™
 Optical 96-Well Reaction Plate  
       with Barcode, Applied Biosystems). Use 1,0 µl DNase/RNase free H2O instead  
      of genomic DNA to include negative controls.  
 
Table 1: Component concentrations and volumes required to PCR amplify one sample 
Components Volume 
Genomic DNA (5 ng/µl)  1,0 μl 
WRAP53 M13-tailed Fwd PCR primer (0,8 µM) 0,75μl 
WRAP53 M13-tailed Rev PCR primer (0,8 µM) 0,75 μl 
BigDye
®
 Direct PCR Master Mix 5,0 μl 
DNase/RNase free H2O (GIBCO, Ref 10977-035) 2,5 μl 
Total volume for each reaction 10,0 μl 
 
1.2) Mix the components well by pipetting up and down, seal the plate with caps  
       (Domed Cap Strip, Thermo Scientific) and centrifuge the reaction plate briefly.  
1.3) Run the PCR amplification in a thermal cycler as displayed in table 2. 
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Table 2: Time and temperature conditions during PCR amplification  
Stage 
Tetrad 2 Thermal Cycler (Bio-Rad) 
Temp Time 
Hold 96°C 5 min 
Cycle 
(35 cycles) 
94°C 30 sec 
63°C 45 sec 
68°C 45 sec 
Hold 72°C 2 min 
Hold 4°C ∞ 
 
STEP 2: Agarose gel electrophoresis (optional) 
2.1) Prepare the agarose gel (recipe in Appendix F). When the gel is hardened,  
       transfer it to the gel chamber and cover it with 1 x TAE buffer (recipe in  
       Appendix F). 
2.2) Mix 2,0 µl PCR-product and 2,0 µl 0,1 % bromophenol blue gel loading buffer  
       (recipe in Appendix F) and load the whole volume into a gel well.  
2.3) Load 2,0 µl DNA ladder (φX 174-Hae III digest, TaKaRa) into the first well in  
       each row of sample loaded gel wells.   
2.4) Run the electrophoresis at 200 V for 30 min, and visualize the results by UV  
       irradiation (GeneGenius Bio Imaging System and GeneSnap Software v7.01.07,  
       Syngene). 
 
Stopping point 1: PCR products can be stored at 4°C over night or at –15°C or  
–25°C for long-term storage.  
 
STEP 3: Cycle sequencing 
3.1) For each forward or reverse reaction, mix the components as displayed in table 3  
       in an appropriate tube. Mix well and centrifuge the tubes briefly. Keep the premix  
       on ice and in the dark using aluminum foil to avoid fluorescence bleaching. 
 
Table 3: Sequencing reaction mix components and volumes required to cycle sequence one sample 
Components Volume for each reaction 
BigDye
® 
Direct Sequencing Master Mix 2,0 μl 
One Sequencing primer: 
• BigDye® Direct M13 Fwd Primer or 
• BigDye® Direct M13 Rev Primer  
1,0 μl 
Total volume for each reaction 3,0 μl 
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3.2) Add 3,0 µl sequencing reaction mix to each well in the respective forward or  
        reverse reaction plate. Keep reaction plates in the dark. 
3.3) Seal the plate with caps and centrifuge the plate briefly. 
3.4) Run the sequencing reactions in a thermal cycler as displayed in table 4. 
 
Table 4: Time and temperature conditions during cycle sequencing 
Stage 
Tetrad 2 Thermal Cycler (Bio-Rad) 
Temp Time 
Hold 37°C 15 min 
Hold 80°C 2 min 
Hold 96°C 1 min 
Cycle 
(25 cycles) 
96°C 10 sec 
50°C 5 sec 
60°C 4 min 
Hold 4°C ∞ 
 
Stopping point 2: The reaction plate can be stored at 4°C over night, or at –15°C or  
–25°C for long-term storage.  
 
STEP 4: Purify the sequencing products 
Remember to keep the reaction plates in the dark. 
4.1) Centrifuge the reaction plate at 100 x G for 1 min. 
4.2) Premix the SAM
™
 Solution and XTerminator
™
 Solution as displayed in table 5  
       in an appropriate tube. 
 
Before using the BigDye
®
 XTerminator
™
 Purification Kit:  
- Make sure there are no particles in the SAM
™
 Solution. Heat the solution to 37°C   
  and resuspend the solution if particles are present.  
- Homogenize the XTerminator
™
 Solution using a high-speed vortexer for 10 sec. 
  Avoid pipetting from the top of the liquid due to rapid sedimentation. 
- Use a sterile scalpel and cut the pipette tips to create wide-bore tips  
  (orifice > 1,0 mm) to aspirate the XTerminator
™
 Solution. 
- Calculate to use 15% more of the SAM
™
 and XTerminator
™
 Solution than needed  
  by the number of samples to be purified through dead volume. The ratio of SAM
™
  
  and XTerminator
™
 Solution should be 4,5:1 (v/v). 
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Table 5: BigDye
®
 XTerminator
™
 Purification Kit components and volumes to purify 96 samples  
Components Volume for each well Volume for 96 wells 
SAM
™
 Solution 45 µl 4968 µl 
XTerminator
™
 Solution 10 µl 1104 µl 
Total volume 55 µl 6072 µl 
 
4.3) Add 55 µl of the SAM
™
 and XTerminator
™
 Solution premix to each sample.  
       Mix the solution in between to prevent bead sedimentation. Seal the plate  
       using caps.  
4.4) Vortex the reaction plate for 30 min at 2000 rpm (Illumina High-Speed  
        Microplate Shaker). 
4.5) Centrifuge the reaction plate at 1000 x G for 2 min. 
 
Stopping point 3: Sealed reaction plates can be stored up to 48 hours in room 
temperature or up to 10 days at 4°C or –20°C before proceeding with capillary 
electrophoresis.   
 
For further information and details, see the BigDye
®
 Direct Cycle Sequencing Kit 
Protocol (Life Technologies). 
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APPENDIX C: Protocol – Microarray gene expression analysis  
Primary reference: One-Color Microarray-Based Gene Expression Analysis, Low 
Input Quick Amp Labeling Protocol version 6.5, May 2010 (Agilent Technologies). 
Microarrays: SurePrint G3 Hmn GE 80x60K Microarray Kit (Agilent Technologies, 
Cat. No. G4851-60510). 
The microarray procedure involves contact with possible hazardous 
compounds. Cy3 is a possible carcinogen. The 2x Hi-RPM Hybridization Buffer 
contains lithium chloride and lithium dodecyl sulfate. Lithium chloride is toxic and a 
potential teratogen, while lithium dodecyl sulfate is harmful by inhalation and 
irritating to eyes, skin and the respiratory system. Triton is a component in the 2x Hi-
RPM Hybridization Buffer and in the Gene Expression Wash Buffer 1 and 2, and is 
harmful if swallowed and a risk of serious eye damage. All chemicals should be 
handled with care and by wearing appropriate personal safety equipment. Wear gloves 
at all times to protect the samples, the delicate microarrays and yourself. 
 
Sample preparation: 
RNA sample concentration: 50 ng/µl RNA  
 
STEP 1: Spike-mix preparation 
1.1) Set heat blocks to 37°C, 65°C and 80°C, and water bath to 40°C. 
1.2) Heat the Spike-mix at 37°C for a few minutes, and centrifuge the tube briefly. 
1.3) Prepare second dilution (1:25) Spike-mix in a new tube  
  Dilution Buffer 48 µl 
  Spike-mix  2 µl 
  Vortex and centrifuge the tube briefly 
1.4) Prepare third dilution (1:20) Spike-Mix in a new tube  
  Dilution Buffer 38 µl 
  Second dilution 2 µl 
  Vortex and centrifuge the tube briefly 
 
STEP 2: Prepare labeling reaction 
2.1) Prepare the T7 Promoter Primer Mix in a new tube on ice 
  Nuclease-free water  5 µl 
  T7 Promoter Primer Mix 8 µl 
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  Vortex and centrifuge the tube briefly 
2.2) Prepare the samples in new tubes on ice 
  Sample (50 ng/µl RNA) 2 µl 
  Third dilution Spike-mix 2 µl  
  Mix the tube gently and centrifuge briefly 
  T7 Promoter Primer Mix 1,3 µl 
  Mix the tube gently and centrifuge briefly 
  Place the sample tubes at 65°C for 10 min 
  Place the sample tubes on ice for 5 min 
  Centrifuge the sample tubes briefly 
2.3) Meanwhile: prewarm the 5x First Strand Buffer at 80°C for 3-4 min, and keep it  
                            in room temperature. 
2.4) Prepare the cDNA Master Mix in a new tube 
   5x First Strand Buffer   20 µl 
   0,1M DTT     10 µl 
   10 mM dNTP mix    5 µl 
   AffinityScript RNase Block Mix 12 µl 
2.5) Add 4,7 µl of the cDNA Master Mix to each sample tube. 
       Mix well by pipetting up and down. 
2.6) Place the sample tubes in the 40°C water bath for 2 hours. 
2.7) Meanwhile: Set heat block to 70°C. 
2.8) Place the sample tubes at 70°C for 15 min. 
2.9) Place the sample tubes on ice for 5 min. 
2.10) Centrifuge the sample tubes briefly. 
 
Stopping point 1: move the sample tubes to –80°C. 
 
2.11) Prepare the Transcription Master Mix in a new tube 
   5x Transcription Buffer   32 µl 
   Nuclease-free water   7,5 µl 
   NTP Mix    10 µl 
   0,1 M DTT    6 µl 
   T7 RNA Polymerase Blend  2,1 µl  
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  Cyanine 3-CTP (keep in dark) 2,4 µl  
 
From here: keep the sample tubes dark at all times using aluminum foil! 
2.12) Add 6 µl of the Transcription Master Mix to each sample tube. 
2.13) Place the sample tubes in the 40°C water bath for 2 hours. 
2.14) Centrifuge the sample tubes briefly. 
 
Stopping point 2: move the sample tubes to –80°C. 
 
 
STEP 3: Purify labeled and amplified cRNA 
3.1) Pre-cool the centrifuge to 4°C. 
3.2) Purify the samples using the RNeasy
®
 Mini Kit (Qiagen). 
       Work in room temperature, as quick and dark as possible. 
       Add the following solution to the sample tubes: 
 DNase/RNase free water 84 µl 
  RLT buffer   350 µl 
  Mix by pipetting 
  Ethanol (100%)  250 µl 
  Mix by pipetting 
3.3) Transfer the whole sample volume (700 µl) to an RNeasy mini column. 
3.4) Centrifuge at 4°C and 13000 rpm for 30 sec. Discard the flow-through. 
3.5) Add 500 µl RPE Buffer to each spin column. 
3.6) Centrifuge at 4°C and 13000 rpm for 30 sec. Discard the flow-through. 
3.7) Add 500 µl RPE Buffer to each spin column.  
3.8) Centrifuge at 4°C and 13000 rpm for 60 sec. Discard the flow-through.  
3.9) Centrifuge at 4°C and 13000 rpm for 30 sec.  
3.10) Place the spin columns in new tubes.   
3.11) Add 30 µl DNase/RNase-free water to each spin column. 
         Incubate for 1 min. 
         Centrifuge at 4°C and 13000 rpm for 30 sec. 
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STEP 4: cRNA quantification 
Quantify the RNA using a NanoDrop
® 
ND-1000 Spectrophotometer (Saveen Werner). 
Use the same DNase/RNase-free water as the cRNA is eluted in to blank the 
spectrophotometer. The DNase/RNase-free water should also be measured. 
Remember to keep the samples dark and on ice while measuring. Before proceeding 
to the hybridization step (step 5), the cRNA yield and specific activity results should 
be examined. A cRNA yield of > 1,65 µg and specific activity of > 9,0 pmol Cy3 per 
µg cRNA are required in the hybridization step. Repeat the cRNA preparation if the 
results deviates the requirements.   
 
µg of cRNA = (Concentration of cRNA (ng/µl) × 30 µl (elution volume)  
           1000 
 
pmol Cy3 per µg cRNA = Concentration of Cy3 (pmol/µl)  
         Concentration of cRNA (ng/µl) 
 
 
In the hybridization step, 600 ng cRNA is added to the reaction. Use the 
spectrophotometric measurements to calculate the required sample volume; 
Sample volume (µl) = 600 ng / cRNA concentration (ng/µl) 
 
According to the procedure, the cRNA sample volume and volume DNase/RNase free 
water added should not exceed 19 µl. Adjust the water volume in accordance to the 
sample volume; 
Volume water (µl) = 19,0 µl – cRNA sample volume (µl) 
 
Stopping point 3: move the sample tubes to –80°C. 
 
 
STEP 5: Hybridization 
Turn on the hybridization oven to 65°C at least one hour before use. 
5.1) Set heat block to 60°C. 
5.2) Prewarm the 10x Blocking Agent at 37°C for 3-4 min. 
5.3) Mix the following components in new sample tubes 
× 1000 
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cRNA    600 ng (calculate the required volume in µl) 
  10x Blocking Agent   5 µl 
  DNase/RNase-free water x µl (adjust to added sample volume)                  
  Total     24 µl 
  Fragmentation Buffer  1 µl 
  Total sample volume  25 µl 
 
5.4) Place the sample tubes at 60°C for 30 min. 
5.5) Place the sample tubes on ice for 1 min. 
5.6) Add 25 µl 2x Hi-RPM Hybridization Buffer to each sample tube. 
       Mix by careful pipetting. 
       Centrifuge in room temperature at 13000 rpm for 1 min. Make sure there is no air  
       bubbles percent. Centrifuge again if necessary to eliminate bubbles. 
5.7) Place the samples on ice, and apply the samples to the array.  
       Use the hybridization gasket slides (Agilent Technologies) to apply the samples.  
       Further apply the SurePrint G3 Hmn GE 80x60K Microarray (Agilent  
       Technologies) with the probes in contact with the samples. Make sure there are  
       no stationary air bubbles impairing hybridized array quality. 
5.8) Place the array in the hybridization oven at 65°C and 10 rpm for 17 hours. 
 
 
STEP 6: Washing and scanning the array 
It is highly recommended to add 0,005% Triton X-102 (Agilent Technologies) to the 
Gene Expression Wash Buffer 1 and 2 (Agilent Technologies) prior to use to reduce 
the possibility of array wash artifacts. Keep the buffer trays on magnet stirrers to keep 
fluids in motion for improved array quality. 
6.1) Prewarm Buffer 2 to 37°C. 
6.2) Wash the array for 1 min in room tempered Buffer 1. 
6.3) Wash the array for 1 min in the 37°C Buffer 2. 
6.4) Slowly lift the array up from Buffer 2 to prevent the formation of buffer  
       droplets on the array. 
6.5) Place the array in a dark, air-protected box and scan as soon as possible. 
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For further information and details, see the One-Color Microarray-Based Gene 
Expression Analysis, Low Input Quick Amp Labeling Protocol version 6.5, May 2010 
(Agilent Technologies). 
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APPENDIX D: Results from the WRAP53 mutation analysis  
 
 
Table 10: WRAP53 sequence alterations detected in the ULL tumor and blood samples. Sequenced 
ULL blood samples are marked *. BC = base change, 1 = heterozygous genotype, 2 = minor 
homozygous genotype, - = data not available. 
Sample ID Location Codon 
Base 
change 
Coding 
description 
Codon 
change 
Amino acid 
(predicted) 
Protein 
change 
Type 
Geno- 
type 
ULL-T-003 Intron 5 - C>T c.731+27C>T - - - BC 1 
ULL-T-007 
Exon 2* 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-009 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-010 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-011 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-014 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-017 Exon 1β* - G>C c.–245G>C - - - BC 1 
ULL-T-020 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-023 Intron 5 - C>T c.731+27C>T - - - BC 1 
ULL-T-024 Intron 6 - C>T c.823–10C>T - - - BC 1 
ULL-T-025 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-026 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-027 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-028 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11* 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-036 
Exon 2* 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-037 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3* 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-038 Exon 1β* - G>C c.–245G>C - - - BC 1 
ULL-T-044 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-053 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-055 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-063 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-064 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-065 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-066 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-069 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-071 Intron 6 - C>T c.823–10C>T - - - BC 1 
ULL-T-072 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
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ULL-T-074 Exon 11* 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-080 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-082 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-083 Exon 1β - G>C c.–245G>C - - - BC 1 
ULL-T-084 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3* 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-085 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-088 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-090 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-093 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-094 Intron 6 - C>T c.823–10C>T - - - BC 1 
ULL-T-097 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-098 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-100 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3* 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-106 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-107 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-109 Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
ULL-T-111 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-113 
Intron 2 - C>G c.432–15C>G               - - - BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-115 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-134 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-137 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-138 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-139 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-141 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-142 Exon 11 522 - c.1566_1567insG or c.1564_1567delCGinsGGG Indel - 
ULL-T-143 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-152 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-155 
Exon 2* 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-162 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-163 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 2 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 2 
Intron 8 - G>A c.1165–30G>A              - - - BC 1 
Exon 10 436 T>C c.1308 T>C GCT>GCC Ala>Ala p.A436A BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-165 Intron 3 - G>A c.530+17G>A - - - BC 1 
ULL-T-171 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-176 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-180 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-184 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
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ULL-T-186 Exon 1β - G>C c.–245G>C - - - BC 1 
ULL-T-196 Intron 5 - C>T c.731+27C>T - - - BC 1 
ULL-T-198 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-199 Exon 11* 522 G>A c.1566 G>A GCG>GCA Ala>Ala p.A522A BC 1 
ULL-T-201 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Intron 2 - C>G c.432–15C>G - - - BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-202 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-209 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
Intron 6 - C>G c.823–10C>T - - - BC 1 
ULL-T-211 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-212 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-218 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-225 Exon 11* 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-227 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-236 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-237 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-242 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-247 Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-253 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11* 522 - c.1565_1568delGC - Indel 1 
ULL-T-256 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-262 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-263 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 3 150 C>T c.450 C>T TTC>TTT Phe>Phe p.F150F BC 1 
Exon 11* 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-268 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 2 
ULL-T-270 Exon 1β - G>C c.–245G>C - - - BC 1 
ULL-T-277 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11* 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
ULL-T-279 
Exon 2 68 C>G c.202 C>G CGG>GGG Arg>Gly p.R68G BC 1 
Exon 11 522 C>G c.1565 C>G GCG>GGG Ala>Gly p.A522G BC 1 
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APPENDIX E: Gene lists from the gene expression study 
 
Table 11: Significant upregulated genes in the MCF-7 cell line 72 hours after siWRAP53#2 
transfection 
ID 
Gene                  
Name 
Fold 
Change 
ID 
Gene                  
Name 
Fold 
Change 
ID 
Gene                  
Name 
Fold 
Change 
1 MMP1 25,8 51 GJB4 4,3 101 THBD 3,2 
2 RGS9 16,0 52 CYP2C8 4,3 102 ANTXR1 3,2 
3 SPOCK1 11,3 53 EPHB6 4,3 103 KLK6 3,2 
4 ITGB8 11,1 54 TNFRSF21 4,2 104 MTL5 3,2 
5 FOXQ1 10,9 55 MGC16075 4,2 105 PSG1 3,2 
6 SPRR1A 9,4 56 SPINK1 4,2 106 TGM2 3,1 
7 ATF3 9,0 57 HES2 4,1 107 ZNF608 3,1 
8 FLJ22536 7,5 58 NUPR1 4,1 108 PSG8 3,1 
9 KLHDC7B 7,5 59 ACTA2 4,0 109 GRB10 3,1 
10 KALRN 7,4 60 CNN3 4,0 110 SLC14A1 3,1 
11 NCF2 7,3 61 CDKN2B 3,9 111 WSCD1 3,1 
12 PXDC1 7,3 62 PSG2 3,9 112 PTGER3 3,1 
13 GPR87 7,3 63 SERPINB5 3,9 113 AQP3 3,1 
14 NCRNA00324 7,2 64 IFIT2 3,8 114 DUSP10 3,1 
15 ALOX5 7,2 65 S100A2 3,8 115 LOXL4 3,1 
16 TCHHL1 7,1 66 KLHL24 3,8 116 NEDD9 3,1 
17 MALL 7,1 67 PTPRH 3,8 117 SEMA7A 3,1 
18 NTN4 7,0 68 PHLDA1 3,8 118 PHF21B 3,0 
19 ARL14 6,5 69 CCL26 3,8 119 FYN 3,0 
20 CLDN1 6,5 70 KLK7 3,7 120 AKR1B15 3,0 
21 INHBA 6,4 71 GABARAPL1 3,7 121 CLSTN2 3,0 
22 MMP24 6,3 72 PID1 3,7 122 CENPV 3,0 
23 GEM 6,2 73 SERPINE2 3,6 123 CLIP2 3,0 
24 RASD1 6,0 74 RHCG 3,6 124 COL5A1 3,0 
25 FLJ13197 5,9 75 TNFSF15 3,6 125 NOG 3,0 
26 IVL 5,9 76 DSCAML1 3,6 126 RASGRP1 3,0 
27 FHL2 5,9 77 DDX60L 3,6 127 CAPN13 3,0 
28 FBXO32 5,8 78 BCAT1 3,6 128 SPRR3 3,0 
29 F2R 5,6 79 SHISA2 3,6 129 KIAA0226L 2,9 
30 SPRR1B 5,6 80 FAS 3,6 130 RFTN2 2,9 
31 NEURL3 5,6 81 FSIP2 3,5 131 PSG9 2,9 
32 CACNG6 5,5 82 WDR66 3,5 132 PLAC1 2,9 
33 LYPD1 5,4 83 ENTPD3 3,5 133 COL20A1 2,9 
34 OLFML3 5,4 84 RCAN2 3,5 134 MAP2 2,9 
35 MMP13 5,3 85 OXTR 3,5 135 TGFBI 2,9 
36 HTR1F 5,3 86 AKR1B10 3,5 136 PMAIP1 2,9 
37 DHRS3 5,2 87 SLIT2 3,5 137 FAM155A 2,9 
38 WLS 5,2 88 GADD45A 3,5 138 SIGLEC15 2,9 
39 NHS 5,2 89 ENOX1 3,4 139 PALLD 2,9 
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40 DNM3 4,9 90 LGR6 3,4 140 PSORS1C1 2,8 
41 PLXNA2 4,9 91 FBN2 3,4 141 RGS20 2,8 
42 KIAA1239 4,8 92 PMEPA1 3,4 142 FAM125B 2,8 
43 LAMC2 4,7 93 MEF2C 3,4 143 ROR1 2,8 
44 MGC20647 4,6 94 ANKRD29 3,4 144 IRAK2 2,8 
45 LRRC4 4,5 95 STAT4 3,3 145 RAB7B 2,8 
46 SAMD4A 4,5 96 ACOXL 3,3 146 CST6 2,8 
47 CHAC1 4,4 97 CCDC80 3,3 147 DDIT3 2,8 
48 COL17A1 4,4 98 LTB 3,3 148 MGLL 2,8 
49 PGM5 4,4 99 LAMB3 3,3 149 SLC7A11 2,8 
50 KIAA1683 4,3 100 ZNF532 3,3 150 CTNNA3 2,8 
 
 
ID 
Gene                  
Name 
Fold 
Change 
ID 
Gene                  
Name 
Fold 
Change 
ID 
Gene                  
Name 
Fold 
Change 
151 APOBEC3H 2,8 201 VWCE 2,4 251 AP1S2 2,2 
152 BBC3 2,8 202 CDH11 2,4 252 RHOU 2,1 
153 TLR2 2,7 203 ARHGAP36 2,4 253 PLD1 2,1 
154 UPP1 2,7 204 CYP1B1 2,4 254 PGM2L1 2,1 
155 CLIP4 2,7 205 VEPH1 2,4 255 OSBPL5 2,1 
156 CAPN8 2,7 206 TP53TG1 2,4 256 LHPP 2,1 
157 TGFB2 2,7 207 LAMA3 2,4 257 ARHGDIB 2,1 
158 PDLIM3 2,7 208 CTF1 2,4 258 LCAT 2,1 
159 ABCA1 2,7 209 INPP1 2,4 259 RND3 2,1 
160 SPATA18 2,7 210 DIO3OS 2,4 260 RELB 2,1 
161 HCN4 2,7 211 FLJ40852 2,4 261 AHR 2,1 
162 GPNMB 2,6 212 LONRF3 2,4 262 AES 2,1 
163 F2RL1 2,6 213 SLC6A8 2,4 263 STAU2 2,1 
164 DAPK2 2,6 214 GSTA4 2,3 264 HRK 2,1 
165 MBP 2,6 215 PAPLN 2,3 265 NDRG4 2,1 
166 FOSL1 2,6 216 CCK 2,3 266 S100A6 2,1 
167 MAF 2,6 217 MME 2,3 267 SLC17A5 2,1 
168 IL6 2,6 218 CMAHP 2,3 268 PROC 2,0 
169 TM4SF1 2,6 219 WNT4 2,3 269 BTG1 2,0 
170 SLC5A10 2,6 220 FRAS1 2,3 270 GLP2R 2,0 
171 TXLNB 2,6 221 ZFP36L1 2,3 271 TNFRSF11B 2,0 
172 ANK1 2,6 222 ABLIM2 2,3 272 ITGA6 2,0 
173 STAMBPL1 2,6 223 ADM2 2,3 273 SEMA5A 2,0 
174 TIMP3 2,6 224 ASNS 2,3 274 HS3ST1 2,0 
175 FAM196A 2,6 225 LHFPL2 2,3 275 ACSS1 2,0 
176 PSG10P 2,5 226 NXNL2 2,3 276 BEX2 2,0 
177 KSR1 2,5 227 FSTL3 2,3 277 XKR6 2,0 
178 RBP1 2,5 228 RUNX2 2,3 278 GLS2 2,0 
179 CACNG1 2,5 229 SLC16A14 2,3 279 
IQCJ-
SCHIP1 
2,0 
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180 ZNF469 2,5 230 CLCF1 2,3 280 WDFY4 2,0 
181 SLCO2A1 2,5 231 BEND7 2,3 281 EYA2 2,0 
182 XYLT1 2,5 232 JAKMIP2 2,2 282 RNU1-5 2,0 
183 CAPS2 2,5 233 TFPI 2,2 283 S100A9 2,0 
184 HSPG2 2,5 234 UCHL1 2,2 284 PRICKLE2 2,0 
185 GULP1 2,5 235 HAPLN3 2,2 285 FAM71E1 2,0 
186 CCDC146 2,5 236 CDH26 2,2 286 ProSAPiP1 2,0 
187 TRIM29 2,5 237 MFGE8 2,2 287 PCBP4 2,0 
188 ALDH1A3 2,5 238 FAM189A2 2,2 288 EDA2R 2,0 
189 TMEM45B 2,5 239 CYB5RL 2,2 289 SLC25A21 2,0 
190 SLC13A3 2,5 240 EVPLL 2,2 290 SLC12A4 2,0 
191 ANXA1 2,5 241 SESN3 2,2 291 EPDR1 1,9 
192 SOX4 2,5 242 TNFSF9 2,2 292 TNFRSF10C 1,9 
193 LAMP3 2,5 243 FAM107B 2,2 293 RHOQ 1,9 
194 PRSS23 2,4 244 ATP1A1OS 2,2 294 AGA 1,9 
195 EPAS1 2,4 245 AUTS2 2,2 295 CROT 1,9 
196 AKR1B1 2,4 246 TNFAIP3 2,2 296 XG 1,9 
197 SLC23A3 2,4 247 POPDC2 2,2 297 FAM105A 1,9 
198 KCNK2 2,4 248 CDKN1A 2,2 298 TUFT1 1,9 
199 MUCL1 2,4 249 FDXR 2,2 299 ST3GAL1 1,9 
200 PLEKHH2 2,4 250 LMO7 2,2       
 
 
Table 12: Significant upregulated genes in the MDA-MB-231 cell line 72 hours after siWRAP53#2 
transfection 
ID 
Gene 
Name 
Fold 
Change 
ID 
Gene              
Name 
Fold 
Change 
ID 
Gene 
Name 
Fold 
Change 
1 VTCN1 5,3 51 POLR2F 2,2 101 SCD5 1,9 
2 SELV 4,3 52 AADAC 2,2 102 HOPX 1,9 
3 HOXB8 3,8 53 SLC10A2 2,2 103 BMP2 1,9 
4 CCDC129 3,6 54 FAM22A 2,2 104 SNRPD3 1,9 
5 HNF1A 3,6 55 SLITRK6 2,2 105 GPR64 1,9 
6 ZNF847P 3,5 56 FTCD 2,2 106 SLC16A14 1,9 
7 EYS 3,4 57 SMCR5 2,1 107 DIP2C 1,9 
8 SYCE3 3,2 58 TTLL9 2,1 108 EREG 1,8 
9 EDA2R 3,2 59 IL13RA2 2,1 109 RINL 1,8 
10 ENKUR 3,1 60 FAM166A 2,1 110 PARM1 1,8 
11 PHACTR1 3,1 61 UCHL1 2,1 111 PSG5 1,8 
12 PTGS2 3,1 62 PPP1R1C 2,1 112 IGKV1-5 1,8 
13 TDO2 3,0 63 ZIM2 2,1 113 MATL2963 1,8 
14 LZTS1 3,0 64 TEX12 2,1 114 PANX2 1,8 
15 NECAB2 2,9 65 NCRNA00167 2,1 115 PPEF1 1,8 
16 LAMA1 2,8 66 FAM83B 2,0 116 KAZALD1 1,8 
17 PTX4 2,8 67 FERMT1 2,0 117 LRRC7 1,8 
18 WWTR1 2,8 68 MED12L 2,0 118 FGFR1 1,8 
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19 KIAA0319 2,8 69 FAM71A 2,0 119 SLC25A34 1,8 
20 CRCT1 2,8 70 HAS2 2,0 120 UTS2 1,8 
21 TEKT3 2,7 71 SSX1 2,0 121 OR10AD1 1,8 
22 C21orf116 2,6 72 COL20A1 2,0 122 NPAS3 1,8 
23 RGS18 2,6 73 FIGF 2,0 123 IL8 1,8 
24 KIAA1841 2,6 74 SLC6A14 2,0 124 ZNF519 1,8 
25 NDST3 2,6 75 FAM18A 2,0 125 NRIP3 1,8 
26 KLK6 2,6 76 MCF2L 2,0 126 CLEC18C 1,8 
27 SPINK14 2,6 77 ARMC2 2,0 127 IL1A 1,8 
28 FRG2C 2,6 78 CAPN3 2,0 128 FST 1,8 
29 TCP11 2,6 79 SPAG16 2,0 129 SSX3 1,8 
30 FLJ12825 2,6 80 TRIM17 2,0 130 TBC1D21 1,8 
31 BCOR 2,6 81 SRRM4 2,0 131 FZD8 1,7 
32 LRRC17 2,6 82 CXCL1 2,0 132 SNX10 1,7 
33 AMZ2P1 2,5 83 EVPLL 2,0 133 ST6GAL1 1,7 
34 MARCH1 2,5 84 B4GALNT1 2,0 134 PLD5 1,7 
35 DHRS9 2,5 85 SCARNA23 2,0 135 TNFSF9 1,7 
36 SNORA46 2,5 86 LTB 2,0 136 PEG10 1,7 
37 SPP1 2,4 87 RXFP3 1,9 137 FAM95B1 1,7 
38 KCNK16 2,4 88 HPX-2 1,9 138 DUSP13 1,7 
39 NPW 2,4 89 MAP2 1,9 139 ZNF204P 1,7 
40 ANP32A 2,4 90 SLC13A3 1,9 140 CMAHP 1,7 
41 GCNT3 2,3 91 PRO1596 1,9 141 ADAMTS4 1,7 
42 KCTD4 2,3 92 CLDN1 1,9 142 SPATA1 1,7 
43 DEFB4A 2,3 93 ANKFN1 1,9 143 LAIR2 1,7 
44 SERPINB5 2,3 94 CXCL3 1,9 144 ABI3BP 1,7 
45 PTPRC 2,3 95 SULF1 1,9 145 ARHGEF9 1,7 
46 OLAH 2,3 96 NR5A2 1,9 146 LAD1 1,7 
47 TMEM14E 2,3 97 SSX4B 1,9 147 ZNF702P 1,7 
48 AKR1C1 2,3 98 CD300LG 1,9 148 DCLK1 1,7 
49 CCDC102B 2,3 99 MLLT11 1,9 149 TRPV1 1,7 
50 SPRR2G 2,2 100 PCDHB15 1,9 150 PI3 1,7 
 
 
ID Gene Name 
Fold 
Change 
ID 
Gene          
Name 
Fold 
Change 
151 CCL3 1,7 201 MUSK 1,5 
152 HS6ST2 1,7 202 SOX4 1,5 
153 TNFRSF11B 1,7 203 MPZL2 1,5 
154 KIAA0754 1,7 204 MEF2C 1,5 
155 ADTRP 1,7 205 ZNF660 1,5 
156 ZNF616 1,7 206 DPYSL5 1,5 
157 CNTNAP3 1,7 207 PRINS 1,5 
158 PELI2 1,7 208 ITGB8 1,5 
159 TIE1 1,7 209 SOD2 1,5 
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160 DNHD1 1,6 210 C1RL 1,5 
161 ADAMTS1 1,6 211 FAM27A 1,5 
162 STC2 1,6 212 FSIP2 1,5 
163 TTC18 1,6 213 COL4A6 1,5 
164 MIG7 1,6 214 SULT1C2 1,5 
165 KISS1 1,6 215 HSD17B2 1,5 
166 RD3 1,6 216 LHPP 1,5 
167 LOX 1,6 217 MDFI 1,5 
168 CLMP 1,6 218 RGS16 1,5 
169 CXCL2 1,6 219 SLC2A14 1,5 
170 C1S 1,6 220 COL8A1 1,5 
171 CYB5RL 1,6 221 CTSC 1,5 
172 CPA3 1,6 222 PIR 1,5 
173 MMP1 1,6 223 NPAS1 1,5 
174 CDK14 1,6 224 SEMA3A 1,5 
175 GTDC1 1,6 225 CD22 1,5 
176 AZGP1P1 1,6 226 TCN1 1,5 
177 MMEL1 1,6 227 DEFB103B 1,5 
178 TM4SF1 1,6 228 BICD2 1,5 
179 SEL1L3 1,6 229 ZBTB32 1,5 
180 NXF3 1,6 230 CYP1B1 1,5 
181 CPA6 1,6 231 FBXO16 1,5 
182 HCLS1 1,6 232 PCDHGB4 1,5 
183 ATXN1L 1,6 233 SLC2A3 1,5 
184 ITGA10 1,6 234 CCDC80 1,5 
185 TET3 1,6 235 MESDC2 1,5 
186 SSX8 1,6 236 REN 1,5 
187 ZMYND8 1,6 237 CACNG6 1,4 
188 TMEM144 1,6 238 SLC7A2 1,4 
189 MCF2L-AS1 1,6 239 FBXO36 1,4 
190 NR3C2 1,5 240 GABARAPL1 1,4 
191 NAMPT 1,5 241 ZNF674 1,4 
192 SCEL 1,5 242 G3BP2 1,4 
193 C1QTNF6 1,5 243 THBD 1,4 
194 DDIT4L 1,5 244 CYP2J2 1,4 
195 ZNF267 1,5 245 NUPR1 1,4 
196 PLCB2 1,5 246 TLCD1 1,4 
197 THBS4 1,5 247 RGS2 1,4 
198 OGFR 1,5 248 DST 1,4 
199 CYBB 1,5 249 NR4A2 1,4 
200 OSBPL5 1,5       
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APPENDIX F: Reagents 
 
 
50x TAE buffer  
Reagents  
Trizma
®
 base, Sigma-Aldrich
®
 Norway AS (Prod. No. T1503) 
EDTA disodium salt, BDH
®
 (Prod. 100935V) 
Glacial Acetic Acid, MERCK (Cat. No. 100063) 
 
 
Procedure 
 
Table 13: Component volumes and amounts to make 50x TAE buffer 
Components Amount  
Trizma
®
 base  242 g 
EDTA disodium salt 100 ml 0,5 M EDTA (pH = 8,0) 
Glacial Acetic Acid  57,1 ml 
MQ-water  up to 1000 ml 
 
1) Scale in 242 g Trizma
® 
base 
2) Add 500 ml MQ-water 
3) Add 100 ml 0,5 M EDTA (pH = 8,0) and 57,1 ml Glacial Acetic Acid 
4) Add MQ-water to adjust to 1000 ml 
Store the buffer in room temperature. 
 
 
1x TAE buffer  
Dilute the 50x TAE buffer 1:10 in MQ-water. 
Store the buffer in room temperature.  
 
 
Agarose gel (1,5% agarose) 
Reagents 
Agarose, Bio-Rad Laboratories (Cat. No. 161-3102) 
GelRed™ Nucleotid Acid Stain, Biotium (Cat. No. 41003-1) 
1x TAE buffer  
 
Procedure 
Table 14: Component volumes and amounts to make agarose gel (1,5% agarose) 
Components Amount  
Agarose  5,25 g 
1x TAE buffer  350 ml 
GelRed
™
 NucleicAcid Stain 35,0 µl 
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1) Mix 5,25 g Agarose and 350 ml 1x TAE buffer in an Erlenmeyer flask 
2) Heat to boiling in a microwave 
3) Swirl the flask gently until all the agarose is completely dissolved 
4) Cool the gel solution to about 65°C 
5) Add 35,0 µl GelRed
™
 Nucleotid Acid Stain (Biotium) 
6) Pour the gel and let it harden for 30 min 
Store the gel by 4°C. Wrap the gel in plastic foil to avoid drying. 
 
 
Gel loading buffer (0,1% Bromophenol blue)  
Reagents 
Bromophenol blue, Bio-Rad Laboratories (Cat. No. 161-0404) 
Ficoll
®
 PM 400, Sigma-Aldrich
®
 Norway AS (Prod. No. F4375) 
1x TAE buffer  
 
Procedure 
Table 15: Component volumes and amounts to make 0,1% Bromophenol blue gel loading buffer 
Components Amount  
Bromophenol blue  0,025 g 
Ficoll
®
 PM 400  5,0 g 
1x TAE buffer  25 ml 
 
1) Scale in 0,025 g Bromophenol blue and 5,0 g Ficoll in a 50 ml tube  
2) Add 25 ml 1x TAE buffer 
3) Ficoll needs time to dissolve properly, so vortex the tube for about 24 hours to  
    get a homogenous solution 
Keep the buffer in room temperature for short-term storage, and by 4°C for long-term 
storage. 
 
 
1x Sequencing buffer  
Reagents 
10x 3730 Buffer with EDTA, Applied Biosystems (Part. No. 4335613) 
 
Procedure 
Dilute the 10x 3730 Buffer with EDTA 1:10 in MQ-water. 
Store the buffer at 4°C. 
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APPENDIX G: Chemicals and equipment 
 
 
Table 16: Chemicals and reagents with supplier and ordering information 
 
  
Chemical Supplier Ordering information 
2x Hi-RPM Hybridization Buffer Agilent Technologies  Part. No. 5188-6420 
10x 3730 Buffer with EDTA Applied Biosystems Part. No. 4335613 
10x GE Blocking Agent Agilent Technologies  Cat. No. 5188-5973 
10% Triton X-102 Agilent Technologies  Part. No. 5188-5903 
25x Fragmentation Buffer Agilent Technologies  Part. No. 5185-5974 
φX 174-Hae III digest TaKaRa Code No. 3405 A 
Absolute alcohol prima Kemetyl Norge AS - 
Agilent Gene Expression Wash Buffer 1 Agilent Technologies Part. No. 5188-5325 
Agilent Gene Expression Wash Buffer 2 Agilent Technologies Part. No 5188-5326 
Big Dye
®
 Direct Cycle Sequencing Kit     Applied Biosystems Part. No. 4458688 
BigDye
®
 XTerminator™ Purification Kit     Applied Biosystems Part. No. 4376484 
Bradford assay Bio-Rad Laboratories Cat. No. 500-0006 
Bromophenol blue Bio-Rad Laboratories Cat. No. 161-0404 
Certified
™
 Molecular Biology Agarose Bio-Rad Laboratories Cat. No. 161-3102 
Cyanine 3 CTP Dye Pack Agilent Technologies Part. No. 5190-2329 
DNase/RNase free H2O GIBCO Ref 10977-35 
Dulbecco`s modified Eagle Medium HyClone, Thermo Scientific Cat. No. AW-L25546 
EDTA disodium salt BDH
®
 Prod. 100935V 
Fetal bovine serum HyClone, Thermo Scientific Cat. No. SV30160.03 
Ficoll
®
 PM 400 Sigma-Aldrich
®
 Norway AS Prod. No. F4375 
Glacial Acetic Acid MERCK  Cat. No. 100063 
GelRed
™
 Nucleic Acid Gel Stain Biotium Cat. No. 41003-1 
HiPerFect Transfection Reagent Qiagen Cat. No. 301704 
KAPA SYBR
®
 FAST Kapa Biosystems Cat. No. KK4602 
LowInput Quick Amp Labeling Kit Agilent Technologies Part. No. 5190-2331 
Monoclonal Anti-β-actin antibody 
produced in mouse 
Sigma-Aldrich
®
  Cat. No. A5441 
Negative Control siRNA (20 nmol) Qiagen Cat. No. 1027310 
Plasmocin
™ 
InvivoGen Cat. code  ant-mpp 
POP-7
™
 Performance Optimized Polymer Applied Biosystems Part. No. 4363929 
RNase Away
®
 Molecular BioProducts Cat. No. 7005 
RNA Spike-In Kit Agilent Technologies Part. No. 5188-5282 
RNeasy MinElute CleanUp Kit  Qiagen Cat. No. 74204 
RNeasy
®
 Mini Kit Qiagen Cat.No. 74106 
Sephadex
™ 
G-50 Superfine GE Healthcare Cat. No. 17-0041-01  
SuperSignal West Femto Maximum 
Sensitivity Substrate 
Thermo Scientific Cat. No. 34096 
Trizma
®
 base Sigma-Aldrich
®
 Norway AS Prod. No. T1503 
WRAP53 C2 antibody Innovagen Cat. No. PA-2020-100 
WRAP53 PCR primers Eurogentec - 
WRAP53 siRNA / Hs_FLJ10385_2 Qiagen Cat. No. SI003889948 
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Table 17: Equipment with supplier and ordering information 
Equipment Supplier Ordering information 
96-well plate septa  Applied Biosystems Cat. No. 4315933 
Agilent’s DNA Microarray Scanner With 
SureScan High-Resolution Technology 
Agilent Technologies Model G2565CA 
Applied Biosystems 3730 DNA Analyzer Applied Biosystems - 
DNA Engine Tetrad 2 Peltier Thermal 
Cycler    
Bio-Rad Laboratories - 
Disposable Scalpels (sterile) Swann-Morton Ref. 0503 
Domed Cap Strip Thermo Scientific Cat. No. AB-0602 
Eppendorf Centrifuge 5804 Eppendorf - 
Eppendorf Mini Spin
®
 Eppendorf - 
Eppendorf Centrifuge 5415D Eppendorf - 
GeneGenius Bio Imaging System Syngene - 
Hybridization Gasket Slides  Agilent Technologies Cat. No. G2534-60014 
Hybridization oven SHEL LAB - 
Illumina High-Speed Microplate Shaker Illumina - 
Lense-cleaning paper, Assistant No.1019 VWR International Art. No. 763-0319 
MicroAmp
™
 Optical 96-Well Reaction 
Plate with Barcode 
Applied Biosystems Part. No. 4306737 
Multiscreen Column Loader 45 UL Millipore Cat. No. CP5SN5099 
MultiScreen
®
 HV Filter Plates Millipore Cat. No. MAHVN4550 
MultiScreen
®
 PCR µ 96  Millipore Cat. No. LSKMPCR50 
NanoDrop
®
 ND-1000 Spectrophotometer     Saveen Werner - 
Powerpac 300 Electrophoresis Power 
Supply 
Bio-Rad Laboratories - 
Safe-Lock Tubes 1,5 ml Eppendorf Order No. 0030 123.328 
Sub-Cell
®
 Model 192 Bio-Rad Laboratories - 
SurePrint G3 Hmn GE 80x60K Microarray 
Kit 
Agilent Technologies Cat. No. G4851-60510 
Therma-Fast
®
96, Non-Skirted Thermo Scientific Cat. No. AB-0600/G 
   
Software   
Agilent Scan Control Agilent Technologies - 
GeneSnap Software, Version 7.01.07 Syngene - 
GeneSpring GX 12.0 Agilent Technologies - 
Feature Extraction v10.7.3.1 Agilent Technologies - 
Ingenuity Pathways Analysis Ingenuity
® 
Systems - 
ND-1000 Software v7.3.1 Thermo Fisher Scientific Inc - 
SeqScape v.2.7 Applied Biosystems - 
 
        
 
 
 
